Cell cycle control and its modulation in HPV infected cells by Lyman, Rachel C.
CELL CYCLE CONTROL AND ITS MODULATION IN
HPV INFECTED CELLS
Rachel C. Lyman
A Thesis Submitted for the Degree of PhD
at the
University of St. Andrews
2009
Full metadata for this item is available in the St Andrews
Digital Research Repository
at:
https://research-repository.st-andrews.ac.uk/
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10023/863
This item is protected by original copyright
This item is licensed under a
Creative Commons License
  
 
 
 
 
 
 
 
 
 
 
Cell Cycle Control and its 
Modulation in HPV Infected Cells  
 
 
 
By 
 
Rachel C Lyman 
 
 
 
 
 
A dissertation submitted to the University of St Andrews in accordance with 
the requirements of the Degree of Doctor of Philosophy in the Bute Medical 
School 
 
 
 
 
 
 
 
 
 
 
 
 
 
School of Medicine, University of St Andrews 
  ii 
 
Abstract 
 
A key effect of human papillomavirus (HPV) infection is to disrupt the normal 
cell cycle in order to subvert the cellular DNA replication machinery. 
Morphologically, condylomata induced by high and low risk HPV types cannot 
be distinguished and many studies have shown that the pattern of viral gene 
expression is similar in condylomata caused by both high risk and low risk 
HPV types. Detailed morphological study of cell cycle protein expression has 
not previously been performed on condylomata infected with low risk HPV 
types. 
 
The findings presented suggest that the mechanisms employed by low risk 
HPV6 or HPV11 to subvert cellular functions in condylomata acuminata are 
similar to those employed by high risk HPVs, with the exception of cyclin D1 
and p53 protein over-expression.  The differences in p53 expression and cyclin 
D1 expression seen between high and low risk HPV infection, reflect the known 
differences between high and low risk types and are in agreement with the 
known differences between high risk and low risk E6 and E7 proteins. PHK 
transduction studies demonstrated HPV E6 and E7 induce changes in cell cycle 
protein expression and that there are differences in cell cycle abrogation 
between HPV6 and HPV16. 
 
Disruption of the p53-MDM2 interaction can lead to activation of the p53 
pathway. HPV infected lesions almost always contain wild-type p53. The 
binding of HPV E6 to p53, and its subsequent targeting for degradation, 
prevents activation of the p53 pathway in HPV infected cells. Cells over 
expressing HPV genes were treated with Nutlin-3, a MDM2-small molecule 
antagonist. The findings presented suggest treatment with Nutlin-3 induces 
cell cycle arrest in cells expressing HPV16 E7 and HPV6 E6 and HPV6 E7. This 
suggests a potential role for Nutlin-3 in the treatment of HPV infected cells. 
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 Preface 
 
Despite much research over the years, the mechanisms involved in the 
interaction between human papillomavirus and host factors are still poorly 
understood. This is due in part to the complicated interactions that occur 
between host and virus. HPVs are classified as high risk or low risk, depending 
on their association with carcinomas. Low risk HPV infections manifest as 
papillomas, and are an example of a successful viral infection. The virus is able 
to undergo replication, avoids detection and does not result in the death of its 
host.  
 
Infection with low risk HPV types cause significant and disfiguring diseases. 
Genital warts are very common throughout the population. Infections occur 
early in sexual life and there is a relationship between genital warts and the 
potential development of pre-cancerous and cancerous lesions, due to co-
infection with non-oncogenic and oncogenic HPVs. Despite this, there is 
relatively little information in the literature on low risk HPV infection 
compared to the information available on high risk HPVs.  
 
More research is required on low risk HPV types and their interaction with the 
host. With this in mind, it is the aim of this thesis to examine productive 
genital viral infection in its natural context, focussing on cell cycle control 
protein expression. In addition, the activation of the p53 pathway by MDM2 
small molecule antagonist, Nutlin-3 in HPV infected cells will be investigated. 
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Chapter 1:  
Introduction  
 
1.1 Introduction to Human Papillomavirus 
Infection 
 
Human papillomaviruses (HPV) are members of the papovaviridae family. 
They are small DNA viruses that infect the mucosae and cutaneous surfaces 
and HPVs have the ability to promote proliferation and transformation of the 
host epithelium causing warts and epithelial tumours [1]. The structure and 
composition of HPV was first demonstrated in human warts by electron 
microscopy in 1949 [2], and HPV DNA has been demonstrated as far back as in 
a 16th century mummy [3]. HPVs are epitheliotropic viruses and target the 
squamous epithelium, which lines the skin and mucosal surfaces of the oral, 
cutaneous and anogenital regions [4]. They are responsible for several mucosal 
and skin lesions; infection with HPV can result in laryngeal papillomas [5-7], 
anogenital condylomas [8], skin warts [2, 9], skin cancer in, for example, 
patients with epidermodysplasia verruciformis [10], and cervical carcinoma 
[11].  
 
1.1.1 Human Papillomavirus Life Cycle 
 
The viral life cycle is tightly linked to keratinocyte differentiation. HPV 
requires basal layer epidermal or mucosal epithelial cells, which are still able to 
proliferate [12]. The virus invades the cells of the basal layer of the epidermis, 
this is presumed to occur via nicks or abrasions. In the cervix, trauma allows 
access to target cells at or near the cervical transformation zone and initial 
  3 
infection occurs in the actively dividing basal epithelial cells [13, 14]. The viral 
genome replicates extrachromosomally in the nucleus of infected keratinocytes 
along with cellular DNA [15, 16]. The viral genome is maintained at low levels, 
thought to be 20 to 50 copies per cell, until the infected cell reaches the upper 
layers of the epithelium. The productive phase occurs in the post-mitotic cells 
of the differentiated strata. On reaching the non-dividing keratinocytes in the 
upper epithelium, the virus undergoes large-scale amplification [17]. Viral 
DNA amplification and progeny production are observed in the more 
superficial, differentiated strata of the epithelium [18, 19]. Capsid protein is 
synthesised and intact virions are released, with the sloughing–off of the 
superficial cells [20]. This process is known as vegetative viral DNA 
replication, and represents a productive viral infection. Vegetative viral DNA 
replication results in koilocytosis, nuclear enlargement, dyskaryosis, 
multinucleation and can in some cases lead to low grade squamous 
intraepithelial lesions (SIL); these lesions may regress, persist or progress [21]. 
 
If the productive stage of the HPV life cycle does not complete, non-permissive 
transformable infection results. In this situation, viral gene expression does 
not take place in a spatially regulated manner, the viral DNA persists either as 
an extra chromosomal element or by integration into the host DNA and virion 
production does not occur. Non-permissive transformable infection may result 
in neoplastic transformation [21]. 
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1.1.1.1 HPV Genome 
HPVs are small double stranded DNA viruses. The virus particle is 50-55 nm in 
diameter and has an icosahedral capsid coat composed of two structural 
proteins. The HPV genome is approximately 7.9 kb in length and can be 
divided into three main regions, namely early (E), late (L) and the long control 
(LCR) regions (see Figure 1.1).  The early region contains six open reading 
frames (ORF); E1, E2, E4, E5, E6 and E7. The early genes are responsible for 
DNA replication, transcriptional regulation and transformation. The late 
region contains two ORFs; L1 and L2. The late genes control the formation of 
the capsid coat. The expression of the ORFs is directed by two major promoters 
(early and late) in HPV16, and three promoters in HPV 6. The HPV transcripts 
undergo differential splicing to generate mRNA [22, 23]. The LCR or upstream 
regulatory region (URR) contains cis-regulatory elements. 
 
 
  
 
 
 
 
 
 
 
 
 Figure 1.1: HPV 6 and HPV 16 Linearised Genome 
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As a consequence of its small size, the HPV genome does not encode the 
essential replication proteins, it depends on the host DNA replication 
machinery to synthesise viral DNA [24]. Viral proteins E1 and E2 bind to the 
viral origin of replication and recruit the host factors required for viral DNA 
synthesis [17].  
 
It is thought the host replication machinery becomes limiting in the 
differentiated cells of the suprabasal compartment of the epithelium [25, 26]. 
The productive stage of the viral life cycle takes place in this compartment, and 
thus it is thought that the virus possesses mechanisms to make these cells 
permissive for DNA synthesis [24]. In order to achieve viral DNA 
amplification, the virus subverts key host cell cycle regulatory factors, resulting 
in re-activation of cellular DNA replication machinery in differentiated 
keratinocytes [27, 28].  
 
1.1.1.2 Viral Genes 
One of the functions of the early genes is to abrogate the host’s cell cycle 
checkpoints. This is achieved through binding to components of the regulatory 
pathway. The G1/S and G2/M cell cycle checkpoints are disrupted and the host 
regulatory proteins that are targeted include; cyclins, cyclin dependent kinases 
and cyclin dependent kinase inhibitors [29], p53 and Retinoblastoma protein 
[30, 31]. 
 
The roles of the viral gene products are discussed in more detail in section 
1.2.3, but are outlined here briefly. The E1 and E2 genes are involved in viral 
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replication and genome maintenance. The E2 protein is the primary viral 
origin of replication (ori) -recognition protein. It recruits E1 to the ori [32, 33]. 
E1 has helicase activity. It catalyses unwinding of the DNA duplex and brings 
DNA polymerase-! and replication protein A (rep A) to the ori [34-36]. The E2 
protein product has three distinct domains; the DNA binding domain at the 
carboxy terminus; the hinge or linker region; and the transactivation domain 
at the amino terminus [37]. E2 can also repress the transcription of E6 and E7 
[38]. E4 is a product of early gene expression, but it is considered a late protein 
as the E4 protein is produced just prior to full viral assembly. E4 is produced 
as a fusion protein, incorporating part of the E1 protein (E1^E4) [39]. The 
exact function is uncertain, but it appears to have a role in the late stages of 
viral production.  The E4 protein disrupts the cytoplasmic keratin network 
[40], suggesting it may have a role in release of virions. HPV1 E4 gene exists as 
multiple species [41, 42]. The E5 gene product interacts with cell membrane 
growth factor receptors, so may have a role in transformation [43]. The main 
transforming proteins are encoded by E6 and E7 (E5 is also thought to have a 
role). E6 binds and degrades p53 and E7 binds and degrades pRb [31, 44, 45].  
E7 is hypothesised to cause suprabasal cells to become permissive for DNA 
synthesis [25, 46]. However its precise role in the life cycle has yet to be 
elucidated.  Under appropriate conditions, E6 and E7 are capable of 
immortalisation and neoplastic transformation. Low risk HPV E6 and low risk 
HPV E7 have separate promoters [47], whereas high risk HPV E6 and E7 are 
transcribed from a bicistronic E6/E7 gene [47-49]. The high risk E6/E7 gene 
cassette yields full-length E6/E7 mRNA and spliced products; E6*I-IV [50, 51]. 
These splicing events are only found in high risk HPV [52]. 
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The L1 and L2 late genes are expressed at the final stages of viral production 
and encode the structural proteins of the viral particles. The L1 gene encodes 
the major capsid protein, which is the predominant molecule in the capsid 
[53]. There are 360 copies of the L1 protein, arranged in 72 pentamers in each 
viral particle [54]. L1 is relatively well conserved amongst papillomaviruses, 
has a self assembly capacity [55] and is the most antigenic of the two late 
proteins [56]. L2 is the minor capsid protein; one L2 protein is at the centre of 
each L1 pentamer and L2 is required to facilitate L1 assembly [54]. L2 is highly 
phosphorylated and binds DNA, suggesting that it may have a role in 
introducing HPV DNA to the virus particle [57]. The Long Control Region 
contains elements that direct gene expression, including the early promoter 
and transcriptional regulatory motifs and the Origin of Replication [58]. 
 
 
Gene Major Functions 
E1 Helicase activity 
E2 Regulation of E6 and E7 expression 
Transactivation of gene expression 
Tethering to mitotic chromosomes 
E4 Disruption of cytokeratin network 
E5 Interaction with growth factor signalling pathway 
E6 Inactivation of p53 
E7 Inactivation of Retinoblastoma protein 
L1 Major capsid protein 
L2 Minor capsid protein 
 
Table 1.1:  Summary of HPV Gene Major Functions  
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1.1.2 Human Papillomavirus Epidemiology 
Human papillomavirus is transmitted via skin to skin contact. It is believed 
that fomite transmission can also occur but is rare.  
 
HPV is the most common viral sexually transmitted disease. The lifetime 
likelihood of acquiring genital HPV is 75-90% [59, 60]. The highest prevalence 
of HPV infection is found in the age groups near sexual debut, where 
prevalence rates are approximately 60% [61]. This very high HPV prevalence in 
the population is in contradiction to the relatively low incidence of invasive 
cervical cancer in the population. The World Health Organisation (WHO) 
estimated the 2005 worldwide incidence of cervical cancer in females to be 
<8/100,000 in developed countries and >45/100,000 in developing countries 
[62]. Infection rates decrease with age and this has been attributed to reduced 
sexual activity, however some studies of highly exposed women, such as 
prostitutes have shown a significant decrease in HPV prevalence with age, 
despite continuously high sexual activity. This loss of viral detection indicates 
type specific immunity to reinfection [63]. 
 
Most people are unaware that they have a genital HPV infection. 1-2% of the 
population have detectable genital warts, and 2-5% of women will have a Pap 
smear indicating cell changes in the cervix [60]. Most cervical infections are 
transient, with over 80% cleared by the immune system within a few months. 
The remaining 20% persist and may go on to promote the development of 
squamous intraepithelial lesions (SIL) [64]. HPV infection is associated with 
benign lesions or invasive carcinomas depending on type [65]. HPV types 
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found preferentially in cancers are known as "high risk" and the types found 
preferentially in non-malignant lesions and warts are labelled "low risk". Both 
low risk and high risk types are involved in genital infection; HPV6 and 11 are 
commonly found in condylomas and HPV16, 18, 31 and 45 in cervical cancer. 
DNA sequence analysis has identified over 100 different types [66]. 
 
1.1.2.1 Genital Warts 
Genital human papillomavirus infection is very common. It is often sub-
clinical and usually resolves spontaneously [67]. Genital warts are caused by 
low risk HPVs, and 90-100% of genital warts are caused by HPV6 and HPV11 
[68]. Although they are benign proliferations that lead to either minor or no 
problems, they are cosmetically disfiguring and lead to adverse psychological 
symptoms. In about 40% of cases, co-infection with high risk HPV occurs [68]. 
Evidence of HPV infection is associated with a 16 fold increased risk of 
developing high-grade SIL in 6 years [69]. Genital warts are generally only 
treated at the patient’s request. However the existence of co-infection with high 
risk HPV types provides a greater rationale for treatment.  
 
1.1.2.2 Laryngeal Papillomas 
 
Ullman first described the viral aetiology of laryngeal papillomas in 1923 [70]. 
Whilst the disease is rare, papilloma is the most common benign laryngeal 
neoplasm, accounting for up to 84% of benign tumours [71]. HPV6 and HPV11 
are the most common types identified [72-74]. Laryngeal papillomatosis is a 
disabling and debilitating disease [75]. It is divided clinically into adult-onset 
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and juvenile-onset [76]. The disease can be life threatening, especially in 
children, as it can disseminate throughout the tracheobronchial tree and result 
in pulmonary papillomatosis leading to uncontrollable and fatal chest infection 
[77]. The transmission of adult-onset disease is related to possible orogenital 
spread and juvenile onset results from vertical transmission during birth [78]. 
Therefore, Caesarean section can be protective [79]. Squamous papillomas of 
the larynx are a serious clinical problem because of their location, resistance to 
treatment, relentless recurrence and tendency to spread [80-82]. 
 
1.1.2.3 Cervical Cancer 
The link between HPV and cervical cancer was first suspected over 30 years 
ago [83]. However HPV was not isolated directly from cancer biopsies until the 
1980's; HPV16 in 1983 and HPV18 in 1984 as reviewed in zur Hausen, 2000 
[12]. There have been a substantial number of epidemiological studies that 
point to high risk HPV as a primary risk factor for cervical cancer. More than 
99% of cervical cancers contain human papillomavirus DNA, [43, 84] and it 
has been identified as the major aetiological factor in cervical carcinogenesis 
[85, 86]. The International Agency for Research on Cancer (IRAC) has 
classified types 16 and 18 as definite carcinogens [64].  
 
Infection with high risk HPV is necessary, but not sufficient to cause cervical 
cancer [12, 14]. Pre-cancerous cervical dysplastic lesions are classified 
histologically as squamous intraepithelial lesions (SIL). Low grade SIL 
(cervical intraepithelial neoplasia (CIN)1) is mild dysplasia and high grade SIL 
(CIN2 and CIN3) is severe and includes carcinoma in situ [87]. The most 
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common clinical manifestation of cervical HPV infection is low-grade dysplasia 
or SIL [88]. About 60% of HPV infections spontaneously regress, 10% progress 
to high-grade SIL [89, 90].   
 
Cervical cancer has a high incidence and mortality, yet is preventable and 
curable if detected early [64]. The strongest risk factor for progression to 
neoplasia and cervical cancer is the persistence of HPV infection (repeated 
detection of HPV of the same genotype) [61]. Persistence of infection is 
dependent on the ability of the individual to clear the infection [61]. 
 
1.1.3 HPV and the Immune Response 
Bovine papillomavirus (BPV) and cotton tailed rabbit papillomavirus (CRPV) 
were used for many years as model systems to study the biology of HPV. In 
recent years, BPV, CRPV and canine oral papillomavirus (COPV) have been 
used to study vaccination the natural host. However, as the virus cannot easily 
be cultured in vitro, the immunology of HPV infection is still poorly 
understood. 
 
HPVs are strictly intraepithelial pathogens so direct exposure of 
immunocompetent cells to the virus proteins does not occur. Genital HPV is 
purely mucosal, there is no bloodstream phase and only about 50-60% of 
women develop serum antibodies [91]. This also has implications for the 
production of a vaccine. It is believed that the virus has evolved efficient 
mechanisms of immune evasion as high levels of antigen are expressed in the 
absence of a host immune response. Despite the apparent evasion of immune 
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surveillance, the immune system is important in the control of HPV infection 
and progression, and cellular immunity is of major importance in the clearance 
of HPV infections [92-94]. People with impaired cellular immunity have 
difficulty in achieving and maintaining clearance of genital warts [95]. 
Immunosuppressed women show an increased incidence and prolonged 
persistence of SIL [96] and women with a lower CD4 T-lymphocyte count have 
an increased risk of developing anogenital HPV-related lesions [97]. 
 
The immune response seen in regressing infections is consistent with a 
delayed-type hypersensitivity reaction. Infiltrates of macrophages, CD4-
positive T-helper cells or CD8-positive cytotoxic T lyphocytes have been 
observed in spontaneously regressing HPV lesions [92, 93]. Down regulation of 
HLA Class I expression and up regulation of HLA Class II expression are 
characteristic events in cervical HPV infection [98], and defects in humoral 
immunity do not appear to pre-dispose to HPV infection [99]. 
 
1.1.4 Prevention of HPV Associated Disease 
As HPV is transmitted by sexual contact it is not unreasonable to think that 
mechanical prevention of anogenital infection is the best method. This is not 
totally successful due to the presence of virus-infected cells at external genital 
sites [12]. There is evidence that the use of condoms can increase regression 
rates, indicating that continued rounds of HPV infection from a partner are a 
determinant of the outcome of sub-clinical high risk HPV infection [67]. It is 
unknown at present if this is also true for genital warts. 
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1.1.4.1 Cervical Screening 
Cervical cancer is characterised by a well-defined pre-malignant phase [100]. 
Examination of exfoliated cervical cells is used to screen for the pre-malignant 
phase. Current screening for HPV infection include the standard Papanicolaou 
(Pap) cytology test. When performed by experienced cytologists and 
gynaecologists, cervical screening has resulted in a dramatic reduction of 
cervical cancer incidence. However in the hands of less experienced 
individuals, there is a high false negative or false positive rate [12]. Moreover, 
the sensitivity of the Pap test is only 70%, this means it will be negative in 30% 
of CIN2/3 on histology [88]. In the UK, screening gives 80% protection against 
cervical intraepithelial neoplasia in the screened population [101]. Cytological 
and histological examinations do not distinguish between the few women who 
progress to invasive cancer from those who present with abnormal smears, but 
whose abnormalities will spontaneously regress [100]. There is still a need in 
the developing world for a cheap, reliable large scale screening programme. 
The Pap test can be used in conjunction with HPV DNA diagnostic tests to 
improve sensitivity and specificity however this results in increasing costs. 
 
1.1.4.2 Vaccination 
It is widely accepted that, in most cases HPV infection is cleared by 
immunological intervention and, although surface localisation of viral antigens 
does not sufficiently stimulate the immune response, vaccination with viral 
structural proteins does lead to induction of an effective immune response 
[102-104]. Currently there are no vaccines that can treat existing HPV 
infection, but there are two vaccines that have been developed for the 
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prevention of cervical cancer. Gardasil® (Merck) is a quadrivalent vaccine 
active against HPV16, HPV18, HPV11 and HPV6 [105] and Cervarix® (Glaxo 
Smith Kline) is a bivalent vaccine that protects against HPV16 and HPV18 
[106]. Both vaccines are based on Virus Like Particles (VLPs) derived from the 
L1 structural protein.  Animal studies have shown that immunisation with L1 
VLPs induces high titres of genotype-specific neutralising antibodies, which 
prevent further infection after challenge with large amounts of the relevant 
genotype [107]. Preliminary data indicates that these prophylactic HPV 
vaccines are effective in preventing infections with HPV and consequently 
epithelial abnormalities caused by the targeted HPV types [62, 108, 109].  
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1.2 Human Papillomavirus and the Cell Cycle 
 
Correct development and tissue homeostasis relies on the correct balance 
between cell division and apoptosis. Too much apoptosis leads to tissue 
atrophy as in Alzheimer’s disease and too much proliferation or too little 
apoptosis can lead to cancer. The cell cycle and apoptotic response are closely 
connected; factors that promote cell division can also promote apoptosis and 
vice versa. Control of the cell cycle and apoptosis are very complicated intricate 
systems that involve numerous genes and proteins, many with several 
opposing functions. Many of the factors involved and their roles have yet to be 
elucidated. In order to understand how HPV disrupts the cell cycle, an 
understanding of the tight controls that govern cell cycle progression and 
apoptosis in the uninfected cell is required.  
 
1.2.1 The Normal Cell Cycle 
The normal cell cycle is a very tightly controlled process, whose purpose is to 
generate genetically identical daughter cells. This is achieved in phases, namely 
G1, S, G2 then M. Interphase is the starting point of a new cell cycle. 
Interphase starts with G1, a gap phase in which the biosynthetic activities of 
cells which proceed at a high rate. During G1, the cell integrates mitogenic and 
growth inhibitory signals and decides whether to proceed, pause or exit the cell 
cycle. Replication of the genome by DNA synthesis occurs in S-phase. S-phase 
begins with the start of DNA synthesis and ends when the DNA content of the 
nucleus has doubled and the chromosomes have replicated. The cell then 
enters G2, a second gap phase. During G2 the cell prepares for division and 
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cells may arrest during this phase. G2 continues until mitosis starts, initiating 
the M-phase. M-phase consists of mitosis (nuclear division) and cytokinesis  
(cytoplasmic division). Mitosis involves chromosome segregation and division. 
During mitosis, the biosynthetic activities of cells proceed very slowly. During 
M-phase, the replicated chromosomes condense, the nuclear envelope breaks 
down, the sister chromatids separate, two new nuclei form and the cytoplasm 
divides to generate two daughter cells. Cytokinesis terminates M-phase and 
marks the beginning of the interphase of the next cell cycle. 
 
The progression and timing of cell cycle events is tightly regulated by the 
synthesis and destruction of kinase protein complexes. These complexes 
consist of a regulatory subunit known as a cyclin and a catalytic kinase subunit 
(a cyclin dependent kinase (CDK)).  During the cell cycle, the levels of cyclins 
oscillate due to periodic changes in their synthesis & destruction [110], whilst 
the CDK levels remains constant. Each cyclin is expressed in the appropriate 
phase of the cell cycle then is rapidly degraded as the cell cycle progresses. It is 
essential that each phase of the cell cycle ends before the next one starts. Entry 
into the next phase of the cell cycle is performed in an irreversible way. Specific 
cyclin/CDK complexes are involved in regulating different phases of the cell 
cycle. Cyclin D/CDK4/CDK6 is associated with G1, Cyclins E/CDK2 and 
A/CDK2/CDK1 are associated with S phase and cyclins B/CDK1 and A/CDK1 
are associated with mitosis (Figure 1.2).  
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Progression through G1/S-Phase  
Progression though G1/S-Phase is controlled by cyclins D, E and A (discussed 
in more detail in section 1.2.1.3). The first cyclins to be induced as G0 cells are 
stimulated to enter the cell cycle are the D-type cyclins [111]. Cyclin D and its 
CDK partner initiates phosphorylation of Rb, which results in the release of the 
E2F transcription factor (discussed in more detail in section 1.2.1.3). The 
products of E2F induced transcription are required for S-phase entry. In mid 
G1, cyclin E is expressed and is then activated by E2F. E2F activation of cyclin 
E enables formation of the cyclin E/CDK2 complex, [112, 113], which is 
required for progression from G1 to S-phase [114]. At the G1/S transition, 
cyclin A accumulates and then persists through S phase [115]. As the cell 
progresses into S-phase, cyclin E is degraded and cyclin A in association with 
Cyclin Associated CDK Function 
A CDK1/CDK2 S phase entry & transition 
Mitosis 
B1, B2 CDK1 G2 exit, Mitosis 
D1, D2, D3 CDK4/CDK6 G0 S 
E CDK2 G1 S 
Figure 1.2: The phases of the cell cycle and expression of cyclin proteins 
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CDK2, forms the major S-phase complex. Cyclin A is required for S-phase and 
passage through G2/M [116]. 
 
Progression through G2/M Phase 
Cyclin B expression starts during S-phase, however entry into mitosis is 
signalled by the formation of the cyclin B/CDK1. Mitosis is regulated by CDK1 
in association with cyclins A and B [117, 118], the main cyclin/CDK complex 
involved in mitosis is cyclin B/CDK1; this is known as mitosis promoting factor 
(MPF). The CDK1 component of MPF is constitutively present and therefore it 
is the accumulation and destruction of cyclin B that is phase-specific. Several 
checkpoints are involved in the control of the G2/M boundary [119, 120]. In 
particular the G2/M boundary checkpoint causes G2 arrest in response to DNA 
damage. 
 
Cell Cycle Checkpoints 
The G1/S and G2/M transitions are the two major checkpoints that are capable 
of arresting the cell cycle. Their role is to prevent the replication of damaged 
DNA and to allow DNA repair or apoptosis [115, 121]. p53 is central to the G1/S 
checkpoint that controls entry of cells into S-phase [122]. In normal cells, DNA 
damage results in an increase in p53 levels. An increase in p53 protein levels, 
results in transcription of the universal CDK inhibitor, p21. p21 binds to and 
inactivates a number of cyclin/CDK complexes preventing phosphorylation of 
Rb and the release of E2F, thereby inducing G1 arrest and preventing the cells 
from entering S-phase. This allows time for DNA repair or apoptosis.   
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Defects during cell division may lead to chromosome abnormalities, these 
defects should be detected and the cell cycle arrest in G2 phase. G2 arrest is 
bought about in part by prevention of activation of cyclin B/CDK1 via 
inhibition of cdc25 [123, 124]. p53 is also involved in G2 arrest. In G2 arrest 
p53 protein expression leads to a decrease in the levels in cyclin B protein by 
attenuation of the activity of the cyclin B promoter [125]. 
 
1.2.1.1 Cyclin/CDK Complexes 
The cyclins were first identified in 1983 in sea urchin egg extract [126]. Nine 
cyclins (A-I) have been identified to date, they very in size from 30-80 kDa  
[127, 128]. They are a large diverse family of proteins that contain a domain 
known as the cyclin box, a homologous region of 100 residues, that is necessary 
to bind and activate CDKs [115, 129, 130]. Cyclins are initially regulated at the 
transcriptional level but, once expressed, are regulated by the level of protein 
abundance, localisation and phosphorylation.  
 
Eight members of the CDK family have been identified to date as reviewed in 
[127, 131, 132]. CDK proteins range in size from 30-40 kDa and share 
approximately 40% homology [133]. CDKs are only active when bound to their 
corresponding cyclin partner. The timing of cyclin expression largely dictates 
CDK activity [134, 135]. Cellular localisation and substrate specificity of the 
CDK is modulated by the cyclin subunit [129, 136].  
 
The binding of CDK to a cyclin results in a conformational change [137, 138].  
This change in conformation re-orientates ATP [133], which allows the transfer 
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of a "-phosphate from ATP to the serine or threonine-hydroxyl group of a 
protein target, which will either result in the gain or loss of function [139].   
 
Cyclins and CDKs are also involved in transcription regulation, DNA repair, 
differentiation and apoptosis [115], [140].  
 
1.2.1.2 Regulation of CDK/Cyclin Complex 
 
There are four major ways in which the CDK/cyclin complexes are regulated; 
1. Association of CDK and cyclin (cyclin activates CDK) 
2. Phosphorylation 
3. Proteolytic degradation 
4. Binding to cyclin dependent kinase inhibitors (CDKIs).  
 
1.2.1.2.1 Association of CDK and Cyclin 
Whilst each cyclin associates with one or two CDKS and each CDK associates 
with one or two cyclins, stoichiometry of cyclin to CDK partner is one to one. 
For example, CDK1 can bind to cyclin A or B and CDK2 can bind to cyclin A or 
E [140]. The various cyclin/CDK complexes perform three functions; 
1. Activation of cellular activities associated with that particular phase in 
the cell cycle 
2. Activation of the cyclin/CDK complex controlling the next stage in the 
cycle 
3. Inactivation of the cyclin/CDK complex from the previous stage 
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1.2.1.2.2 Phosphorylation 
Formation of the CDK/cyclin complex is regulated by both protein-protein 
interactions and by reversible phosphorylation [133]. Upon association with its 
appropriate cyclin, the CDK displays basal activity. Complete activation 
requires phosphorylation at a conserved threonine that is proximal to the ATP-
binding cleft located in its T-loop to fully open its catalytic cleft [141, 142]. This 
is achieved by the CDK-activating kinase (CAK) [143, 144]. The phosphate is 
removed by the phosphatase KAP after the cyclin partner has been degraded 
[121]. 
 
Phosphorylation on one or two residues in the ATP-binding site of the CDK can 
keep the cyclin/CDK complex in an inactive state [121].  Activation is achieved 
by removal of the phosphate group from the ATP-binding site on the CDK by 
members of the Cdc25 family of phosphatases [121]. 
 
1.2.1.2.3. Proteolytic Degradation 
The main pathway employed for the degradation of cell cycle components is 
the ubiquitin-mediated proteasome system. In 1991, Glozter et al., [145] 
demonstrated that cyclin B was targeted for destruction by ubiquitination. Two 
major proteolytic systems are involved in regulating the cell cycle; ligase 
activation and substrate activation. Ligase activation is carried out by 
anaphase-promoting complex (APC). Substrate activation is carried out by 
Skp1/Cullin/F-box proteins (SCF).  SCF recognises phosphorylated substrates, 
whereas the APC directly recognises substrates. Both are E3 complexes that 
facilitate the transfer of ubquitin from the active site of an E2 enzyme to a 
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substrate, marking it for destruction by the 26S proteosome [146]. Both 
complexes share a core organisation; the association of a cullin-like protein 
with a protein containing a zinc finger domain [146].  
 
The SCF complex is employed at the end of G1, through S-phase and into early 
G2; G1 cyclins are ubiquitinated by the SCF, whereas the APC is active at the 
end of G2 and mediates the transition through mitosis; SCF targets include 
cyclin E, p27 and p21 [147-149]. APC targets include the mitotic cyclins, cyclin 
A and B [150-152]. A family of proteins containing an F-box sequence motif 
[153] provide target specificity for SCF. Whereas proteins containing WD-4o 
repeats provide target specificity for the APC [154, 155]. 
 
1.2.1.2.4 Binding to Cyclin Dependant Kinase Inhibitors  
Seven CDKIs have been identified to date [156]. They are divided into two 
families, the Cip/Kip family and the INK4 family. Members of the Cip/Kip 
family interact with all CDK/cyclin complexes; The INK4 family interact with 
specific CDKs. 
 
The Cip/Kip family bind to preformed cyclin/CDK complexes [157, 158], family 
members include p21, p27 and p57. In vitro they have been shown to block the 
activities of all cyclin/CDK, with different potencies [157].  
 
The INK4 family interact with specific CDKs, family members include p16INK4a, 
p15INK4b, p18INK4c and p19INK4d. The INK4a locus contains two overlapping 
genes, p16INK4a (p16) and p14ARF (Alternative Reading Frame) (p14); both have 
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identical exons two and three, but different promoters and a different first 
exon. Due to frameshifting, the amino acid sequences are not related, however 
both function as tumour suppressors [159, 160]. The INK4 family bind 
monomeric CDK4 or CDK6 [161, 162] at a site that overlaps with the region 
required for cyclin binding [163]. They inhibit the cyclin/CDK complexes 
involving CDK4, CDK6 and cyclin D and are expressed at mid-G1 phase. 
 
1.2.1.3 Cell Cycle Regulatory Proteins Relevant to This 
Study 
 
1.2.1.3.1 Cyclin D 
The D cyclins are the first to be induced as G0 cells are stimulated to enter the 
cell cycle [111]. D cyclins link mitogenic stimuli and the cell cycle machinery 
[164].  They are unique in that they respond to external signals, such as growth 
factors and unlike other cyclins, the levels of cyclin D do not oscillate; the level 
is controlled by the presence of growth factors including; epidermal growth 
factor, insulin growth factors I and II, and hormones [165, 166]. The binding of 
growth factors to receptors initiates a signal transduction pathway that 
activates transcription factors that are responsible for the transcription of 
cyclin D, for example AP-1, ATF3 and Myc [167, 168]. The signal transduction 
pathway varies, however it is thought the MAP kinase pathway is involved 
[169].  
 
Cyclin D associates with and activates CDK4 and CDK6 [115]. Cyclin D and its 
CDK partners target the tumour suppressor protein retinoblastoma (Rb) and 
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Rb-related proteins; p107 and p130 (Rb pocket proteins) for phosphorylation 
[170, 171].  Phosphorylation of Rb by D-type cyclins and their CDK partners 
results in the dissociation of Rb from the E2F family proteins.  The E2F family 
of proteins are transcription factors that play a critical role in the regulation of 
the cell cycle (discussed further in Section 1.2.1.3.4). Once the activating E2Fs 
are released from their pRb-mediated inhibition, they are able to bind to the 
promoters of their target genes and activate transcription [172]. The expression 
of E2F-regulated gene products are required for S-phase entry [115]. Cells 
lacking Rb do not require cyclin D/CDK activity for cell cycle progression [173].  
 
Cyclin D has been shown to interact directly with oestrogen receptor, causing 
up regulation, transcription, and stimulating proliferation [174]. 
CyclinD/CDK4 also tethers the Kip/Cip family of cyclin dependent kinase 
inhibitors, relieving cyclin E/CDK2 from Kip constraint later in the cycle [175], 
[176].  
 
1.2.1.3.2 Cyclin E 
Cyclin E is expressed in mid G1, peaks at the G1/S boundary [177] and is rate 
limiting for the passage through G1 [178, 179]. It is activated by E2F1 and, if 
E2F1 is not active, cyclin E is not expressed [180]. Activation of cyclin E 
enables formation of the cyclin E/CDK2 complex, [112, 113]. The cyclin 
E/CDK2 protein complex is required for progression from G1 to S-phase [114]. 
Cyclin E/CDK2 phosphorylates the Rb family members on different sites to 
that of cyclin D [181] and it is thought this dual phosphorylation is required for 
full inactivation of the Rb proteins [182-184]. Cyclin E also participates in 
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maintaining Rb in its hyperphosphorylated state [185], forming a positive feed 
back loop and further enabling activation of  other E2F responsive genes, 
including cyclin A [186].  
 
Cyclin E activity is still required in cells lacking Rb [114], cyclin-E induced S-
phase and completion of the cell cycle can occur in the absence of E2F-
mediated transcription [187], suggesting there may be additional critical 
substrates for cyclin E/CDK2. Expression of c-myc and ras can induce cyclin E 
kinase activity and S-phase transition by antagonising cyclin E/CDK2 inhibitor 
p27 [187]. 
 
Cyclin E is normally expressed during a defined window at the G1-S transition. 
This tight window of expression is controlled by periodic transcription [188] 
and self-phosphorylation [189]. In yeasts and higher eukaryotes, repression of 
cyclin E is mediated by a multi-protein complex. A complex containing 
hypophosphorylated pRb, histone deacetylase (HDAC) and SWI/SNF is 
recruited to E2F-transcription factors bound to the cyclin E promoter and this 
acts to silence transcription [190]. 
 
Cyclin E/CDK2 also phosphorylates histone H1 and thus may be important in 
chromatin rearrangement required during genome replication [115]. 
Dysregulation of cyclin E expression leads to chromosome instability [191]. 
Insufficient cyclin E results in G1 arrest whereas over-expression results in 
premature S-phase entry and genomic instability [114, 191].  
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1.2.1.3.3 Cyclin A 
Cyclin A is expressed soon after cyclin E. It accumulates at the G1/S transition 
and persists through S phase [115]. It is required for S-phase entry and passage 
through the G2/M checkpoint [116]. Cyclin A binds to CDK2 as soon as cyclin E 
levels decrease, and then, in late S-phase, to CDK1. Cyclin A is regulated in part 
by the E2F transcription family [192] and participates in a negative feed back 
loop for E2F regulation [115]. 
 
Cyclin A/CDK2 is known to phosphorylate Cdc-6 [193]. Phosphorylation 
regulates sub-cellular location and phosphorylated Cdc-6 relocates from the 
nucleus to the cytoplasm. Hence, Cyclin A/CDK2 phosphorylation of Cdc-6 has 
been implicated in the prevention of the re-replication of DNA [193].  
 
Cyclin A/CDK2 also phosphorylates Skp2 and Cdc-20, two components of the 
proteolytic pathway involved in progression of the cell cycle [194, 195]. Skp2  is 
a mediator of ubiquitin dependent proteolysis of  cyclin A and an important 
regulator of S-phase [194]. Cdc-20 binds and activates the APC. APC 
ubiquitination of substrates is involved in exit from mitosis [195]. Data 
suggests Cdc-20-cyclin A interaction is specifically involved in APC mediated 
degradation of cyclin A [195]. Cyclin A degradation proceeds cyclin B 
degradation. It has also been suggested that Cdc-20 function could be 
regulated through phosphorylation by cyclin A/CDK2 [195]. These findings 
indicate cyclin A/CDK2 are key factors in the prevention of 
premature/inappropriate activation of APC. Whilst the functional 
  27 
consequences of Cdc20-phosphorylation by cyclin A are unclear, it is suggested 
that is affects the sub-cellular location [195]. 
 
Depletion of cyclin A from G1 cells results in inhibition of DNA synthesis [196] 
and over-expression causes premature entry into S phase [197]. Cyclin A has 
been found to co-localise with sites of DNA replication [115], and cyclin 
A/CDK2 is involved in apoptosis [198, 199]. 
 
1.2.1.3.4 Cyclin B 
Cyclin B expression starts during S-phase. Whilst cyclin B is expressed in late 
S-phase, cyclin B/CDK1 complexes only become active in late G2, when it is 
required for entry into mitosis [200, 201]. Mitosis is regulated by CDK1 in 
association with cyclins A and B [117, 118].  
 
Cyclin B/CDK1 is located in the cytoplasm late in S-phase, but relocates to the 
nucleus just prior to mitosis [117]. To prevent premature mitosis the cyclin 
B/CDK1 complex is inactivated by phosphorylation of CDK1 [202]. Activation 
of CDK1 requires de-phosphorylation [203].  
 
Cyclin B and its CDK partner regulate most of the processes during mitosis, 
including chromosome condensation and segregation [196]. For cells to exit 
mitosis, cyclins A and B must be degraded [115]. Cyclin B/CDK1 is able to 
prevent DNA replication. Cyclin B/CDK1 phosphorylates mini-chromosome 
maintenance protein-4 (MCM-4) blocking its interaction with DNA [204]. 
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Whilst cyclin B is a positive regulator of the G2-M transition, proteolysis of 
cyclin B is necessary for cells to exit mitosis, [205, 206] this demonstrates that 
cyclins can possess both positive and negative regulatory roles. Cyclin B 
degradation is regulated by the APC and Cdc-20 [207]. Previous work has 
suggested that cyclin B/CDK1 is involved in the regulation of this degradation 
[115].  
 
Cyclin A and cyclin B in association with CDK1 also phosphorylate some 
cytoskeletal proteins such as lamins, histone H1 [115]. This ultimately results in 
the disassembly of lamin polymers as the cell enters mitosis [208]. 
 
1.2.1.3.5 CDK Inhibitor p21 
The universal CDK inhibitor p21CIP/WAF/SD1 (p21) induces growth arrest, 
possesses pro-apoptotic functions and can prevent cells from undergoing 
apoptosis under certain conditions [209]. It has an essential role in cell cycle 
arrest following DNA damage [210]. Cell cycle progression is inhibited by p21 
in two ways;  
1. Inhibition of cyclin/CDK complexes. 
2. Inhibition of DNA synthesis by binding Proliferating Nuclear Antigen 
(PCNA).  
Over-expression of p21 leads to arrest in G1 and G2 [211] or S-phase [212], p21 
also facilitates the transition of G1 to S-phase and G2 to M-phase [213]. Cyclin 
D1 and its CDK partner are inactivated by p21 protein. One molecule of p21 per 
complex appears to permit CDK activity whilst two molecules per complex 
inhibit kinase activity and block cell cycle progression [214]. p21 can bind and 
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inactivate cyclin A/CDK2 complexes [209]. p21 binds to PCNA, and the 
resulting p21-PCNA complex blocks the role of PCNA in the DNA polymerase 
complex, thus preventing its action in DNA replication (but not its role in DNA 
repair) [214]. p21 has also been implicated in terminal differentiation and 
senescence [215]. The mechanisms by which it prevents cells from undergoing 
apoptosis are to date not well understood [209]. 
 
1.2.1.3.6 Tumour Suppressor p53 
The p53 protein is a transcription factor that can inhibit cell cycle progression 
or induce apoptosis in response to DNA damage.  The downstream pathways 
mediated by p53 are cell cycle regulation and apoptosis. The “Guardian of the 
Genome” was first described in 1979 [213], and was the first tumour 
suppressor gene to be identified [213]. In more than 50% of human cancers, 
p53 is dysfunctional demonstrating its importance as a tumour suppressor.  
 
p53 is normally "off" and is activated in response to cell stress or damage. Tight 
regulation of its activation is imperative for preventing tumourigenesis and 
maintaining normal cell growth. The protein is kept at a low concentration in 
the cell by its relatively short half-life (about 20 minutes) [214]. The amount of 
p53 in the cells is determined by the degradation rate, not the production rate. 
It is accepted that p53 is ubiquitinated in the nucleus, shuttled to the 
cytoplasm (directly or indirectly) by MDM2, then recognised by the 26S 
proteosome for degradation. DNA damage stops this ubiquitination process, 
resulting in the accumulation of p53 [216]. Following exposure to genotoxic 
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and non genotoxic stress, p53 is stabilised, accumulates in the nucleus and 
forms tetramers, capable of binding DNA [217].  
 
There are at least three independent ways in which the p53 network can be 
activated; 
1. DNA damage 
2. Aberrant growth signals 
3. Induction: by chemotherapeutic drugs, UV light, protein kinase 
inhibitors 
Once activated, p53 regulates the expression of genes involved in cell cycle 
arrest or apoptosis. Cells containing mutant p53 no longer undergo apoptosis 
or cell cycle arrest in response to cellular damage. p53 activity is regulated by 
post transactional modifications [216]. These include stabilisation, 
ubiquitination, phosphorylation and acetylation, and these modifications affect 
the overall structure and activity of p53 [216]. The modification profile of p53 
drives towards a particular cell response [216]. The post-translational 
modifications result in a change in confirmation, which results in a change in 
folding, allowing access to the DNA binding domains. These conformational 
changes can also be brought about by antibodies, drugs and peptides [218]. 
Accumulation of p53 is associated with transcription of p53 responsive genes, 
including Bax (BCL2 associated X protein), p21 and GADD45 [219], which are 
associated with growth arrest and apoptosis, and MDM2, involved in control of 
p53 levels via a feedback loop [220].  
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1.2.1.3.3 MDM2 
The murine double minute gene 2 was first described in 1987 as one of the 
genes amplified on the double minute chromosomes present in a 
spontaneously transformed murine cell line, 3T3DM [221]. MDM2 is a key 
negative regulator that inhibits p53 and, in 1992, it was observed that over 
expression of MDM2 led to the inhibition of p53-mediated transactivation 
[222]. MDM2 is a key target of p53 and p53 activity is kept under tight control 
by MDM2 [223].  
 
p14ARF is the predominant regulator of MDM2 [213, 216]; MDM2-mediated 
p53 degradation is abrogated by increased expression of p14 and p14 directly 
inhibits MDM2 [224]. p14 can bind to the central/C-terminal portion of the 
MDM2 protein. It usually localises to the nucleolus and sequesters MDM2 in 
the nucleolus away from p53. Through its interaction with MDM2, the MDM2-
p53 auto-regulatory feedback loop is disturbed, leading to increased p53. p14 is 
regulated primarily at the transcriptional level and is independent of p53 and 
MDM2 [213]. 
 
MDM2 is thought to exert its control over p53 via an autoregulatory feed back 
loop [213, 217, 225]. The actual mode of control is still not fully understood. 
p53 binds to the regulatory region of MDM2 and stimulates RNA transcription, 
MDM2 mRNA is then translated into protein and the MDM2 protein binds to 
p53 and stimulates p53 ubiquitination. The subsequent degradation of p53 
reduces transcription of the MDM2 gene, allowing p53 levels to rise again and 
completing the loop. This is a basic model, as additional regulatory steps must 
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be imposed and lag times involved, otherwise a steady state situation would 
occur [225]. 
 
p53 activation of MDM2 expression leads to repression of p53 by three 
mechanisms [226]; 
1. MDM2 binds to the transactivation domain of p53 and blocks its ability 
to modulate transcription 
2. MDM2 promotes the nuclear export of p53 
3. MDM2 serves as a ubiquitin ligase that promotes p53 degradation 
 
MDM2 and p53 accumulate in the nuclei of stressed cells [217]. Stommel and 
Wahl, 2004 [217] propose DNA damage-induced degradation of MDM2 as the 
mechanism by which p53 is activated, based on the following findings; DNA 
damaging agents rapidly destabilise MDM2, MDM2 destabilisation correlates 
with and is necessary for p53 transcription activation, MDM2 destabilisation 
requires DNA damage-dependent PI-3 kinase family members; and the half-
life of MDM2 in DNA damaged cells is as short as 5 minutes. 
 
Increasingly, literature suggests that the auto-regulatory feedback loop is just a 
naive model of the interaction, and the fate of cells is dependent on the relative 
ratios of MDM2 and p53 or the stabilities of the proteins. Whatever the specific 
mechanism is, MDM2 and p53 are maintained in an antagonistic relationship 
in which MDM2 neutralises its partner p53 [225]. 
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1.2.1.3.4 Retinoblastoma Pathway 
The Retinoblatoma protein (Rb) pathway involves interactions between 
Rb/E2F, cyclin D/CDKs and p16INK4A and is central to the regulation of the 
G1/S transition [214]. 
 
Rb is a member of the ‘pocket protein’ family, which also includes Rb 
homologues, p107 and p130. The Rb family of tumour suppressor genes play a 
pivotal role in host cell cycle regulation [227]. Rb has a critical role in 
regulating G1 progression and is a key component of the molecular network 
controlling the G1/S restriction point. Rb has been shown to bind and regulate 
a large number of cellular proteins, including members of the E2F family of 
transcription factors [228].  
 
E2F is a heterodimeric transcription factor, implicated in cell cycle control in 
many organisms. To bind DNA, E2F proteins form obligate heterodimers with 
a related family of DP proteins [229, 230]. Each sub-unit is encoded by several 
genes, creating a family of different E2F proteins [230, 231]. E2F binding sites 
are found in the promoters of several replication genes (reviewed in [180]). 
Hence, E2F is thought to control cell-cycle progression via transcriptional 
activation of genes for DNA synthesis [232, 233]. E2F/DP heterodimers can 
act as both activators and repressors of transcription [234]. Repression is due 
to the recruitment of Rb proteins to promoters [235, 236], and is thought to 
antagonise gene expression through histone deacetylation and chromosome 
remodelling [237, 238]. 
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The interaction between E2F and the pocket proteins is controlled by CDK-
dependent phosphorylation [239]. INK4a family member, p16 is a negative 
regulator of cyclin D/CDK4 [214], the major target of cyclin D/CDK4 is the Rb 
protein. Over expression of p16 in cells with a functional Rb results in G1 arrest 
(it has no effect in Rb negative cells) [173]. The main regulation of intracellular 
levels occurs at the transcriptional level and p16 mRNA is very stable [240]. 
Accumulation of p16 mRNA and protein have been reported in response to 
inactivation of the Rb protein [161, 241], but p16 expression does not simply 
reflect the status of Rb. p16 expression remains constant during the transition 
from quiescence to proliferation and during cell cycle progression [242]. It is 
possible that induction of p16 expression occurs only after prolonged 
proliferation in the absence of functional Rb [243]. Inactivation of p53 can also 
result in up regulation of p16 [240].  
 
In quiescent cells, hypophosphorylated Rb and p130 are present in complexes 
with the E2F family of transcription factors [244, 245]. Binding to E2F inhibits 
transcriptional activation capacity and, in some cases, converts E2F factors 
from transcriptional activators to transcriptional repressors [115]. Rb is 
phosphorylated by CDKs in the mid-to-late G1 phase of the cell cycle.  
Phosphorylation of pocket proteins Rb and p130 results in the release of E2F 
proteins and allows them to act as activators of transcription. The Rb protein 
regulates E2F/DP transcription factor complexes; E2F1, E2F2 and E2F3 and 
DP1, DP2 and DP3 [214]. E2F target genes that are up-regulated as a result of 
Rb inactivation include genes required for the completion of the G1/S-phase 
transition as well as genes necessary for DNA replication, including cyclins E 
and A, CDK1, PCNA, dihydrofolate reductase, thymidine kinase and DNA 
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polymerase ! [115, 160, 214, 246]. E2F and cyclin E are thought to collaborate 
to elicit the onset of S-phase, and their activities may converge at the point of 
initiation of DNA replication [247, 248]. Deregulated E2F activity can trigger 
the initiation of DNA replication [249]. 
 
1.2.1.3.5 Ki67 
Ki67 is a large (395kDa) nucleolar phosphoprotein, expression of which is 
tightly linked to the cell cycle [250, 251]. It shares structural similarities to 
other proteins involved in cell cycle regulation (forkhead-association domain) 
[252]. Ki67 protein is not detectable in non-cycling cells [253] and is 
commonly used as an indicator of proliferation. Ki67 is present in S, G2 and M 
phases, but is absent in G0 and expression in G1 varies; cells passing from G1 
to G0 lack Ki67 but cells that enter G1 after M-phase express Ki67 [253]. The 
functions of this protein have yet to be defined [254]. Whilst it localises to the 
nucleolus, its absence in non-proliferating cells shows that it is not essential for 
nucleolar function. Experiments have suggested that it is essential for DNA 
replication [255, 256], has a novel DNA binding activity  [254] and may have a 
role in ribosome biogenesis [257]. Ki67 location within the nucleolus is very 
dynamic [258] and the alteration in sub-cellular localisation during the cell 
cycle is accompanied by changes in phosphorylation [251]. 
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1.2.2 Apoptosis 
Programmed cell death [259] is manifested as apoptosis [260]. It is an 
essential component of normal development and homeostasis and is critical for 
the elimination of diseased, infected or damaged cells. Insufficient apoptosis 
can manifest as cancer or auto-immunity, whilst accelerated cell death is 
evident in acute and chronic degenerative diseases, immunodeficiency and 
infertility. Every cell in the body is capable of expressing the components of the 
apoptotic pathways and as a result is able to undergo rapid self-destruction. 
Embryonic studies have shown mutations in the key components of the 
apoptotic pathways are lethal. Apoptosis can be induced by a wide range of 
different intrinsic signals such as nutrient depletion, hypoxia or 
chemotherapeutic drugs [261]. The natural apoptosis pathway is switched on 
by the engagement of apoptosis-inducing ligands to their corresponding 
receptors [262]. 
 
The morphological features of apoptosis are distinct from the features 
observed in cells undergoing pathological, necrotic death [263]. Apoptotic cells 
effectively package themselves up into small membrane bound vesicles. They 
lose substrate attachment and become rounded. The cell shrinks and 
chromatin condenses, membrane blebbing can be seen. The DNA is 
fragmented into lengths of approximately 200bp. During the final stages of 
apoptosis, the cell is broken into multiple apoptotic bodies and these are 
phagocytosed. The morphological changes seen are caused by a set of cysteine 
proteases, specifically activated during apoptosis, known as the caspases [263].  
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1.2.2.1 Caspase Cascade 
The caspase cascade is the central machinery of apoptosis. Caspases are highly 
conserved throughout evolution. Over a dozen have been identified in humans 
and about two thirds function in apoptosis [264]. The caspases, which are 
ubiquitously expressed, participate in a cascade, triggered in response to 
apoptotic signals [265]. The finale is the disassembly of the cell brought about 
by the cleavage of a set of proteins. Once activated the caspases cleave a variety 
of polypeptides, including major structural elements of the cytoplasm, the 
nucleus and components of the DNA repair machinery [264]. Activated 
caspases selectively cleave a set of proteins, which results in inactivation of the 
target protein. Caspases can also activate proteins directly by cleaving off a 
negative regulatory domain, or indirectly by inactivating a regulatory subunit 
[263]. Two major types of caspase exist; initiator caspases and effector 
caspases. Initiator caspases are activated through regulated protein-protein 
interactions and effector caspases are usually activated by an upstream caspase 
[263]. Initiator caspases are regulated by their association with cofactors; they 
activate the effector caspases by the proteolytic cleavage of an effector pro-
caspase. It is the effector caspases that are responsible for disassembling the 
cells. 
 
Two alternate pathways initiate the apoptotic response; the mitochondrial or 
'intrinsic' pathway and the death receptor or 'extrinsic' pathway [262] (Figure 
1.3). The selection of pathway is dependent on the amount of active caspase-8 
formed at the death-inducing signalling complex (DISC) [262]. In some cells, 
the amount of active caspase-8 is sufficient to directly initiate apoptosis; these 
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are known as type I cells. In type II cells the amount is insufficient and 
mitochondria are used as amplifiers [262]. The different "death signals" exert 
very different effects on different cell types and the resultant response depends 
on the signals perceived and proteins expressed by the cell. 
 
The Mitochondrial Pathway 
The BCL2 family of proteins are the central regulators in the mitochondrial 
pathway. BCL2 inhibits apoptosis, by binding to and inhibiting Apoptotic 
protease activity factor 1 (Apaf) protein. This prevents Apaf from activating 
pro-caspase-9, the major initiator caspase involved in the mitochondrial 
pathway (activates caspase-3). Bax is a member of the BCL2 family. It is 
thought that the binding of Bax to BCL2 results in the release of Apaf allowing 
activation of caspase-9 leading to apoptosis. 
 
The Death Receptor Pathway 
 
Death receptors are members of a sub-family of the tumour necrosis factor 
(TNF) receptor family, and they are characterised by an intracellular domain 
known as the death domain [266]. Death receptors are activated by their 
natural ligands, the TNF family [262]. Death receptors include CD95, TNF-
related apoptosis-inducing ligand-R TRAIL1 and TRAIL2. When the ligands 
bind their death receptors, the death domains attract FADD (Fas associated 
death domain protein). FADD is an intracellular adaptor protein, which 
recruits inactive proforms of certain members of the caspase protease family 
[262]. Caspase-8 and caspase-10 are recruited to the DISC. These function as 
initiator caspases, are cleaved at the DISC and yield active initiator caspases 
[262].  
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The apoptotic machinery is under tight control, regulated by various proteins 
at different levels [262]. FADD-like interleukin-1 B-converting enzyme-like 
proteases (FLICE/caspase-8) inhibitory proteins or FLIPs, interfere with the 
initiation of apoptosis by directly interfering with death receptors [267]. FLIPs 
bind to the DISC, inhibiting the processing and activation of initiator caspase-8 
[262]. BCL2 family members influence the permeability of the mitochondrial 
membrane. They are divided into anti-apoptotic and pro-apoptotic types 
according to their function [268]. Inhibitor of apoptosis proteins (IAPs) bind 
to and inhibit caspases. They may also function as ubiquitin ligases [262]. The 
natural (CD95/TNF) mediated apoptosis can be inhibited by FLICE/caspase-8 
inhibitory proteins and type II cell death can be inhibited by over expression of 
BCL-2 or BCLXL [269]. 
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Intrinsic Pathway 
 
Extrinsic Pathway 
 
Figure 1.3: The two alternate apoptotic pathways. 
Initiator caspases include; caspase 2, 8, 9 and 10, effector caspases 
include caspase 3, 6 and 7 and cleaved cytokeratin is an example of a 
death substrate. 
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1.2.3 The Effects of HPV Infection on the Cell Cycle 
and Apoptosis 
 
In order to achieve a productive viral infection, HPVs subvert key host cell 
cycle regulatory factors, resulting in the re-activation of cellular DNA 
replication machinery in differentiated keratinocytes.  
 
1.2.3.1 Functions of Early Genes 
1.2.3.1.2 HPV E1 
The E1 gene encodes the largest of the HPV proteins, a nuclear phosphoprotein 
that is essential for HPV replication. Over expression of Bovine E1 has been 
shown to result in a decrease in the duration of G1 and increase in the duration 
of S and G2 phases via a cyclin D1-dependent pathway [270]. 
 
E1 protein has ATP-binding helicase activity and interacts with numerous 
components of the DNA replication machinery, including DNA 
polymerase/primase and replication protein A (RP-A) [271, 272]. E1 binds 
cyclin E and a reduction in binding to cyclin E results in significant reduction 
in HPV replication [273].  E1 is recruited by E2 and subsequently binds with 
high affinity to the viral origin of replication located in the LCR [274]. 
 
1.2.3.1.2 HPV E2 
E2 is a multifunctional protein, required throughout the viral life cycle [275, 
276]. It is involved in the inhibition of E6 and E7 expression and E2 can both 
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promote and inhibit apoptosis.  E2 has a role in regulating viral and cellular 
replication by abrogation of a mitotic checkpoint [277].  
 
The HPV E2 protein has three distinct domains that can be expressed 
separately and still retain their function [278]; a conserved N-terminus and C-
terminus, separated by a hinge region [279]. The N-terminus is a 
transactivation domain that serves as a platform for cellular transcription 
factors [280, 281]. The C-terminus forms a DNA binding and dimerisation 
domain [282, 283]. The E2 protein product is a transcription factor that 
regulates the transcription of E6 and E7 [38]. E2 binds to sites adjacent to the 
promoter responsible for E6 and E7 transcription (P67 in HPV16) [27]. 
Increased expression of E2 results in repression of E6 and E7. Conversely, 
disruption of the E2 repressor gene by viral integration results in the loss of 
transcriptional regulation. This in turn results in up-regulation of expression of 
the transforming proteins E6/E7 [284]. E2 is reported to have both pro-
apoptotic and anti-apoptotic functions. In high risk HPV infections, it has been 
shown to induce apoptosis above a threshold level [285] and E2 mediated cell 
death appears to be a result of E2 activation of caspase-8 [286]. In HPV18, E2 
activates apoptosis via caspase-8 activation, (unpublished from [37]). E2 also 
tethers the HPV episomes to host DNA during mitosis; E2 anchors the viral 
episomes to mitotic chromosomes and is critical for correct segregation [287]. 
High risk E2 is also reported to have a role in host genomic instability [288]. 
E2 expression has been associated with S phase arrest and re-replication of 
cellular DNA. Over expression of E2 results in an increase in genome copy 
number, suggestive of multiple rounds of replication in the absence of a mitotic 
event; and an increase in cyclins A and E [277]. Decreased levels of p53 have 
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been observed in cells expressing high levels of E2, suggesting possible 
abrogation of p53 function [277]. Cells that lose E2 expression as a result of 
integration show a selective survival advantage [61].  It is widely accepted that 
loss of E2 expression in high risk HPV infections is a key event in the 
progression to cancer. 
 
1.2.3.1.3 HPV E4 
The function of HPV E4 is not known, and different activities have been 
reported for various HPV types. Over-expression studies have revealed that it 
is involved in replication [41, 289-291], release of virions [40, 288, 292, 293] 
and apoptosis [294].  
 
E4 protein is expressed late in infection, from a differentiation-dependent 
promoter, upstream of the E1 gene [295]. The E4 protein is translated from 
spliced E1^E4 transcripts, in which the first five amino acids from the E1 
protein are fused to the E4 coding sequence [39]. Both the E1^E4 and L1 
proteins of HPV11 are encoded on a bicistronic E1^E4^L1 transcript [296, 
297]. The E1 and E4 mRNAs share the same initiation codon and it has been 
suggested that splice site selection controls the relative abundances [298]. 
HPV1 E1^E4 protein is post-transcriptionally modified during terminal 
differentiation by phosphorylation [299] and removal of sequences from the N-
terminus [300, 301]. Co-localisation of HPV11 E1^E4 and L1 in differentiated 
keratinocytes was reported by Bryan & Brown, 2000 [293], who suggest a role 
for the E1^E4 protein in the late stages of the viral development cycle [293]. 
HPV 16 E1^E4 associates with the cytokeratin network, causing it to collapse 
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[40] and it has been shown to associate with mitochondria and induce 
apoptosis [294]. E4 is the most abundantly expressed HPV protein in 
productive HPV infection and E1^E4 accumulates in differentiating cells of the 
upper epithelial layers [294].  Whilst transcripts are present at low levels in 
undifferentiated cells and there is very low level translation, transcripts are up 
regulated upon cellular differentiation [291].  
 
1.2.3.1.4 HPV E5 
HPV E5 function is not well characterised. Its structure is similar to Bovine 
papillomavirus (BPV) E5 [303], which functions as a cell transforming protein, 
exerting its effects via stimulation of growth factor receptor signal transduction 
pathways [304].  
 
The HPV16 E5 gene encodes a small hydrophobic protein, typically found in 
membrane compartments, including the Golgi [305]. It has been reported to 
associate with epidermal growth factor receptor [306] and acts as a 
transforming protein in some papillomaviruses [307]. A study by Schiffman et 
al., 2005 [308] reports that high risk HPV types code for an E5 protein, 
whereas most low risk types either lack a definable homologous E5 ORF 
and/or a translation start codon for E5. However one study reports that HPV6 
E5a genes can transform NIH 3T3 cells [309].  The E5 protein is able to reduce 
the amount of the death receptor superfamily member, CD95 receptor, at the 
cell surface [310]. However it is likely this only occurs during low risk HPV 
infection as part of the productive virus life cycle, as E5 is often deleted in 
cervical carcinoma cells [311]. 
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1.2.3.1.5 HPV E6 
The E6 protein interacts with many cellular proteins inducing important 
changes in the host cell, E6 expression results in disruption of the cell cycle 
checkpoints [21]. It also blocks apoptosis, alters the transcription machinery 
and disturbs cell to cell interactions [227]. The expression of E6 protein results 
in the loss of p53-mediated DNA repair pathways. 
 
E6 protein complexes with the cellular protein, E6 Associated Protein (E6AP), 
a ubiquitin-3, ligase and p53, facilitating p53 degradation via the ubiquitin-
dependent proteolytic system [312]. E6AP was found to mediate the binding of 
E6 to p53 [313].  Some studies indicate that the amount of expressed E6 is 
proportionate to the inhibition of p53 activity [314, 315]. There is evidence that 
E6 also has p53-independent transforming and growth regulating activities 
[316, 317]. E6 also increases the rate of transcription of telomerase and 
vascular endothelial growth factor (VEGF) [227]; telomerase is important in 
the maintenance of telomere length, thus cell immortalisation and VEGF is 
involved in endothelial growth. E6 deregulates G2/M control by influencing 
kinase activity at a post translational step, distinct from complex formation. E6 
leads to increased CDK2 associated histone H1 kinase activity [119]. E6 protein 
proteolytically inactivates certain pro-apoptotic factors such as p53 [45], BAK 
[318], BAX [319] and c-Myc [320].  
 
E6*I is the most abundant of the high risk HPV splice products found in 
cervical carcinomas and cervical cancer lines [47, 49, 321]. E6*I has been 
shown to bind to viral E6 and cellular E6AP [52] and has an inhibitory effect 
  46 
on E6-mediated p53 degradation [322]. It has also been shown that E6*I can 
induce apoptosis in a p53-dependant manner [323]. The intracellular ratio 
between the E6 splice variants has implications for the commitment of cells to 
undergo apoptosis [261]. HPV18 E6*I can interact with both E6 and E6AP and 
prevent E6-mediated degradation of p53 [52]. Quantitative changes in E6/E6* 
stoichometry may maintain the half-life of survival proteins such as BAK and 
BAX [324]. High risk HPV E6 has been reported to interfere with TNF signal 
transduction [261]. High risk HPV also binds and targets for degradation the 
human homologue of the Drosophila discs large tumour suppressor (hDIg) 
and the membrane–associated guanylate kinase inverted (MAGI) family of 
scaffold proteins [325, 326]. 
 
1.2.3.1.6 HPV E7 
The E7 protein interacts with various host proteins that are important 
regulators of cell growth, especially those involved in transition from G1 to S 
phase [21, 227]. This interaction results in deregulation of the cell cycle, 
leading to increased cell proliferation, and high risk HPV E7 can induce 
immortalisation and transformation.  
 
E7 binds to and functionally inactivates pRb [44] and members of the 
retinoblastoma family proteins [227, 327]. E7 binding results in the 
uncontrolled release of transcriptionally active E2F from Rb. This release of 
E2F results in progression of the cell cycle and the loss of cell cycle-dependent 
regulation of E2F responsive genes. E7 inhibits p21 by directly binding to the 
specific region corresponding to the PCNA binding site in the carboxy terminus 
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overlapping with the CDK binding site, blocking the ability of p21 to inhibit 
CDK activity and PCNA-dependent DNA replication, thus preventing the G1 to 
S phase transition [328].  E7 inactivates pRb and indirectly induces p16 
expression. p27 expression is decreased when cyclin E is activated as a result of 
E2F release. High risk HPV E7  can also bind to and inactivate p27 [329]. Both 
high risk and low risk HPV E7 can induce S phase re-entry in a fraction of post-
mitotic, differentiated cells, involving interaction with the pRb family [330]. 
Expression of E7 alone increases apoptosis [261]. E7 controls the metabolic 
half life of pRb [331]; its reduced intracellular availability may diminish its 
anti-apoptotic activity, contributing to E7 prone apoptosis. E7 can also 
attenuate the apoptotic response [332]. 
 
High risk HPV E6 and E7 oncoproteins can independently lead to the 
immortalisation of human cells. However, this is at a reduced efficiency when 
compared to combined E6/E7 [333, 334]. This indicates the complementary 
and synergistic effect of the two. E6 is impaired by p16, yet E7 can bypass this 
inhibition by directly activating cyclins A and E. E6 prevents E7 induced 
apoptosis by degrading p53 and BAK [318, 335]. E7 alone stabilises p53, blocks 
MDM2-mediated p53 degradation and in E7-expressing cells p53 remains 
nuclear [224]. 
Some clear differences between high risk and low risk HPV proteins have been 
documented. These are discussed in more detail in Section 1.2.3.5.  
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Figure 1.4: Diagram indicating HPV interaction with the cell cycle 
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1.2.3.2 Productive Viral Infection 
 
There are numerous studies available on the functions of the viral gene 
products and how they could potentially interfere with the host cell cycle and 
apoptosis machinery. This data results from over-expression studies.  Whilst 
this data is interesting, it is important to study gene function in naturally 
occurring HPV infection. To address this, the study of productive HPV 
infections is required. 
 
Early findings using antisense RNA probes for HPV6 and 11 by Stoler et al., 
1989 [19], revealed that strength of signal increased in the more differentiated 
cells of the stratified epithelium. The biggest increase in transcript levels 
accompanied the transition from stratum spinosum to stratum granulosum, 
with the koilocytes being the most transcriptionally active. They reported that 
E1 and E2 expression was very strong and restricted to the nuclei of the low 
layers, E4 and E5 ORFs were the most intensely expressed, appearing in the 
basal and parabasal cells, the E6 and E7 probes resembled E4 and E5, but with 
less intensity and L1 and L2 transcripts were always restricted to the 
superficial layers of the epithelium. They also reported viral DNA signal 
intensity increasing with increasing differentiation. They noted little or no 
signal in the basal cells and the strongest signals were observed in the 
superficial layers of the epithelium, in clefts between adjacent papillae. 
 
The productive cycle of HPV infection can be divided into three discrete 
phases; early events, late events and assembly & release. Middleton et al., 2003 
[336] proposed a model of productive infection, based on the detection of HPV 
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life cycle markers (Figure 1.5). The early events are marked by the expression 
of E6 and E7 in the lower epithelial layers. The late events are marked by the 
expression of E4, which coincides with the onset of vegetative viral genome 
amplification [302]. Cells express minichromosome maintenance (MCM) and 
E4 as they progress up the epithelium. Genome amplification is assumed to be 
limited to the region where E4 expression overlaps the expression of proteins 
necessary for DNA synthesis such as MCMs.  The expression of MCM is lost 
and cells express E4 alone. Finally cells expressing E4 and L1 or E4 alone are 
detected at the superficial layers of the epithelium. Expression of the L1 and L2 
proteins allows assembly and release of the virions [28]. 
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The use of antibody markers as indicators of the different cell cycle phases, 
have revealed that the order of the phases is conserved across different HPV 
types. However, there are major differences in the timing of expression 
between the viral types [298]. In high and low risk HPV types, the severity of 
the neoplasia is dependent upon the distribution of the viral gene products 
[336].  
Figure 1.5: Expression data suggest a model of productive HPV infection.  
Reproduced with kind permission from Middleton, Peh et al., 2003. 
 
A. The precise stage in the virus life cycle supported at any particular point is determined by 
the combination of markers expressed. The differentiated epithelium is represented 
diagrammatically on the left, and the arrows on the right represent the markers expressed.  
 
The dark blue circles represent nuclei of uninfected or non-permissive cells and the red circles 
represent E7 protein expression (as determined by MCM expression). The E4-expressing cells 
are green.  
 
The red arrow represents expression of E6 and E7 (and other early region proteins). E7 is 
expressed from the early promoter (p97 in HPV16), which also directs the expression of E6. 
The green arrow represents E4 protein expression (and other proteins whose genes lie 
downstream of the differentiation-dependent promoter (p670 in HPV16)). The orange arrow 
represents expression of L1 and L2 (the virus capsid proteins)  
 
B. The stages in the papillomavirus productive cycle as revealed by use of life cycle markers. 
The red arrow represents the distribution of cells in S phase and the turquoise arrow represents 
the distribution of amplified viral DNA (by in situ DNA hybridization).  
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1.2.3.3 Viral Integration 
In low-grade lesions, HPV genomes are present as episomes. However, during 
progression to high-grade lesions or carcinomas, the genome is found 
integrated into the host genome. Viral integration frequently results in the 
uncontrolled cellular proliferation that leads to transformation.  
 
The mechanism by which the virus integrates is still poorly understood. The 
frequency of viral integration into host chromosomes correlates with lesion 
grade, with integration a rare event in low grade SIL (CIN1) and common high 
grade SIL (CIN2/3) [86, 337]; integration can be found in almost all cervical 
carcinomas [64, 337]. When viral DNA integrates into the host, it is as a single 
copy or as multiple head to tail random repeats (concatemers). Viral 
integration results in the remodelling of both viral and host genome [65]. 
There is no pattern as to the site of integration in the host cell, though it can 
often be found at replication sites and chromosome fragile sites [65, 86]. This 
raises the possibility that integration is brought about by the host’s DNA repair 
mechanisms. The viral break point is more consistent. Integration frequently 
results in disruption of the viral E2 gene, leading to loss of function of this gene 
[338] and consequent upregulation of E6/E7 transcription. Although 
disruption of the E2 gene is the most frequently observed viral site disrupted 
by integration, it is not the only site or the only route that can lead to increased 
E6 and E7, an alternative route observed is increased stability of E6/E7 mRNA 
[284]. Amplification of viral episomal DNA has also been observed in cervical 
carcinomas; this amplification requires intact E1 and E2 demonstrating these 
ORFs are not always disrupted [86, 339]. 
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Whether viral integration is a cause or effect is a question that may never be 
answered, but it is known that integration almost always accompanies 
progression. 
 
1.2.3.4 HPV and Chromosome Aberrations 
 
Abrogation of the cell cycle checkpoints leads to defects in DNA repair and 
chromosome segregation. One of the effects of HPV infection, particularly 
linked with high risk HPV types, is the induction of genetic instability. Studies 
have shown, as the stage and grade of disease progresses, there are increasing 
abnormalities in host chromosomes [21, 261].  
 
Studies have shown chromosome instability to be linked to viral integration in 
cell lines. In early passages of the cell line studied (W12) where there is no viral 
integration, there is no chromosomal abnormality (structural or numerical), 
high-level chromosome instability developed in W12 cells after integration 
[277, 340]. At the passages when HPV is first integrated, chromosomal 
instability leading to aneusomy was observed and later passages, which contain 
integrated HPV DNA show both numerical and structural chromosomal 
instability [277]. The increasing instability is linked to increasing levels of E7 
resulting from disruption of the E2 gene. In a report looking at naturally 
infected lesions [341], chromosome imbalance was not related to the 
disruption of E2. However, E2 gene disruption was related to the presence of 
invasive disease. The authors note that numerical chromosome abnormalities 
were significantly more frequent in invasive cervical carcinoma than cervical 
intraepithelial neoplasia. This raises the possibility that the chromosome 
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instability is due to the state of the host genome following viral integration and 
not the virus. 
 
Despite the occurrence of many genetic changes, and a lot of investigation in 
this area, a pattern of change or a consistent relationship between HPV DNA 
integration and host chromosome abnormalities has yet to be established. 
 
1.2.3.5 Differences Between High and Low Risk HPV 
Types 
 
Whilst HPVs are aetiologically linked to carcinomas of the anogenital tract, the 
most common lesions associated with the virus are benign and self-limiting 
warts, condylomata and papillomas. Low risk HPV infections do not lead to 
cervical cancer, whereas high risk HPV types have been identified as causative 
agents in at least 99% of cervical cancers [78] and more than 50% of anogenital 
cancers [261]. There are many factors that may contribute to the differences in 
biological behaviour between high and low risk HPV. The following are some of 
the possible explanations. 
 
In order to act as oncogenes, high risk HPV E6 and E7 proteins are uncoupled 
from their normal function during the regular permissive life cycle [24]. The 
E6 and E7 proteins of high risk HPV bind more efficiently to the cell cycle 
regulatory proteins and interfere with the G1/S and G2/M checkpoints more 
effectively than the low risk HPV proteins [21, 342]. It is therefore possible that 
the difference between the ability of high- and low risk HPV types to induce 
immortalisation and transformation lies in their differing abilities to interact 
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with the cell cycle components. For example, increased and more widespread 
expression of p53 and p21 proteins is observed in lesions infected with low risk 
HPV compared to those infected with high risk HPV [343]. In high risk HPV 
infected tissues, there is no p53 detectable due to degradation by E6 and E6AP. 
 
High risk E7 binds to and degrades pRb thus releasing E2F, abrogating the 
need for D type cyclin kinases for cell cycle progression in cells lacking Rb 
[173]. In low risk HPV infected tissues, cyclin D1 is still required [344, 345] to 
release the E2F transcription factor from pRb to drive cell cycle progression. 
 
In low-grade dysplastic lesions, high risk HPV E6/E7 transcripts are detected 
at very low levels in the basal cells. However, in the differentiated upper layers 
of the epidermis, an increase in the levels is observed [224]. In high-grade 
lesions and cervical carcinomas, high levels of high risk HPV E6/E7 can be 
found throughout all the layers [227]. This indicates that progression of a 
lesion from low grade SIL (CIN1) to high grade SIL (CIN2/3) is accompanied 
by deregulation of the intracellular control mechanisms of HPV transcription 
in the basal cells [227], with high levels of E6 and E7 contributing to cell cycle 
dysregulation and chromosome instability. This does not occur in lesions 
infected with low risk HPVs. 
 
E2 localisation in cell lines varies according to HPV type. Low risk HPV E2 
protein is nuclear in the majority of cell lines tested, whereas high risk HPV E2 
protein was found in both nucleus and cytoplasm [37]. High risk HPV E2 
induces apoptosis via p53-dependent and independent pathways [346]. Low 
risk E2 fails to induce apoptosis [346]. 
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Differences in E4 localisation have been demonstrated, HPV16 E4 associates 
with cellular intermediate filament network and HPV11 E4 associates with the 
cornified envelope of the cells [298]. 
 
Basal cell tetrasomy is seen in lesions infected with high risk HPV but not those 
infected with low risk HPV [347].  HPV16 E6 and E7 co-operate to uncouple 
centriosome duplication from division, resulting in the induction of mitotic 
defects and genetic instability [348]. This is not seen in low risk HPV 
infections. 
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1.3 Treatment of HPV-Associated Disease 
 
The current therapies for the treatment of HPV-associated disease result in 
eradication of the dysplasia, not eradication of the infecting virus. To date 
there is no treatment that is successful in eradicating the causal agent, human 
papillomavirus itself.  
 
 
1.3.1 Treatment of Genital Warts 
If left untreated, visible genital warts may increase in size and number, remain 
the same or resolve on their own [349]. There is a perception that if genital 
warts are treated or removed they become less infective. Reduction in HPV 
viral DNA resulting from the treatment may impact on future transmission. 
Currently there is no data to indicate whether the treatment of genital warts 
eliminates infectivity so the primary goal of treatment is to alleviate symptoms 
and remove symptomatic warts. Treatment can be patient applied, for example 
topical antiproliferative agents and immunomodulators, or provider 
administered for example antiproliferative agents, immunomodulators, 
cryotherapy and destruction/excision (See Table 1.2). 
 
Pregnant women with anogenital warts are treated by ablation of the lesion by 
cryotherapy or Trichloroacetic Acid (TCA) to reduce the risk of transfer to the 
neonate during delivery. In some cases, delivery by caesarean section may be 
indicated [67]. 
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Treatment Mode of Action Administered by 
Podophyllotoxin Antiproliferative Patient 
Imiquimod Immunmodulator Patient 
Podophyllin Antiproliferative Provider 
Trichloroacetic Acid  Caustic Provider 
Bichloroacetic Acid Caustic Provider 
Cidoforvir Anti-viral Provider 
Cryotherapy Freezing Provider 
Excision Physical ablation Provider 
Photodynamic Therapy Physical ablation Provider 
 
 
 
 
1.3.2 Treatment of Anogenital Neoplasia 
The main method for the treatment of anogenital neoplasia is removal of the 
abnormal area or destruction of the abnormal cells. Methods include; laser 
therapy, “cold” coagulation (removal of abnormal cells by heat) and 
cryotherapy. Removal of the abnormal tissue then allows normal cells to grow 
in place.  
 
1.3.3 Development of Novel Therapies 
Currently, the regimens employed for the treatment for HPV-associated 
disease are ineffective, expensive, and most require a skilled physician and 
repeated application. None of the treatments described specifically targets 
human papillomavirus, the causal agent. By drawing on our understanding of 
how HPV subverts the host cell cycle control mechanisms, we can attempt to 
develop potential therapies to specifically target HPV infected cells. 
Table 1.2: Table to show examples of current therapies available 
for  the treatment of Genital Warts. 
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1.3.3.1 Activation of the p53 Pathway 
Activation of the p53 pathway is a key event in the prevention of uncontrolled 
cellular proliferation. p53-dependent apoptosis is an important mechanism 
which can suppress transformation in oncogene-expressing cells [350]. Cancer 
cells are exceptionally sensitive to p53 reactivation [351].  
 
Activation of p53 in cells with defective p53 can be achieved via; p53 gene 
therapy (delivery of wild type p53); exploitation of mutant p53 (ONYX-015 is a 
mutated adenovirus that replicates preferentially in cells with mutant p53, 
killing them) and rescuing mutant p53 [351]. 
 
Activation of p53 in cells with wild type p53 can be achieved via small molecule 
activators of the p53 response, for example, Leptomycin B (nuclear export 
inhibitor [352, 353]) and Roscovitine (CDK inhibitor [354, 355]). Or direct 
activation of p53 via non-genotoxic activation, for example MDM2-
antagonisits [351]. 
 
 
It is widely accepted that blocking E6 mediated degradation and thus 
reactivating p53 would result in growth arrest and apoptotic response in HPV 
infected cells. Conversely, activation of the p53 pathway has potential as a 
therapy in HPV infected cells. As p53 is wild type in HPV infected cells, non-
genotoxic activation of p53 has potential as a therapeutic approach. 
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1.3.3.2 Small-Molecule Antagonists of MDM2 
Recent studies have shown that disruption of the p53-MDM2 interaction can 
lead to the activation of p53 and tumour growth inhibition [356]. Any agent 
that can block the binding of MDM2 to p53 could potentially result in the 
stabilisation of p53 and activation of the p53 pathway. Treatment of cells with 
an inhibitor of the MDM2-p53 interaction would be expected to result in; 
• Stabilisation and accumulation of p53 as a result of blockage of its 
nuclear export and degradation 
• Activation of MDM2 expression 
• Activation of other p53-regulated genes and the p53 pathway 
 
MDM2 possesses a relatively deep hydrophobic pocket, filled primarily by 
three side chains from the helical region of the peptide. The existence of this 
pocket means that one would expect low molecular weight compounds to fit in 
and block the interaction of MDM2 with p53 [357].  
 
1.3.3.3 Nutlin 
The Nutlins (Nutley Inhibitors) were identified as potential MDM2 inhibitors 
by Vassilev et al., 2004 [357]. The Nutlins are a series of cis-imidazole 
analogues, that displace recombinant p53 from its complex with MDM2 [357]. 
They can activate p53 through preventing MDM2 binding, which results in the 
stabilisation and activation of p53 [358]. Vassilev et al., 2004, found that wild-
type p53 accumulates in the nucleus of cells treated with Nutlin-1. This in turn 
led to an elevation in the levels of MDM2 and p21, in a manner consistent with 
activation of the p53 pathway. p53 activation and apoptosis induction by 
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MDM2 was enantiomer specific (an enantiomer is one of two mirror image 
forms of an optically active molecule), with only the active enantiomer of 
Nutlin-3 able to activate the expression of p21 and MDM2 genes [358]. 
 
Nutlin binds in the p53-binding pocket with high selectivity, therefore 
releasing p53 from MDM2 negative control [359]. The imidazoline scaffold 
replaces the helical backbone of the peptide and directs the projection of the 
three groups [357]. As Nutlin does not bind p53 directly it does not interfere 
with its activity.   
 
HPV infected lesions almost always contain wild type p53, so it is reasonable to 
hypothesise that Nutlin-3 could potentially be used to treat HPV-associated 
disease via induction of the p53 pathway. It is hypothesised that Nutlin-3 
treatment would result in limited induction of the p53 pathway in cells infected 
with high risk HPV types due to the high affinity with which high risk E6 
protein binds to p53. However, treatment with Nutlin-3 should induce 
activation of the p53 pathway in cells infected with low risk HPV types, as E6 
binds with much lower affinity and p53 protein is detected in lesions infected 
with low risk HPV.  
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1.4 Aims of this Thesis 
 
 
1. To investigate cell cycle protein expression in condylomata infected with low 
risk HPVs 
 
2. To assess the ability of Nutlin-3 to activate the p53 pathway in cells 
expressing low and high risk HPV genes 
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Chapter 2:  
Materials and Methods 
 
2.1 Cell Culture 
 
Antibodies and solutions are given in section 2.12. 
2.1.1 Cell Lines 
HCT116 (Gift from Dr P. Edwards, University of Cambridge), colorectal 
carcinoma cell line was cultured in McCoys 5A medium (Sigma, Steinheim, 
Germany) supplemented with 10% (v/v) fetal bovine serum (FBS) (Globe 
Pharm, Surrey, UK) and 100u/ml penicillin, 100µg/ml streptomycin, 
0.292mg/ml L-glutamine (PSG) (Gibco, Paisley, UK). 
 
PC3 (Gift from Professor A. Riches, University of St Andrews), prostate derived 
adenocarcinoma cell line was cultured in McCoys 5A media supplemented with 
10% (v/v) FBS and PSG. 
 
Primary Human Keratinocytes (PHK) (PromoCell, Heildelberg, Germany) 
were cultured in PromoCell Keratinocyte Growth Medium-2, plus Supplement 
Mix (KGM2/S) (PromoCell).  
 
 U2OS (European Collection of Cell Cultures (ECACC, Wiltshire, UK)), an 
osteogenic sarcoma cell line was cultured in McCoys 5a medium (Sigma) 
supplemented with 10% (v/v) FBS and PSG. 
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The amphotropic packaging lines PA317 containing the retrovirus vectors 
LXSN, LXSN 16E6, LXSN 16E7, LXSN 16E6E7, LXSN 6E6 and LXSN 6E7 
(American Type Culture System (ATCC, LCG Promochem, Teddington, UK), 
were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco) 
supplemented with 10% (v/v) FBS and PSG. The retrovirus vectors contain 
HPV DNA fragments, Moloney murine leukemia virus (MoMuLV) promoter-
enhancer sequences and a gene controlling resistance to neomycin transcribed 
from the SV40 promoter. 
 
2.1.2 Cell Culture 
 All tissue culture was performed in a category 2 biosafety tissue culture hood. 
Where required appropriate personal protective equipment was worn. All cell 
lines used were adherent. Cell lines were maintained in a either a T75 tissue 
culture flask (75cm2 surface area) (Nunc (Europe) Ltd, Hereford, UK) 
containing 14mls of medium or a T25 tissue culture flask (25cm2 surface area) 
(Nunc) containing 4mls of medium, at 37oC, 5% (v/v) CO2 until ready to 
harvest. The primary cells were maintained in a T75 containing 10mls medium 
or a T25 containing 5mls of medium at 37oC, 5% (v/v) CO2 until ready to 
harvest. 
 
2.1.2.1 Trypsinisation of Cell Lines 
 
Cells were subcultured 1/10 on covering 70-80% of the tissue culture flask 
surface. Cell culture medium was replaced with 4mls 1x phosphate buffered 
solution (PBS) (Oxoide, Basingstoke, UK) and cells washed by gentle swirling, 
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the PBS wash was removed and the monolayer covered with 2ml 0.5% (v/v) 
Trypsin/EDTA (Gibco), the flask was placed at 37oC until the cells detached. 
An equal volume of pre-warmed media was added, the cell suspension was 
aspirated then centrifuged at 150 g for 3 minutes. The supernatant was 
discarded and the cells resuspended in fresh pre-warmed media and flasks 
were seeded appropriately. 
 
 2.1.2.2 Resuscitation of Cell Lines 
 
Cryovials containing the frozen cell stocks were removed from liquid nitrogen 
and warmed in a water bath at 37oC for 2-3 minutes until thawed, then 
immediately transferred to a 15ml centrifuge tube, to which pre-warmed 
culture media was added, drop wise. Cells were centrifuged at 150 g for 3 
minutes, resuspended in fresh media to remove all traces of dimethyl 
sulphoxide (DMSO), then seeded appropriately.  
 
2.1.2.3 Cryopreservation of Cell Lines 
Trypsinisation was performed as described in 2.1.2.1. The resulting pellet was 
resuspended in 90% routine culture media, 10% (v/v) DMSO ((BDH), VWR, 
Lutterworth, UK)) and frozen to -70oC in an isopropanol-filled cryofreezing 
container (Nalgene, Nalge Europe Ltd, Hereford, UK) to maintain a freezing 
rate of -1oC per minute, as assured by the manufacturer. After 24 hours the 
cells were transferred to liquid nitrogen (-196oC) for long-term storage. 
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2.1.2.4 Trypsinisation of Keratinocytes 
 
PHKs were subcultured when they covered 60-80% of the surface of the flask 
using the PromoCell DetachKit. Cell culture medium was replaced with 5ml 
Hepes Balanced Salt Solution and cells washed for 30 seconds by gentle 
swirling. The wash was removed and the monolayer covered with 100µl 
Trypsin/EDTA per cm2. When 50% of the cells detached, the flask was tapped 
to loosen the remainder, when the cells completely detached, 100µl/cm2 
Trypsin Neutralising Solution was added and the cell suspension was removed 
to a centrifuge tube. Cells were centrifuged at 150 g for 3 minutes, the 
supernatant was discarded and the cells resuspended in fresh pre-warmed 
KGM-2/S and flasks were seeded appropriately. 
 
2.1.2.5 Resuscitation of Keratinocytes 
The frozen vial was thawed in a 37oC water bath until approximately 90% of 
the freeze medium thawed, removed from water bath and gently shook until 
fully thawed. The contents were gently resuspended in 5ml pre-warmed culture 
media in a T25 flask. 
 
2.1.2.6 Cryopreservation of Keratinoctyes 
Cells were trypsinised as described in 2.1.2.4 the cell pellet was resuspended 
gently in Cryo-SFM (PromoCell) at a concentration of 1-5 x106 cells per ml. 
Cells were gradually frozen to -70oC in an isopropanol-filled cryofreezing 
container to maintain a freezing rate of -1oC per minute. After 24 hours the 
cells were transferred to liquid nitrogen (-196oC) for long-term storage. 
  67 
2.2. Retroviral Transduction 
2.2.1 Primary Human Keratinocyte Transduction 
The growth of the LXSN packaging cell line and the PHKs to be infected was 
co-ordinated so that cells were ready on the same day. The success rate of the 
transduction is dependent on the growth stage of the cells involved. PHKs were 
grown in T25 tissue culture flasks and infected at the 8-cell stage. The 
packaging lines were cultured in T75 flasks, when the growth of cells was semi 
confluent, the media was changed to KGM-2/S, 24 hours later the infective 
supernatant was harvested. 
 
The infective packaging line supernatant was filtered through a 0.45 µm filter 
(Millipore (UK) Ltd, Watford, UK). 2.5 ml of this was added to 2.5 ml of pre-
warmed KGM-2/S plus 12 µg/ml Polybrene (hexadimethrine bromide) (Sigma-
Aldrich, Dorset, UK) (to achieve a final concentration of 6 µg/ml) and used to 
replace the PHK culture media. Infections were left for 6-8 hours then the 
medium was replaced with fresh, pre-warmed KGM2/S. These were left 
overnight (16-18 hours) then Geneticin® (G418 sulphate) (Gibco) selective 
agent was added at a final concentration of 150 µg/ml. Cells were monitored 
daily and when all the cells in the non-infected control flask were dead, 
selection was removed and the transduced cells were harvested. 
 
2.2.2 U2OS Transduction 
The method was followed as for transduction of PHK cells, with the following 
changes; U2OS cells were grown in a T75 flask and infected at 60% confluency 
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to achieve maximum number of cells in active cell cycle. The total volume of 
supernatant was increase to 10ml; 5mls of filtered infective supernatant plus 
5mls of DMEM and G418 selection was at a final concentration of 500µm.  
 
2.2.3 Chamber Slides 
For the purposes of drug treatment and subsequent immunocytochemistry, the 
cells were cultured on chamber slides (Nunc). Cells were counted in a Coulter 
Counter (Beckman Coulter (UK) Inc., High Wickham, UK) and seeded 
appropriately so as to achieve 50% confluency 24 hours later. Cells were 
maintained in 2.5mls of appropriate medium at 37oC, 5% (v/v) CO2. 
 
2.2.4 Nutlin Treatment 
Cells underwent Nutlin treatment 1-2 days after they had been seeded. This 
was to allow recovery from the trypsinisation and to ensure there was an 
adequate number of live cells in the flask. Nutlin-3 (Roche, West Sussex, UK) 
was added to give a final concentration of 5µM for 48 hours (unless otherwise 
stated). Cells were then harvested immediately.  
 
2.2.5 Cytospin 
A cytospin was performed on the supernatant from the chamber slides.  Two 
mls of supernatant was spun at 800 rpm for 7 minutes in a Shandon-2 
Cytospin centrifuge (ThermoShandon, Cheshire, UK). The slides were stained 
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with a 5 second haematoxylin QA (Vector Laboratories) dip, then examined for 
the presence of apoptopic bodies. 
 
2.3 Immunocytochemistry of Monolayer 
Cells 
 
The cell lines grown on chamber slides were harvested and fixed.  The chamber 
slides were washed twice in PBS, fixed in ice cold 100% (v/v) methanol for 30 
minutes. Slides were assembled in a Coverplate and Sequenza ® slide rack 
(Immunon, ThermoShandon, Cheshire, UK). The slides were stained for 
Cytokeratin 18 (CK18) and the cell cycle control proteins p21, p53 M30 or 
activated Caspase-3, antibody dilutions are given in Table 2.1, p66. Detection 
was performed using the Vectastain Elite ABC kit (Vector Laboratories, 
Peterborough, UK) immunoperoxidase system with Diaminobenzidine (DAB) 
detection (DakoCytomation, Ely, UK) as described in section 2.10. Slides were 
counterstained with haematoxylin QA and mounted in Dibutyl Phthalate 
Xylene (DPX) mounting medium (Sigma-Aldrich). 
 
 
2.4 Analysis of Immunocytochemistry 
Following immunocytochemistry (ICC), the chamber slides were examined 
under a light microscope. The positive and negative cells were counted and the 
number of positive cells was expressed as a percentage of the total cell count. 
Cell counting was performed using the running mean method. An example 
graph is given in Appendix A1. The results were then plotted as the percent of 
positive cells in the form of histograms. 95% confidence intervals (CI) were 
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calculated from the standard error of the proportion as follows: 
  SEP = #[p(1-p)/n]; 95% CI = Proportion +/- (SEP x 1.96).  
Each tranduction experiment was performed twice and the results were 
pooled. Each Nutlin-3 treatment and subsequent protein detection was also 
performed in duplicate and the results pooled. Hence, four separate slides were 
scored for each antibody. 
 
 
2.5 Clinical Material 
With ethics approval from the Tayside Tissue Bank (see Appendix A2), 
formalin fixed paraffin embedded archival anogenital condylomata from the 
Department of Pathology, Ninewells Hospital, Dundee were selected and 
anonymised. Diagnoses were confirmed by a consultant pathologist (Professor 
C.S.Herrington). Four-!m sections were mounted onto Super Frost Plus glass 
microscope slides (VWR, Lutterworth, UK).  
 
2.5.1 DNA Extraction 
Four 4-µm thick, formalin fixed, paraffin wax embedded (FFPE) sections were 
cut into a microtube. Sections were dewaxed in two changes of 500µl 
Histoclear (VWR) for 5 minutes, centrifuged at 1050 g for 10 minutes, then 
washed twice in 96% (v/v) ethanol for 5 minutes, centrifuged as before then 
air-dried at 55oC for an hour and incubated overnight at 55oC with 200µg/ml 
proteinase K (Sigma-Aldrich) in 200mM Tris-HCl pH 8.0, 1mM EDTA. The 
digest was stopped by heating to 95oC in a heating block for 20 minutes, then 
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centrifuged at 5000 rpm for 10 minutes. A 15!l aliquot of supernatant was 
used for each PCR reaction. 
 
2.5.2 HPV Typing 
A 140-150bp fragment from the HPV L1 gene was amplified using the 
GP5+/GP6+ primer system after Jacobs et. al., 1995 [360]. 
 
GP5+ Sequence: TTTGTTACTGTGGTAGATACTAC (Sigma-Genosys) 
GP6+ Sequence: GAAAAATAAACTGAAATCATATTC (Sigma-Genosys) 
 
Each 50 µl reaction mix contained; 
o 25 µl of ReadyMix Taq (Sigma) to give final concentrations of 1.5 
U Taq polymerase, 10mM Tris-Hcl pH 8.3, 50 mM KCl  
o 3.5 mM MgCl2 
o 50 pmol each primer (GP5+ and GP6+) 
o 15µl Template DNA, negative control (water) or positive control 
(1µl HPV 6 DNA in 14µl of water). 
 
Initial denaturation was at 94oC for 4 minutes, followed by 40 cycles of 
denaturation at 94oC for 30 seconds, primer annealing at 40oC for 1 minute, 
primer extension at 72oC for 30 seconds then a final extension step at 72oC for 
4 minutes. 
 
Ten !l of the PCR product was analysed on a 2% agarose gel (Bioline, London, 
UK) stained with ethidium bromide (Sigma). The gel was electrophoresed in 1 
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x Tris-Borate-EDTA (TBE) at 150v. The L1 band was excised and purified using 
the QIAquickTM gel extraction kit (Qiagen, Sussex, UK), then sequenced in both 
directions (University of Dundee Sequencing Service or Gene Service, 
Cambridge). HPV type was determined by NCBI BLAST analysis 
(www.ncbi.nlm.gov/BLAST/) of the nucleotide sequences obtained. 
 
HPV DNA negative samples were checked for DNA quality by amplification of 
the $-Globin gene (de Rosa Husman et. al., 1995)[361].  
 
PCO3: ACACAACTGTGTTCATAGC (Sigma-Genosys) 
PCO5: GAAACCCAAGAGTCTTTCTCTG (Sigma-Genosys) 
 
Each 50 µl Reaction mix contained; 
o 25 µl of ReadyMix Taq (Sigma) to give final concentrations of 1.5 
U Taq polymerase, 10mM Tris-Hcl pH 8.3, 50 mM KCl 
o 1.5 mM MgCl2 
o 200 µM each dNTP 
o 50 pmol each primer 
o 10 µl template DNA or negative control (water) or Positive 
control (SiHa DNA) 
 
Initial denaturation was at 95oC for 4 minutes, followed by 40 cycles of 
denaturing at 95oC for 60 seconds, primer annealing at 55oC for 2 minutes, 
primer extension at 72oC for 90 seconds then a final extension step at 72oC for 
4 minutes. 
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Ten !l of the PCR product was analysed on a 1.5% agarose gel stained with 
ethidium bromide. 
 
2.5.3 Dewaxing 
FFPE sections were slide mounted, 4 µm thick, baked overnight at 60oC in an 
oven, then used within 1 month. Slide mounted sections were dewaxed in two 
changes of Histoclear, for 5 minutes, rocking then washed twice with 100% 
(v/v) ethanol for 2 minutes rocking, then 100% (v/v) methanol for 2 minutes 
rocking followed by a final wash in tap water. Slides were kept in water and 
used within 1 hour. 
 
 
2.6 HPV DNA In Situ Hybridization on 
Lesions 
 
HPV type was confirmed and the morphological localization of HPV DNA was 
analysed by in situ hybridization (ISH) with DISH REMBRANT® Digoxigenin 
labeled DNA probes (Pan Path, Amsterdam, Holland) for HPV 6 or HPV 11. 
Slide mounted sections were dewaxed, digested with 8mg/ml pepsin (800-
2500 u/mg, Sigma) in 0.02N HCl at 37oC for 10 minutes then dehydrated for 2 
minutes with a graded series of alcohol washes (70%, 96% then 100%). Ready-
to-use probe was applied to the slides (10-20µl), which were then denatured at 
95oC for 5 minutes. Hybridisation was performed at 37oC overnight. Hybrids 
were washed in Pan Path wash buffer, 15 minutes at room temperature, then 
detected by incubation with monoclonal anti-digoxigenin (Roche) and 
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visualized with the EnVision+ System-HRP DiaminoBenzoic Acid (DAB) 
detection kit (DakoCytomation) see section 2.10. Sections were counterstained 
with haematoxylin QA and mounted in DPX mounting medium. 
 
2.7 Immunocytochemistry of Lesions 
Slide mounted sections were dewaxed then a high temperature antigen 
unmasking technique was used; slides were boiled in a pressure cooker in 
10mM citric acid, pH6.0 for 15 minutes at full power in a 850W microwave. 
Following a block of 5% (v/v) hydrogen peroxide or a 1% (w/v) bovine serum 
albumin (BSA), according to the detection kit instructions, slides were stained 
for; Cyclins A, B1, D1, E, p21, p53, cleaved caspase-3 and ki67. Antibody 
dilutions are given in Table 2.1.  
 
Detection of cyclin D1, p21, p53, Ki67, and Caspase-3, was performed using the 
Vectastain Elite ABC Peroxidase kit, Mouse or Universal as appropriate with 
DAB visualisation. Detection of Cylins A, B1 and E was performed using the 
EnVision+ System-HRP (DAB) detection kit as this offered the increased 
sensitivity required (see Section 2.10). Sections were counterstained with 
haematoxylin QA and mounted in DPX mounting medium. 
 
 
2.8 Combined Staining (ICC/ISH) on Lesions 
Immunocytochemistry (ICC) was performed as described above for p21 and 
Ki67 and detected using the EnVision G/2 System/AP (permanent red) 
(DakoCytomation) detection kit. Following completion of ICC, In situ 
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hybridisation (ISH) was performed as described above, from the dehydration 
step onwards. Hybrids were detected by incubation with monoclonal anti-
digoxigenin (Roche) and visualized with the EnVision+ System-HRP (DAB) 
detection kit. Slides were not counterstained but were mounted in DPX. 
 
2.9 Dual Staining (p21 and p53) on Lesions 
Slide-mounted sections were dewaxed then the high temperature antigen 
unmasking technique described above was used. The primary antibodies used 
were mouse monoclonal p21 and rabbit polyclonal p53 (see Table 2.1). The 
primary antibodies were pooled and incubated together for 60 minutes at 
room temperature; each primary antibody was then detected separately. 
Fluorescent and chromogenic detection methods were employed. 
Chromogenic Detection: p21 was detected directly using the EnVision+ 
System-HRP (DAB) detection kit. p53 was detected with an anti-rabbit 
biotinylated (BT) secondary antibody (DakoCytomation) 1/300, incubated for 
30 minutes at room temperature followed by a streptavidin-AP conjugated 
tertiary antibody (Roche) 1/1000, incubated for 30 minutes at room 
temperature. Detection was performed using the AP chromogen from the 
EnVisionG/2 System-AP (Permanent Red) detection kit. 
Fluorescence Detection: p21 was detected directly with anti-mouse FITC 
(Sigma-Aldrich) and p53 was detected directly with anti-Rabbit Texas Red 
(Vector Laboratories). The detection order was reversed such that both 
antibodies were detected in both orders. 
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2.10 Detection Systems 
All detections were performed according to the kit manufacturers’ instructions; 
any deviations are stated in the protocol. All steps are performed at room 
temperature. 
 
2.10.1 Vectastain Elite ABC Kit  
Slides were quenched for endogenous hydrogen peroxide in 0.3% (v/v) 
hydrogen peroxide (VWR) in 70% (v/v) methanol. Slides were incubated in 
blocking serum for 20 minutes, incubated in primary antibody diluted in kit 
block for 30 minutes, washed twice in PBS for 2 minutes, incubated for 30 
minutes in biotinylated secondary antibody followed by two PBS washes, 
incubated for 30 minutes in ABC Reagent, washed twice in PBS then incubated 
in DAB peroxidase substrate solution for 10 minutes. The reaction was stopped 
by a tap water rinse. 
 
2.10.2 EnVision+ System-HRP (DAB) 
Sections were quenched for endogenous peroxidase by incubation in the kit 
peroxidase block for 5 minutes and then washed twice in Tris-Buffered Saline 
(TBS) for 2 minutes. Primary antibody was diluted in 1% (w/v) BSA and 
incubated for 1 hour. Sections were washed for 2 minutes in TBS twice, then 
incubated with peroxidase labelled polymer. Finally sections were incubated in 
Substrate Chromogen (DAB) for 10 minutes. The reaction was stopped by a tap 
water wash. 
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2.10.3 EnVisionTM G/2 System/AP (Permanent 
Red) 
Following a 30 minute block in 1% (w/v) BSA, sections were incubated in 
primary antibody diluted in 1% (w/v) BSA for 1 hour. Sections were washed 
twice in TBS for 2 minutes then incubated in Rabbit/Mouse LINK for 30 
minutes, washed twice in TBS and incubated in AP Enzyme (Enhancer) for 30 
minutes, washed twice in TBS then incubated in Substrate Working Solution 
(Permanent Red) for 5-15 minutes. The reaction was stopped by a tap water 
wash. 
 
2.11 Western Blotting 
Cells were cultured in a T25 flask. Each experiment had a 48 hour 5µM Nutlin-
3 treatment (unless otherwise stated) and untreated negative control. Cells 
were harvested immediately following Nutlin treatment. The Western blots 
were performed in duplicate. 
 
2.11.1 Cell Harvest 
Following treatment the cells were trypsinised as previously described in 
section 2.1, with the exception that the flask supernatant was kept. The cell 
pellet was resuspended in 1ml PBS, centrifuged at 150 g for 3 minutes. An 
aliquot was removed for cell count and the PBS wash was repeated. The cell 
pellet was resuspended in 100µl of Sample Reducing Buffer (see Table 2.3), 
aspirated 10 times using a 25 gauge needle (Millipore) then heated in a heating 
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block at 95oC for 5 minutes. The reduced sample was allowed to cool and kept 
frozen at -20oC until use. 
 
2.11.2 Electrophoresis & Transfer 
A Biorad Mini Protean 11 ® Cell Gel casting and running rig was used. A 10% 
resolving gel was prepared from; 30% Acrylamide-bis (Severn Biotch Ltd, 
Kidderminster, UK), 10% (w/v) SDS (BDH), 10% (w/v) APS (Sigma), 1.5M Tris 
(BDH) pH 8.8, TEMED (Gibco). This was poured into the casting rig with an 
ethanol overlay. Once set the ethanol was tipped off and the stacking gel was 
poured on top; 30% Acrylamide-bis, 10% (w/v) SDS, 10% (w/v) APS, o.5M Tris 
pH 6.8, TEMED. 
  
The set gel was transferred from the casting rig to the running rig, 5µl of 
sample plus 5µl of Reducing Sample Buffer was loaded, then run at 100V in 
Running Buffer (see Table 2.3) until the pre-stained protein marker (New 
England BioLabs, Ipswich, UK) had run to the bottom of the gel. The gel was 
then placed in a transfer cassette with nitrocellulose membrane (VWR). The 
cassette was placed in a transfer rig containing Blot Buffer; (100ml 10x stock 
(see Table 2.3), 850ml water, 50ml methanol) transfer was run at 60V for 45 
minutes. 
 
2.10.3 Antibody Incubation 
The membrane was washed in PBS-T then stained with 0.1% (w/v) Ponseau 
Solution in 5% (v/v) acetic acid (Sigma) to check for a successful transfer, the 
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membrane was cut according to the protein marker size bands (to allow 
detection of more than 1 primary antibody on a single blot), then washed in 
PBS-T and blocked in 5% (w/v) non fat milk (Marvel) in PBS-T for 1 hour at 
room temperature, rocking. Primary antibody was prepared in 5% block and 
incubated at 4oC overnight, rocking. Primary antibodies used were; p53, p21, 
Cleaved caspase-3, M-30 and $-Actin (see Table 2.2 for dilutions). 
 
The membrane was washed in PBS-T for 1o minutes, 3 times and then 
incubated in 1/10,000 biotinylated secondary antibody (Pierce, 
Northumberland, UK) (anti-rabbit or mouse as appropriate) in 2.5% block for 
30 minutes rocking at room temperature. The membrane was washed in PBS-T 
for 1o minutes 3 times then detected. 
 
2.10.4 Detection 
Electrochemiluminescence was used to detect any bound antibody. The 
membrane was incubated with ImmobilonTM Western Chemiluminescent HRP 
Substrate (Millipore) for 60 seconds, excess liquid removed, the membrane 
was wrapped in cling film then placed in a dark cassette. In the dark room, 
photographic film (Fujifilm Super RX, Fuji, Japan) was placed on the 
membrane and an initial exposure of 30 seconds was used. Exposure time was 
adjusted accordingly depending on the image quality from the 30 second 
exposure. The films were washed in X-ray developer (Kodak, Geneve, 
Switzerland) for 1-2 minutes, fix (Kodak) for 2 minutes then washed in tap 
water for 2 minutes and hung to dry. 
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2.12 Antibodies and Solutions  
 
Table 2.1: Antibodies used for Immunohistochemistry 
Antibody Clone Dilution  Supplier 
Cyclin A 6E6 1/50 Vector Laboratories 
(Peterborough, UK) 
Cyclin B1 7A9 1/20 Vector Laboratories 
Cyclin D1 SP4 1/100 Neomarkers (Suffolk, UK) 
Cyclin E 13A3 1/200 Vector Laboratories 
Cleaved  
Caspase-3 
ASP175 1/100 Cell Signalling (New England 
Biolabs (UK), Hitchin, UK) 
Cytokeratin 18 LE65 1/100 Kind gift from E. B Lane, 
University of Dundee 
Ki67 MM1 1/200 NovoCastra Laboratories Ltd 
(Newcastle, UK) 
M30 CytoDEATH 1/20 Roche (Penzberg, Germany) 
p21 SX118 1/25 DakoCytomation 
p53 (Mouse 
monoclonal) 
DO1 1/50 Kind gift from Sir Professor David 
Lane, University of Dundee 
p53 (Rabbit 
polyclonal) 
CM1 1/5000 Kind gift from Sir Professor David 
Lane, University of Dundee 
 
 
Table 2.2: Antibodies used for Western Blotting 
Antibody Clone Dilution  Supplier 
$-Actin  1/30,000 Sigma-Aldrich 
Cleaved Caspase-3 ASP175 1/800 Cell Signalling 
p21 SX118 1/300 DakoCytomation 
p53  
(Mouse 
monoclonal) 
DO1 1/1000 Kind gift from Sir Professor David 
Lane, University of Dundee 
M30  1/500 Roche 
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Table 2.3: Solutions 
 Concentration Made-up From 
Blotting Buffer 10x Tris 30 g/l 
Glycine 144 g/l 
Citric Acid  
pH6.0 
10 mM  
PBS-T 
Oxoid Sachet: 
dilute in water 
1x o.o5% (v/v) Tween-20 
Reducing 
Sample Buffer 
1x 10% (w/v) SDS 
20% (w/v) Glycine 
0.5M Tris pH6.8 
0.05% (v/v)Bromophenol blue 
100mM DDT 
Running Buffer  
pH7.5 
10x Tris 30 g/l 
Glycine 144 g/l 
SDS 10 g/l 
TBS  
pH7.5 
 10mM Tris-Base 
150mM NaCl 
TBS-T  10mM Tris-Base 
150mM NaCl 
0.05% (v/v) Tween-20 
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Chapter 3: 
Investigation of Cell Cycle Control 
Protein Expression in Anogenital 
Condylomata Infected with Low Risk 
HPV Types 
 
3.1 Main Themes & Objectives 
 
The viral types that infect the genital tract are divided into two risk groups 
according to disease pathology. High risk types, such as HPV16 and 18, are 
associated with anogenital carcinomas, whereas low risk types, such as HPV6 
and 11, are associated with benign genital warts. 
 
Despite the differences in pathogenesis between high and low risk HPV 
infection, the productive viral life-cycle (viral DNA amplification and 
production of progeny virions) of both depends on squamous differentiation 
and occurs in benign papillomas [362].  This suggests that disruption of cell 
cycle control in suprabasal keratinocytes may be similar, regardless of HPV 
type. 
 
Much work has been performed on HPV-induced cell cycle disruption in high-
risk HPV infected squamous intraepithelial lesions (SILs), with the findings for 
low risk HPV types being derived largely from their inclusion as controls in 
these experiments. Expression of p21, p53 and the cyclins is well documented 
in high risk infections and normal tissue. However, little is known about their 
expression in low risk HPV infection or the effects that the low risk virus has 
on cell cycle protein expression in condylomata acuminata.  
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The main objective was the investigation of the effects of productive viral 
infection on host cells in its natural context. This was achieved by the 
examination of the positive and negative cell cycle regulators p53 and p21, and 
the cell cycle control proteins cyclins A, B1, D1 and E, in condylomata 
acuminata infected with low risk HPV. Ki67 and activated caspase-3 were 
included to assess proliferation and apoptosis respectively.  
 
This work has been published in the Journal of Lower Genital Tract Disease  
(Lyman R, Wilson M, Herrington, CS. Cell Cycle Control Protein Expression is 
Disrupted in Anogenital Condylomata Infected with Low-risk HPV Types. J 
Low Genit Tract Dis 2008; 12:224-231).  
 
 
3.2 Methods 
3.2.1 HPV Typing 
Twenty-seven lesions were analysed from 6 different anatomical sites; cervix 
(9), anus (3), perineum (2), vulva (9), vagina (2) and penis (2). DNA was 
extracted for PCR analysis as described in Section 2.5, then HPV type was 
determined by BLAST analysis of the nucleotide sequences obtained. The 
morphological localisation of HPV DNA was analysed by In-situ hybridization 
as described in Section 2.6. 
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3.2.2 Immunohistochemistry 
 Four-!m sections were mounted on glass microscope slides and detection of 
cyclin A, cyclin B1, cyclin D1, cyclin E, p21, p53, Ki67, and Caspase-3, was 
performed as described in Section 2.7.  
 
3.2.3 Detection of p21 Relative to Ki67 
Slide-mounted sections were dewaxed then combined immunocytochemistry 
and In-situ hybridisation (ICC/ISH) was performed as described in Section 
2.8. 
 
3.2.4 Detection of p53 Relative to p21 
Slide-mounted sections were dewaxed then dual IHC was performed as 
described in Section 2.9. 
 
3.2.5 Scoring of Lesions 
The data represented in Figures 3.14 and 4.14; Protein Expression in Lesions 
by Strata, was generated by examination of strata. Each strata was then scored 
according to which protein of interest was expressed. For example, each 
condyloma that expressed p21 in the basal/parabasal layer was scored once. If 
the histogram bar indicates 20% on the basal/parabasal layer, this indicates 
that 2/10 condyloma were positive for p21 protein in the parabasal layer. 
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The data represented in Figures 3.3, 3.14 and 3.15; Proportion of Cells 
Expressing Each Protein in Condyloma, was generated from the overall 
impression of positive cells.  Each condylomata was by assessed by eye, as to 
the approximate percentage of cells (less than 30, 30 to 70 or more than 70) 
that were positive in that particular strata. For example, when looking at the 
basal/parabasal layer column, if the blue (less than 30%) extends to the 
number three, this indicates 3/17 condyloma had less than 30% of cells 
positive for cyclin A in the basal/parabasal layer.  
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3.3 Results 
3.3.1 HPV Type 
Of the 27 condylomata examined, PCR sequencing identified HPV6 in 17 and 
HPV11 in 8. Of the HPV6 positive condyloma, 9 were vulval, 2 were perineal, 2 
were cervical, 2 were penile, 1 was anal and 1 was vaginal. Of the HPV11 
positive condyloma, 5 were cervical, 2 were anal and 1 was perineal. All the 
specimens that were HPV positive by PCR were also positive by ISH. The two 
samples that were PCR negative were also negative by ISH for both HPV6 and 
HPV11 DNA. 
 
3.3.2 Cell Cycle Regulatory Proteins are Up-
regulated in HPV Infected Condylomata 
 
Compared with adjacent normal squamous epithelium, which was present in 
13 condylomata and the HPV-negative lesions, there was aberrant expression 
of all the proteins examined, except caspase-3 and to some extent cyclin B1, in 
HPV-positive lesions. The HPV-negative lesions showed the same cell cycle 
expression pattern as that seen in the normal epithelium. Representative 
images of protein expression in normal epithelium and HPV-negative lesions 
are given in Figures 3.1a and 3.1b. 
 
3.3.2.1 Cyclin Expression 
Cyclin A expression was observed in the basal/parabasal layer in the majority 
(92%) of the HPV positive lesions. Expression was strong, involving between 
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50-75% of cells in the basal/parabasal layer. Expression decreased in the low 
stratum spinosum, with only 24% of the lesions expressing cyclin A in this 
region. Expression was observed again in some nuclei in the mid stratum 
spinosum, but reduced again in the upper stratum spinosum where only 36% 
of lesions expressed cyclin A (Figures 3.2a, 3.3a and 3.4).  
 
Cyclin B1 was very weakly expressed in only a few nuclei in each stratum. 
Expression was observed in the basal/parabasal layers in 84% of lesions, 
reducing slightly in the low stratum spinosum. Expression then continued to 
reduce significantly as the cells progressed through the epithelium (Figures 
3.2b, 3.3b and 3.5).  
 
Cyclin D1 was strongly expressed in all condylomata in the basal/parabasal 
layers, in nearly all nuclei. Expression extended to the low stratum spinosum 
in only half the condylomata. In the mid to upper stratum spinosum, 
expression was only seen in the koilocytes (Figures 3.2c, 3.3c and 3.5). 
 
Cyclin E expression was very intense. Expression was predominantly observed 
in the mid stratum spinosum, with 80% of samples expressing cyclin E, 
compared to only 20% in the low stratum spinosum (Figures 3.2d, 3.3d and 
3.6). The pattern of expression suggests that cyclin E is not switched on until 
cyclin D1 has been degraded. 
 
Morphologically, cyclin E was detected above cyclin A within the epithelium 
and its expression appeared to localise to areas with viral DNA amplification 
(Figure 3.8).
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Cyclin E 
p53 p21 Ki67 
Cyclin D Cyclin B Cyclin A 
Figure 3.1a Panel Showing the Staining Pattern for Normal Tissue. 
Taken at x200 magnification 
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Figure 3.1b Panel Showing the Staining Pattern for a HPV Negative Condyloma. 
Taken at x100 (top image) and x200 (bottom image) magnification. 
Cyclin A 
p21 Ki67 
p53 
Cyclin E 
Cyclin B Cyclin D 
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Figure 3.2: Protein Expression in Condylomata Acuminata by Strata. 
Histograms showing the proportion of lesions expressing each protein in non koilocytic cells of the 
basal/parabasal cells (B/PB), low stratum spinosum (LS), mid stratum spinosum (MS), upper 
stratum spinosum (US), stratum corneum/granulosum (C/G) and in koilocytic cells (K) in 
condylomata acuminata (CA) (n=25) and adjacent normal tissue (NT) (n=13). Error bars are 95% 
Confidence intervals, derived from the standard error of proportions (95% CI = 1.96 xSEP). 
Cyclin E expression was not observed in normal epithelium. 
 
a. Cyclin A Distribution 
d. Cyclin E Distribution c. Cyclin D1 Distribution 
b. Cyclin B Distribution 
e. p53 Distribution f. p21 Distribution 
h. HPV DNA Distribution g. Ki67 Distribution 
NT 
CA 
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Figure 3.3: Proportion of Cells Expressing Each Protein in Condylomata Acuminata. 
Histograms showing the proportion of positive cells in each lesion in non koilocytic cells of the 
basal/parabasal cells (B/PB), low stratum spinosum (LS), mid stratum spinosum (MS), upper 
stratum spinosum (US), stratum corneum/granulosum (C/G) and in koilocytic cells (K) in 
condylomata acuminata (n=25). 
30-70% 
<30% 
70<% 
g. Ki67 
e. p53 f. p21 
d. Cyclin E c. Cyclin D 
a. Cyclin A b. Cyclin B 
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Figure 3.4: Panel Showing the Staining Pattern for Cyclin A. 
Representative images of cyclin A staining pattern in HPV6; a (vulval) and b (perineal) and 
HPV11; c (cervical) and d (perineal) positive lesions.  
Taken at x100 (i), x200 (ii) and x400 (iii) magnification. 
 
 
 
 
 
 d)i d)ii d)iii 
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b)iii b)ii b)i 
a)iii a)ii a)i 
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Figure 3.5: Panel Showing the Staining Pattern for Cyclin B. 
Representative images of cyclin B staining pattern in HPV6 (a and b) and HPV11 (c and d) positive 
lesions.  
Taken at x 100 (i), x 200 (ii) and x 400 (iii) magnification. 
 
 d)i d)ii d)iii 
c)iii c)ii c)i 
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a)ii 
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Figure 3.6: Panel Showing the Staining Pattern for Cyclin D. 
Representative images of cyclin D staining pattern in HPV6 (a and b) and HPV11 (c and d) positive 
lesions.  
Taken at x 100 (i), x 200 (ii) and x 400 (iii) magnification. 
 
d)i d)ii d)iii 
a)iii 
c)iii 
b)iii 
c)ii 
b)ii 
a)ii 
c)i 
b)i 
a)i 
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Figure 3.7: Panel Showing the Staining Pattern for Cyclin E. 
Representative images of cyclin E staining pattern in HPV6 (a and b) and HPV11 (c and d) positive 
lesions.  
Taken at x 100 (i), x 200 (ii) and x 400 (iii) magnification. 
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Figure 3.8: Panel to Illustrate the Relationship between Cyclin A, Cyclin E and DNA.  
Cyclin E (b) was detected above cyclin A (a).  
Taken at X40 (i,iii) and x200 (ii, iv) magnification. 
Combined staining of cyclin E and HPV DNA (d-f) demonstrates cyclin E (Brown) appears to co-
localise to areas with viral DNA (blue/black). 
Taken at x200 (i) and x400 (ii) magnification. 
a)ii 
b)iii 
a)iv 
a)i 
a)iii 
b)ii 
b)i 
b)iv 
d)i 
d)ii e)ii 
e)i f)i 
f)ii 
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3.3.2.2 p53 and p21 Expression 
Expression of p53 was restricted to the low layers of the epithelium in the 
majority of condylomata with considerable reduction in expression in the 
intermediate layers. All lesions expressed p53 in the majority of nuclei in the 
basal/parabasal layers. This decreased slightly to 72% of lesions in the low-mid 
stratum spinosum with a significant reduction in expression in the upper 
stratum spinosum (Figures 3.2e, 3.3e and 3.9). Expression of p21 in the 
basal/parabasal layers was very low; less than half the lesions expressed p21 in 
this area. Expression increased significantly in the intermediate layers, where 
it was observed in the majority (88%) of lesions (Figure 3.2f, 3.3f and 3.10) 
suggesting that p21 expression increased as p53 expression decreased. 
Expression of both p53 and p21 decreased in the upper epithelium. Expression 
of p21 was considerably more widespread than p53 in this region, consistent 
with p53-independent expression of p21. This was confirmed by co-localisation 
studies of p21 and p53: combined staining identified nuclei containing only 
p21, confirming p53-independent expression. Combined staining of p21 and 
HPV DNA confirmed that expression of p21 protein was far more widespread 
than viral DNA amplification, but occasional nuclei contained both p21 protein 
and viral DNA (Figure 3.11). 
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Figure 3.9: Panel Showing the Staining Pattern for p53. 
Representative images of p53 staining pattern in HPV6 (a and b) and HPV11 (c and d) positive lesions.  
Taken at x 100 (i), x 200 (ii) and x 400 (iii) magnification. 
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Figure 3.10: Panel Showing the Staining Pattern for p21. 
Representative images of p21 staining pattern in HPV6 (a and b) and HPV11 (c and d) positive lesions.  
Taken at x 100 (i), x 200 (ii) and x 400 (iii) magnification. 
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Figure 3.11: Expression Pattern of p21 and HPV DNA  
HPV DNA (a), p21 expression (b).  
Taken at x100 (i) and x200 (ii) magnification.  
Combined staining of p21 and HPV DNA (C) demonstrates the presence of nuclei that have stained 
positive for both p21 protein (red) and HPV DNA (brown) are present (arrows).  
Taken at x400 magnification. 
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3.3.2.3 Ki67 and Caspase 3 Expression 
 
Ki67 expression was strong and widespread (nearly all nuclei). All of the HPV 
positive lesions expressed Ki67 in the basal/parabasal layers. Only 3 lesions 
(12%) expressed Ki67 in the low stratum spinosum, but Ki67 re-expression was 
seen in all lesions in the mid stratum spinosum (Figures 3.2g, 3.3g and 3.12). 
Activated caspase-3 was seen, weakly expressed in only occasional cells with a 
random distribution. 
 
3.3.2.4 Relationship between Ki67 Expression and HPV 
DNA 
 
In the localised areas of the condylomata positive for HPV DNA, Ki67 was no 
longer restricted to the parabasal layers. Combined staining of Ki67 with HPV 
DNA confirmed that Ki67 could be found in all strata of the epithelium below 
those in which HPV DNA could be detected; However Ki67 was generally 
undetectable in the superficial epithelium in cells above the point at which 
HPV DNA was detectable by ISH (Figure 3.13). 
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Figure 3.12: Panel Showing the Staining Pattern for Ki67. 
Representative images of Ki67 staining pattern in HPV6 (a and b) and HPV11 (c and d) positive lesions.  
Taken at x 100 (i), x 200 (ii) and x 400 (iii) magnification. 
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Figure 3.13: Ki67 Protein and HPV DNA Expression.  
Where HPV DNA is detected (ai), Ki67 expression is no longer restricted to the B/PB layers  
(aii). Taken at x40 magnification.  
Combined staining of Ki67 protein and HPV DNA (b) demonstrates Ki67 protein expression 
(red) stops where HPV DNA appears (brown) in the upper layers of the epithelium.  
Taken at x100 (i), x200 (ii) and x400 (iii and iv) magnification.  
Ki67 is re-expressed in the mid-stratum spinosum (c and d).  
Taken at x200 and x400 magnification. 
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3.3.3 Comparison of Lesions Infected with HPV6 
and HPV11 
 
The staining patterns for HPV6 compared to HPV11 positive condylomata 
acuminata can be seen in Figures 3.14, 3.15 and 3.16. Differences were 
observed in the distribution of some of the cell cycle proteins in HPV6 
compared to HPV11 positive lesions.  
 
Expression of p53 was more widespread in HPV11 than HPV6 positive 
condylomata, with p53 restricted to the lower stratum spinosum in the 
majority of HPV6 positive condylomata (Figure 3.14e). There was a difference 
in cyclin A distribution, with HPV11 lesions expressing more cyclin A than 
HPV6 lesions, particularly in the mid stratum spinosum where all of the HPV 
11 lesions expressed cyclin A compared to only 40% of HPV6 lesions (Figure 
3.14a). Expression of cyclin E was clearly linked to areas of active viral 
replication but differences in expression between lesions infected with HPV6 
and 11 were not observed (Figure 3.14d). 
 
HPV6 and 11 DNA was detected in the upper/superficial layers, in focal 
clusters. HPV6 DNA was more widespread, with expression observed in lower 
strata (Figures 3.14h and 3.17) and with a stronger signal than HPV11 DNA. 
HPV6 DNA positive areas involved more nuclei than HPV11 positive areas and 
HPV6 appeared to extend vertically, whereas HPV11 appeared to extend 
horizontally. These differences were mirrored by the Ki67 expression pattern. 
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a. Cyclin A Distribution b. Cyclin B Distribution 
c. Cyclin D1 Distribution d. Cyclin E Distribution 
e. p53 Distribution f. p21 Distribution 
g. Ki67 Distribution h. HPV Distribution 
Figure 3.14: Protein Expression in HPV6 and HPV11 Lesions by Strata. 
Histograms showing lesions expressing each protein in HPV6 (n=17) compared to 
HPV11 (n=8) positive condylomata acuminata in non koilocytic cell; basal/parabasal 
cells (B/PB), low stratum spinosum (LS), mid stratum spinosum (MS), upper stratum 
spinosum (US), stratum corneum/granulosum (C/G) and in koilocytic cells (K).  
Error bars are 95% Confidence intervals, derived from the standard error of proportions 
(95% CI = 1.96xSEP). 
 
 
 
11 
6 
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Figure 3.15: Proportion of Cells Expressing Each Protein in HPV6 Positive 
Condyloma. 
Histograms showing the proportion of positive cells in each lesion in non koilocytic cells of the 
basal/parabasal cells (B/PB), low stratum spinosum (LS), mid stratum spinosum (MS), upper 
stratum spinosum (US), stratum corneum/granulosum (C/G) and in koilocytic cells (K) in 
condylomata acuminata (n=17). 
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Figure 3.16: Proportion of Cells Expressing Each Protein in HPV11 Positive 
Condyloma. 
Histograms showing the proportion of positive cells in each lesion in non koilocytic cells of the 
basal/parabasal cells (B/PB), low stratum spinosum (LS), mid stratum spinosum (MS), upper 
stratum spinosum (US), stratum corneum/granulosum (C/G) and in koilocytic cells (K) in 
condylomata acuminata (n=8). 
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<30% 
70<% 
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c. Cyclin D 
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Figure 3.17: Panel Showing the Staining Pattern for HPV DNA. 
Representative images of HPV DNA staining pattern for HPV6 (a and b) and HPV11 (c and d) 
positive lesions.  
Taken at x 100 (i), x 200 (ii) and x 400 (iii) magnification. 
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3.4 Discussion 
 
Whilst morphologically the two HPV negative condyloma were 
indistinguishable from HPV positive condyloma, the cyclin expression pattern 
reflected that seen in normal epithelium. It was assumed that these lesions 
were not due to the presence of HPV infection, hence were excluded from the 
study. Condylomata acuminata infected with low risk HPV have aberrant 
expression of cell cycle regulators p53 and p21, cell cycle control proteins A, D1 
and E and proliferation indicator Ki67.  
 
The basal and parabasal epithelial layers showed aberrant expression of cyclin 
D1, p53 and Ki67 proteins. This observation is consistent with the virus driving 
maintenance replication in these layers. Ki67 is an indicator of proliferation 
[363, 364], cyclin D1 is required for passage through G1 into S-phase [365] and 
p53 is involved in the G1/S checkpoint [366] and plays a major role in the 
control of proliferation.  
 
The low to mid stratum spinosum had aberrant expression of cyclins E and A, 
and p21, (p53 to some extent) and Ki67. The expression of cyclins E and A and 
Ki67 is consistent with the virus driving reactivation of the cell cycle S-phase in 
order to ensure viral DNA amplification. Cyclins E and A are required to drive 
S-phase progression [367, 368], however p21 is described as a universal 
inhibitor and over expression results in the inhibition of proliferation [369]. 
This apparent anomaly is discussed below. Ki67 expression localised to areas 
that expressed cyclin A, and also to areas that exhibited viral DNA 
amplification. In normal tissue, these layers have stopped proliferating and are 
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undergoing differentiation. The activation of these cell cycle control proteins is 
therefore due to the presence of HPV.  
 
HPV DNA was only detected in the superficial layers and detection was 
predominantly in the koilocytes of the upper epithelium, with occasional 
detection in koilocytes of the mid stratum spinosum. This was not surprising as 
it is only in the superficial layers that the viral DNA copy number is high 
enough for visualisation. In the superficial layers, the cyclins are no longer 
expressed, in agreement with progression of the viral life cycle to the 
production of late proteins in preparation for assembly and release of virions. 
 
The observations in this thesis reveal that the pattern of cell cycle disruption is 
similar in condylomata acuminata infected with HPV6 or HPV11 to those 
infected with high risk HPV, with the exception of cyclin D1 and p53 protein 
over-expression.  
 
Over-expression of p53 in condylomata infected with low risk HPVs reflects the 
reduced binding affinity of low risk E6 to p53 compared to high risk E6 [370]. 
In high risk HPV infection, viral E6 together with cellular E6 Associated 
Protein (E6-AP) efficiently targets p53 for ubiquitin-mediated degradation 
[371] and p53 is rapidly degraded as the virus progresses through the stratum 
spinosum. However aberrant expression of p53 has been observed in all low 
grade cervical lesions in previous studies regardless of HPV type [343-345]; it 
has also been reported in primary human keratinocytes expressing HPV E7 
episomally, but expression is lost when E7 is integrated in these cells [24]. 
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Cyclin D is required for the activation of cdk4/6, which inturn phosphorylates 
pRb, releasing E2F and hence allowing S-phase progression. In high risk HPV 
infections the presence of cyclin D1 is not required due to the inactivation and 
degradation of pRb by oncogenic E7 [372]. High risk E7 binds to and degrades 
pRb thus releasing E2F, abrogating the need for D type cyclin kinases for cell 
cycle progression in cells lacking Rb [173]. This thesis shows that in low risk 
HPV infected tissues, cyclin D1 is still required. It is most likely that D1 is 
required to release the E2F transcription factor from pRb to drive cell cycle 
progression. This distinction in D1 expression between low and high risk 
infected lesions has been reported previously in squamous intraepithelial 
lesions of the cervix [344, 345] and is consistent with the difference in binding 
affinities of the E7 proteins. The binding affinities of low risk HPV E7 to pRb 
are much lower than those of high risk HPV E7 proteins [373]. 
 
Co-expression of both positive and negative cell cycle regulators has been 
demonstrated in high risk infected lesions (cyclin A and p21, and Ki67 and 
cyclin A) [374] and other reports suggest that viral proteins can bypass or 
inhibit the actions of the CKIs [328, 329, 375]. HPV E7 is reported to reactivate 
S phase in post-mitotic differentiated keratinocytes [330], the induction of 
cyclin E over-expression by high risk HPV E7 has previously been reported 
[376] and Cheng et al., [25] reported that low risk HPV E7 also induces cyclin 
E (and cyclin A) in primary human keratinocytes. Appropriately timed 
expression of E7 results in induction of cyclin E, which can overcome the p21 
induced cell cycle arrest [330, 377]. Experiments in HTLV-1 infected cells have 
demonstrated that p21 can act to push cells through the G1/S phase. This is 
achieved through the formation of stable p21/cyclin D/cdk4/6 complexes, 
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which result in the sequestering of p21 from cyclin E/cdk2 pushing the G1/S 
transition [378]. 
 
The staining pattern seen for p53 and p21 proteins indicated p53-independent 
expression of p21. This was confirmed by combined staining for p21 and p53. 
Although p21 is often considered to be a p53-dependent gene, widespread 
expression of p21 independently of p53 has been reported in other studies, 
both in the context of HPV infection and in other tissue types [379-381]. 
Aberrant expression of p21 reported in viral infection may be due to several 
factors; it may be a host response to the unscheduled DNA synthesis 
reactivated [380] or p21 may be induced to prevent apoptosis [209]. Low risk 
HPV E7 protein has been reported to stabilise p21 in some differentiated cells 
[224, 330]. Whilst cells expressing p21 protein were more widespread than 
those exhibiting viral DNA amplification, combined staining for both p21 and 
HPV DNA demonstrated that some nuclei contained both p21 protein and 
amplified HPV DNA. Whilst some reports suggest that p21 protein over-
expression and HPV DNA detection are mutually exclusive [380, 381], other 
studies have reported koilocytes that contain both p21 protein and high-copy 
HPV DNA consistent with our findings [330, 377]. 
 
Ki67 expression was restricted to the basal and parabasal layers in the majority 
of lesions. The observation that Ki67 is re-expressed in the mid to upper 
stratum spinosum, in localised areas that exhibit viral DNA amplification, is of 
particular interest. The co-localisation of Ki67 and viral DNA amplification to 
the same areas of the epithelium (combined with the knowledge that Ki67 has 
a relatively short half life [382]), suggests that HPV may be influencing Ki67 
  113 
expression. That Ki67 is no longer expressed in the superficial layers when 
viral DNA is detectable suggests that Ki67 expression is no longer required 
after the switch to productive replication. These observations indicate that 
Ki67 may play a role in the viral life-cycle.  
 
Koilocytic cells are morphologically distinguished by atypical nuclei and 
perinuclear halos; they are characteristic in HPV infected tissues. Koilocytic 
cells expressed predominantly cyclin A, cyclin E, p21, Ki67 and HPV DNA. 
With the exception of Ki67 expression, this pattern is similar to that reported 
in vitro in E7 expressing PHKs in raft culture [381], it is possible these are the 
cells in which HPV has succeeded in inducing S-phase re-activation. Whilst 
HPV DNA was predominantly detected in the koilocytes, not all koilocytes 
contained detectable HPV DNA. This would suggest that the morphological 
changes seen in koilocytes are not directly related to the amplification of HPV 
DNA. An alternative hypothesis is that koilocytic morphology results from 
expression of the E1^E4 protein, which induces sub-cellular reorganisation of 
cytokeratin [294]. 
 
Comparison of lesions infected with HPV6 with those infected with HPV11 
revealed that the most apparent difference in cell cycle protein expression was 
the distribution of cyclin A in relation to HPV DNA. Cyclin A expression was 
more widespread in HPV11 than HPV6 lesions, with cyclin A expression seen 
lower in the epithelium in HPV11 lesions. In the HPV11-infected lesions, there 
appeared to be an inverse relationship between cyclin A expression and HPV 
DNA detection. All of the HPV11 lesions were positive for cyclin A expression 
in the mid stratum spinosum, but there was no DNA amplification in this 
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stratum. However, in the upper stratum spinosum, HPV DNA was detected in 
all of the lesions, whilst the expression of cyclin A was significantly reduced. In 
contrast in the HPV6 infected lesions, cyclin A was expressed in the mid and 
upper stratum spinosum in less than half of the lesions, yet nearly all lesions 
exhibited HPV DNA amplification in both the mid and upper stratum 
spinosum. I cannot find any information in the literature that could help 
explain the difference in cyclin A expression and DNA detection in HPV 
infected lesions. It is possible that HPV11 infection results in the stabilisation 
of cyclin A. It should be borne in mind that just because a cyclin is stabilised it 
is not necessarily actively involved in the cell cycle. 
 
These observations suggest that HPV6 initiates DNA replication lower in the 
epithelium than HPV11, which may explain the generally more exuberant 
nature of condylomata infected with HPV6. The finding that HPV6 DNA was 
more widespread within individual lesions than HPV11 is in contradiction to 
findings in laryngeal papillomatosis where it is reported that HPV11 is more 
exuberant than HPV6 [383, 384]. However in laryngeal papillomatosis, host 
factors play a more significant role in the viral life cycle [383].  
 
These findings suggest that the mechanisms employed by low risk HPV6 or 
HPV11 to subvert cellular functions in condylomata acuminata are similar to 
those employed by high risk HPVs, with the exception of cyclin D1 and p53 
protein over-expression.  The differences in p53 expression and cyclin D1 
expression seen between high and low risk HPV infection, reflect the known 
differences between high and low risk types and are in agreement with the 
differences between high risk and low risk E6 and E7 proteins.  
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E6 and E7 are the main proteins involved in the disruption of the normal cell 
cycle, for this reason it was decided to look at the effects of E6 and E7 in more 
detail. This was achieved by transduction of these genes into cell lines, to 
produce cell lines that stably over-expressed HPV E6 or HPV E7.  
 
Activation of the p53 pathway is key in the control of cell cycle progression and 
apoptosis. HPV infected cells contain wild-type p53 and p53 is expressed in 
condylomata acuminata infected with low risk HPV types. For these reasons it 
was decided to investigate if a small molecule antagonist of MDM2 (Nutlin-3) 
could induce p53 activation in cells expressing HPV E6 and E7 genes. 
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Chapter 4: 
Activation of the p53 Pathway in HCT116 
Cells by Nutlin-3. 
 
4.1. Main Themes & Objectives 
 
The main objective was to attempt to reproduce the results as published in 
Vassilev et al., 2004 [357]; to determine if Nutlin-3 treatment of a cell line 
expressing wild-type p53 protein could result in cell cycle arrest and apoptosis 
via activation of the p53 pathway.  
 
The cell lines used in the study by Vassilev et al., 2004, were selected according 
to their p53 status. HCT116, a colorectal cancer cell line was the positive 
control cell line. It expresses wild-type p53 and has an intact p53 pathway. PC-
3, a p53-null prostate cancer cell line, was the negative control line. Vassilev et 
al., selected p21 protein as the indicator protein for activation of the p53 
pathway. It is not possible to use p53 protein, as this is not expressed by the 
negative control line. The M30 (cytoDEATH) neo-epitope was selected as an 
indicator of early apoptosis. The M30 antibody binds to a caspase-cleaved 
epitope of the cytoskeletal protein cytokeratin 18. 
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4.1.1 Activation of the p53 Pathway 
Aim: To establish if Nutlin-3 treatment could induce expression of p21 protein 
(p21) and the M30 neo-epitope (M30), in cells expressing wild-type p53 
(HCT116), but not in p53-null cells (PC-3). 
 
4.1.2 Nutlin-3 Concentration  
Aim: To establish the concentration of Nutlin-3 (N-3) required to activate the 
p53 pathway as determined by induction of expression of p21 and M30.  
 
4.1.3 Treatment Time 
Aim: To establish the time of Nutlin-3 treatment required to activate an 
apoptotic response, as measured by induction of M30 neo-epitope expression. 
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4.2. Methods 
 
The control cell lines HCT116 and PC-3 were cultured as described in Section 
2.1, then seeded at 1 to 5 x105 cells into chamber slides as described in Section 
2.2.3.  
 
Cytokeratin 18 (CK18) detection was performed on the HCT116 and PC-3 cell 
lines. Expression of CK18 demonstrates that M30 can be used to detect early 
apoptosis, as the M30 antibody binds to a caspase-cleaved epitope of 
cytokeratin 18 (a cytoskeletal protein). 
 
Following Nutlin-3 treatment, the cells were fixed and immunocytochemistry 
was performed for p21 and M30 as described in Section 2.3. The stained and 
mounted slides were examined under a light microscope and the number of 
positive and negative cells were scored using the running mean method 
(Section 2.4). The results were plotted as histograms of the proportion of 
positive cells +/- 95% confidence intervals, calculated as described in Section 
2.4. 
 
 4.2.1 Activation of the p53 Pathway 
HCT116 and PC-3 were treated with a final concentration of 3µM (this 
concentration was used in the Vassilev study) Nutlin-3 for 24 and 48 hours, 
then examined for the expression of p21 and M30. In addition, as a p21 
response was identified by immunocytochemistry, HCT116 cells were 
examined for the expression of p53 and p21 by Western blot analysis. 
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4.2.2 Nutlin-3 Concentration  
HCT116 and PC-3 cells were treated with a range of Nutlin-3 concentrations for 
24 and 48 hours. Concentrations of Nutlin-3 were; 3µM, 4µM, 5µM, 6µM, 7µM 
and 8µM. Cells were then examined for the expression of p21 and M30. 
 
4.2.3 Treatment Time 
HCT116 cells were treated for a range of times with 5µM Nutlin-3. Treatment 
times were; 72, 96, 120, 144 and 168 hours. The 24 and 48 hour data was taken 
from the previous experiment. Cells were then examined for the expression of 
p21 and M30. 
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4.3. Results 
4.3.1 Nutlin-3 Induces Activation of the p53 
Pathway in HCT116 Cells 
 
There is a clear induction of p21 protein expression following Nutlin-3 
treatment in HCT116 cells (50% of cells express p21), whilst Nutlin-3 appears 
to have little effect on PC-3 cells (less than 6% of cells express p21). M30 is not 
expressed in either cell line following 3µM Nutlin-3 treatment (Figure 4.1a). 
Induction of p53 protein was confirmed by Western blot analysis (Figure 4.1b). 
 
 
 
 
 
 
 
Figure 4.1a: Induction of p21 Protein in HCT116 and PC3 Cells 
Histogram showing p21 and M30 expression in HCT116 and PC3 cells, untreated and 
treated with Nutlin-3 (+N3). 
All cell counting was performed using the running mean method. 
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4.4.2 Optimum Concentration of Nutlin-3 Treatment 
At 5µM Nutlin-3 treatment, over 80% of cells express p21 at 24 hours 
treatment and over 90% at 48 hours treatment. Of untreated cells, less than 
10% of cells express p21 protein. At Nutlin-3 concentrations over 6µM, the 
number of p21 positive cells drop off (Figure 4.2a). M30 expression is not 
altered by Nutlin-3 concentration, less than 10% of cells express M30. The 
untreated control lines appear to express more M30 than the Nutlin-3 treated 
cells and M30 expression is at it highest at 8µM 48H (Figure 4.2b). The 
optimum concentration for Nutlin-3 treatment was taken to be 5µM. An 80-
90% expression was considered sufficient to demonstrate induction. 
 
HCT116 
p53 
p21 
!-Actin 
+ - 
 
 
Figure 4.1b: Induction of p53 and p21 Protein in HCT116 Cells 
Western blot showing p53 and p21 expression in HCT116 cells untreated (-) and treated 
with Nutlin-3 (+). 
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Figure 4.2:  Optimum Nutlin-3 Concentration 
Histogram showing p21 positive (a) and M30 positive (b) HCT116 cells over a range of 
Nutlin-3 concentrations (3µM to 8µM) 
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4.4.3 Nutlin-3 Treatment Time 
At 24 hours of 5µM Nutlin-3 treatment, 81% of cells were positive for p21 
protein. This reached a maximum of 98% of cells expressing p21 at 168 hours 
of Nutlin-3 treatment. In the untreated control cells, expression of p21 protein 
was observed in less than 5% of cells and expression remained constant with 
increasing treatment time. Prolonged treatment with Nutlin-3 did not induce 
M30 expression, indicating no apoptotic response was initiated. Less than 10% 
of Nutlin-3 treated cells expressed M30. An interesting observation was that 
expression of M30 increased over time in the untreated cells. The highest 
expression was seen at 144 hours when 20% of untreated HCT116 cells were 
M30 positive, compared to 3% at 24 hours. The time course experiments did 
not go beyond 168 hours as by this stage the cells were almost confluent and 
contact inhibition would have begun (Figure 4.3a and 4.3b).  
  124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3:  Nutlin-3 Treatment Time 
Histogram showing p21 positive (a) and M30 positive (b) HCT116 cells following 
different treatment times in hours (5µM N-3). 
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4.5 Discussion 
 
Nutlin-3 treatment of HCT116 cells induced a p21 protein response. It was 
assumed the p21 expression is a result of activation of the p53 pathway, as p21 
is directly induced by p53 [385, 386]. Induction of p53 protein was confirmed 
by Western blot analysis. Whilst there was some expression of p21 in the 
negative control cell line, the expression was very low and is likely to be a result 
of normal p21 levels expressed in actively cycling cells. Nutlin-3 treatment of 
cells did not induce apoptosis in either cell line as indicated by lack of M30 
expression. 
 
Whilst 5µM Nutlin-3 treatment clearly induced a p21 response at 24 hours 
(Figure 4.1), prolonged treatment with Nutlin-3 for 7 days did not induce M30 
expression (and therefore an apoptotic response) (Figure 4.3). The decrease in 
the number of p21 positive cells at a Nutlin-3 concentration of 7µM and above 
is most likely due to non-specific toxicity, i.e. The cells are beginning to die 
rather than activate p53 and p21 pathways. This is supported by the increase in 
M30 expression seen at 48 hours, 8µM Nutlin-3 treatment.  
 
An interesting observation was that Nutlin-3 treatment appeared to protect the 
cells from apoptosis. M30 expression was higher in untreated cells than in 
Nutlin-3 treated cells (Figure 4.3). The high p21 levels in the absence of 
apoptosis in Nutlin-3 treated cells suggests that the cells may be in G2 arrest 
[387] and raises the possibility that Nutlin-3 may cause G2 arrest in cells with 
an intact p53 pathway. 
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Vassilev et al., 2004, [357] did not directly measure an apoptotic response in 
HCT116 cells; they report the presence of apoptotic bodies in the cells treated 
with the active enantiomer (Nutlin-3a). They observed that Nutlin-3a 
treatment resulted in TUNEL positivity in SJSA-1 cells and they stated the 
HCT116 cell line was not as sensitive to Nutlin-3a treatment as the SJSA-1 cell 
line. SJSA-1 cells contain an amplified MDM2 gene [388]. It has recently been 
reported that whilst the ability of p53 to induce cell cycle arrest is preserved, 
the ability to induce apoptosis is altered in many tumour-derived cell lines and 
the strongest apoptotic response is seen in lines with aberrant MDM-2 
expression [389].  
 
Nutlin-3 consists of two entantiomers, Nutlin-3a and Nutlin-3b. Whilst both 
have nearly identical physical and chemical properties, enantiomer-b is 150 
times less potent in binding to MDM2 [357]. The commercially available 
Nutlin-3 that was used for the experiments contained a mixture of both 
enantiomers with no specified concentration of each. For this reason it is not 
possible to calculate the exact concentration of each enantiomer that was 
applied to the cells. It is possible that enantiomer-b bound initially but then 
was displaced due its lower binding affinity. 
 
Vassilev et al. employed two very diverse cell lines. HCT116 is a colorectal 
cancer cell line and PC-3 a prostate cancer cell line. It is possible that these two 
different lines would have inherently different responses following treatment 
with Nutlin-3 and that the differences observed, may not be due solely to the 
difference in p53 status. A more robust approach would be to derive a p53-null 
line from the p53-wild type cells, thereby controlling for other factors. 
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However, this would not control for the effect of other changes associated with 
transformation, which are likely to lead to alterations in cell cycle or apoptotic 
pathways, or both. Hence, primary cells, and their derivatives, were used in the 
subsequent investigations. 
 
As a read-out for activation of the p53 pathway, p21 protein expression is used. 
Although there is no data published to suggest Nutlin-3 may directly induce 
p21 protein, this cannot be ruled out. Neither can p53-independent 
mechanisms of p21 protein activation. The lack of detection of an apoptotic 
response may just reflect a lack of M30 neo-epitope detection. With these 
points in mind, the subsequent investigations employ two indicator antibodies 
for each pathway investigated. 
 
In this study, the cell counting method was employed to investigate activation 
of the p53 pathway and activation of the apoptotic response. Whilst the cell 
counting method is very time consuming, it allows the exclusion of any cells 
with abnormal staining, offers the ability to observe staining intensity and 
allows observation of the presence of any apoptotic cells. As the cells are 
cultured on a slide then fixed and stained, this method means that only 
adherent cells are included in the population counted. Cell counting does not 
allow for quantification of protein expression levels. A Fluorescent Activated 
Cell Counting method (FACs) would have allowed for a non-subjective count, 
detection of both adherent and non-adherent cells, and would have allowed a 
much higher through-put of cell number. However, it would not have been able 
to exclude any cells that were non-specifically stained and it would not have 
given a read-out of intensity of staining. The FACs method was not available at 
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this time. Western blot analysis of the data provides a semi-quantitative 
assessment of protein expression levels as it reflects the total amount of 
protein expressed by the whole population included. Western blot analysis 
cannot exclude any non-specifically stained cells or detect the presence 
apoptotic bodies and does not allow analysis at the single cell level. 
Nevertheless, Western blotting confirmed increased p53 and p21 expression in 
response to Nutlin-3 treatment. 
 
The main objective of these investigations was to identify it were possible to 
induce a p53 response (as measured by an increase in p21 expression) 
following Nutlin-3 treatment in cells containing wild type p53. To conclude, 
Nutlin-3 treatment of HCT116 cells results in an increase in both p21 and p53 
proteins, with possible cell cycle arrest, but not apoptosis. 
 
HPV infected lesions almost always contain wild-type p53 [390, 391]. HPV E6 
binds directly to p53, and targets p53 for degradation [45].  This prevents 
activation of the p53 pathway, despite the cell sensing the virus. Nutlin binds 
in the p53 binding pocket, releasing p53 from MDM2 and its negative control 
[359]. It is reasonable to hypothesise that Nutlin-3 could potentially be used to 
treat HPV-associated disease. In theory, Nutlin-3 will bind to MDM2, 
preventing MDM2 mediated degradation of p53 and causing an increase in p53 
levels. The levels of p53 would increase higher than would normally be 
experienced in a HPV infected cell, with the virus unable to produce enough E6 
protein to target all of the p53 for degradation. If the p53 pathway can be re-
activated in HPV infected cells, the cells should arrest and may go on to 
apoptose.  
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It is hypothesised that Nutlin-3 treatment will have limited impact on the p53 
pathway in cells infected with high risk HPV types due to the low levels of p53 
protein present. A significant p53 response may however be induced in cells 
infected with low risk HPV types. 
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Chapter 5:  
The Effect of Nutlin-3 on Cells 
Expressing HPV16 Genes 
 
5.1. Main Themes & Objectives 
 
The main objectives of this study were to examine the effects of high risk HPV 
E6, E7 and E6/7 over-expression on the cell cycle and to investigate if 
treatment with Nutlin-3 could induce activation of the p53 pathway in cells 
expressing HPV16 E6, E7 and E6/E7 genes. This was achieved by examination 
of expression of p53 and p21 proteins as indicators of activation of the p53 
pathway and activated caspase-3 (C-3) and the M-30 neo-epitope (M30) as 
indicators of apoptosis.  
 
PA317 packaging lines producing amphotrophic retroviruses encoding HPV 
open reading frames (ORF), were used to stably infect primary human 
keratinocytes (PHKs). Retroviral transduction was used as this method is very 
efficient and is known to be effective for primary cells. PHKs were used as 
these cells most closely represent the host cells in natural HPV infection.  
 
As the investigation progressed, it became apparent that the primary cell line 
was very difficult to manipulate. The PHKs were very sensitive to contact 
inhibition and on insertion and expression of the low risk genes, the rate of 
proliferation slowed significantly. For these reasons it was decided to also 
transduce a second cell line. The purpose of the non-PHK line was to use this 
cell line to establish and optimise protocols. In addition, this cell line would act 
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as a control for the data generated from the experiments performed with the 
PHK lines.  The cell line selected was U2OS, an osteosarcoma cell line that is 
known to have a functional p53 pathway and pRb and MDM2 [392, 393]. 
U2OS has previously been used in many experiments involving HPV genes. It 
has a faster replication time and is not as sensitive to contact inhibition as the 
PHKs. U2OS is easier to culture and maintain, and continues to cycle at a 
reasonable rate following transduction. 
 
5.1.1 Activation of the p53 Pathway  
Aim: To establish if treatment with Nutlin-3 could induce activation of the p53 
pathway in cells expressing HPV16 E6 (16E6), HPV16 E7 (16E7) or HPV16 
E6/E7  (16E6/7) genes. 
 
5.1.2 Induction of apoptosis 
Aim: To establish if treatment with Nutlin-3 could activate an apoptotic 
response in cells expressing 16E6, 16E7 or 16E6/E7 genes. 
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5.2. Materials & Methods 
 
The cells were cultured as described in Section 2.1. and retroviral transduction 
was performed as described in Section 2.2. The transduced cells were seeded 
into chamber slides as described in Section 2.2.3. Chamber slides were seeded 
with 5x105 to 1x106 cells and were left for 1-2 days until they reached 50% 
confluency before treatment with Nutlin-3. Following Nutlin-3 treatment, the 
cells were fixed and immunocytochemistry was performed as described in 
Section 2.3. The stained and mounted slides were examined under a light 
microscope and the number of positive and negative cells was scored (Section 
2.4). The results were plotted as histograms of the proportion of positive cells 
+/- 95% confidence intervals, calculated using the running mean method as 
described in Section 2.4. The U2OS cells were also cultured in T25 flasks and 
western blot analysis was performed as described in Section 2.10. 
 
 5.2.1 Activation of the p53 Pathway 
Transduced PHKs were treated with 5µM Nutlin-3 for 24 and 48 hours, then 
examined for the expression of p53 and p21 proteins. 
 
Transduced U2OS cells were treated with 5µM Nutlin-3 for 48 hours, then 
examined for the expression of p53 and p21 proteins. 
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5.2.2 Induction of Apoptosis 
Cytokeratin 18 (CK18) detection was performed on the PHKs and U2OS cells. 
Expression of CK18 demonstrates that M30 can be used to detect early 
apoptosis, as the M30 antibody binds to a caspase-cleaved epitope of 
cytokeratin 18 (a cytoskeletal protein). Both the PHK and U2OS lines were 
positive for CK18. 
 
Transduced PHKs were treated with 5µM Nutlin-3 for a maximum of 5 days. 
Cells were examined for C-3 and M30 expression at 2 days, 3 days, 4 days and 
5 days of Nutlin-3 treatment.  
 
Transduced U2OS cells were treated with 5µM Nutlin-3 for 48 hours, then 
examined for the expression of C-3 and M30. 
 
A cytospin was performed on the supernatants of Nutlin-3 treated transduced 
PHKs and U2OS cells as described in Section 2.2.5, then examined for the 
presence of apoptotic bodies.  
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5.3 Results 
5.3.1 Nutlin-3 Induces p53 and p21 Protein 
Expression in PHKs Expressing HPV16 Genes 
 
Nutlin-3 treatment induced expression of both p53 and p21 in the 16E7 
expressing line and induced expression of p21 protein in the 16E6 and 16E6/7 
expressing lines (Figure 5.1).  
 
Of the 16E6 expressing PHKs, very few were positive for p53 protein (less than 
7%), both in the treated cells and in the untreated control cells. There was a 
slight p21 response following Nutlin-3 treatment; 30% untreated and 37% in 
Nutlin-3 treated. In the 16E7 expressing PHKs, treatment with Nutlin-3 
induced a moderate response. The number of cells expressing p53 increased 
from 45 to 86% following Nutlin-3 treatment, whilst the number of cells 
expressing p21 increased from 50 to 84%. The 16E6/7 expressing PHKs 
expressed very little p53; less than 3% of both treated and untreated cells 
expressed p53. Expression of p21 was observed in 23% of untreated cells 
increasing to 43% following Nutlin-3 treatment. Nutlin-3 treatment of the PHK 
vector only control line (LXSN) resulted in induction of both p53 and p21. p53 
positive cells increased from 42 to 86% and p21 positive cells increased from 
48 to 75%. The levels of p53 and p21 positive cells in the untreated lines were 
much higher than those seen in HCT116 control cells. 
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p53 
p21 
p53 +N3 
p21 +N3 
Figure 5.1: Induction of p53 and p21 Protein Expression in PHKs 
Expressing HPV16 Genes. 
Histograms showing the percent of cells positive for p53 and p21 protein with  
(+N3) and without Nutlin-3 treatment. 
16E7 LXSN 16E6 16E6/7 
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5.3.2 Nutlin-3 Induces p53 and p21 Protein in 
U2OS cells Expressing HPV16 Genes 
 
Each transduced line showed some level of induction of p53 and p21 protein 
following Nutlin-3 treatment (Figures 5.2a and 5.2b). 
 
16E6 expressing U2OS cells showed a slight induction in the number of cells 
positive for the cell cycle proteins following Nutlin-3 treatment. Cells positive 
for p53 increased from 37 to 58% and p21 positive cells increased from 18 to 
53%. The levels seen in 16E7 expressing U2OS cells reflected the results seen 
for the vector only control lines. Following Nutlin-3 treatment p53 positive 
cells increased from 37 to 92% and p21 positive cells increased from 29 to 72%. 
The p53 positive 16E6/7 expressing U2OS cells showed a slight increase from 
34 to 49%, whilst p21 expression was very low in the untreated cells. Only 7% 
of cells were p21 positive; this increased to 45% following Nutlin-3 treatment. 
The vector only control cells showed the biggest response to Nutlin-3 
treatment with the number of p53 positive cells increasing from 35 to 97% 
following Nutlin-3 treatment. The number of p21 positive cells increased from 
24 to 90% following Nutlin-3 treatment. The Western blot analysis showed 
similar patterns of induction of p53 and p21 by Nutlin-3 (Figure 5.2b). 
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Figure 5.2b: Western Blot of Cell Cycle Protein Expression In U2OS Cells  
Expressing HPV16 E6 and E7 Genes. 
U20s cells transduced with HPV16 genes untreated (-) and treated with Nutlin-3 (+). 
16E7 LXSN 16E6 16E6/7 
Figure 5.2a: Induction of p53 and p21 Protein Expression in U2OS Cells 
Expressing HPV16 E6 and E7 Genes. 
Histograms showing the percent of cells positive for p53 and p21 protein with 
(+N3) and without Nutlin-3 treatment. 
p53 
p21 
p53 +N3 
p21 +N3 
 
!-Actin 
p21 
p53 
LXSN 16E6/7 16E6 16E7 
+ + + + - - - - 
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5.3.3 C-3 and M30 protein are not Induced by 
Nutlin-3 in PHKs Expressing HPV16 Genes 
 
 
Treatment with Nutlin-3 for 48 hours did not induce significant expression of 
C-3 or M30 in PHKs expressing HPV16 E6 and E7. Less than 4% of transduced 
PHKs (treated or untreated) expressed either C-3 or M30. Less than 7% of the 
vector only control cells expressed C-3 or M30 (Figure 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16E6 16E7 LXSN 
C3 +N3  
++N3 
C3 
M30 
M30 +N3 
Figure 5.3: Apoptotic Marker Protein Expression in PHKs  
Expressing HPV16 E6 and E7. 
Histograms showing the percent cells positive for C3 and M30 with (+N3) and 
without Nutlin-3 treatment (48H). 
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The results from the 5 day Nutlin-3 treatment (Figure 5.4) suggest a slight 
increase in expression of C-3 and M30 in treated cells compared to untreated 
cells in the 16E7 expressing PHKs. However, this increase was not 
demonstrated in the 48 hour apoptosis experiment. The vector only control 
cells (LXSN) show a steady increase in the numbers of cells expressing C-3 and 
M30 over the 5 day experiment, M30 expression increased from 0.9 to 2.4% of 
cells. Morphologically, there was no evidence of apoptotic bodies on the 
chamber slides, or in the cytospin preparations of the supernatants.  
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Figure 5.4: Expression of C-3 and M30 Proteins in PHKs Over 5 Days. 
Histogram showing percent of PHKs expressing C3 and M30 with (+N3) and 
without Nutlin-3 treatment. 
C3 +N3 
M30 
M30 +N3 
C3 
5 day 4 day 3 day 2 day 
5 day 4 day 3 day 2 day 
LXSN 
PHK + 16 E6 
5 day 4 day 3 day 2 day 
PHK + 16 E7 
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5.3.4 C-3 and M30 Protein are not Induced by 
Nutlin-3 in U2OS cells Expressing HPV16 Genes 
 
There was no induction of apoptosis following Nutlin-3 treatment of U2OS 
cells and no apparent pattern to expression levels of apoptosis markers before 
or after Nutlin-3 treatment (Figure 5.5a). Expression of C-3 and M30 was seen 
in less than 5% of cells (treated and untreated). The Western blot analysis 
reflected the results seen in the ICC, with no induction of C-3 or M30 (Figure 
5.5b). Morphologically, there was no evidence of apoptotic bodies on the 
chamber slides, or in the cytospin preparations of the supernatants. 
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C3 
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ol 
16.5 
25 
47.5 
LXSN 16E6 16E7 16E6/7 P 
KDa - - - - + + + + 
M30 
!-Actin 
16E6 16E7 16E6/7 LXSN P 
47.5 
83 
16.5 
32.5 
25 
62 
+ + + + - - - - 
Figure 5.5b: Western Blot of Apoptosis Marker Proteins in U2OS Cells  
Expressing HPV16 E6 and E7 and E6/E7 Genes 
U2OS cells transduced with HPV16 genes treated with Nutlin-3 (+) and untreated (-);  
Positive control sample =P (16E7 expressing PHK treated with Leptomycin B). 
Note the weak expression of M30 (arrows) in the positive control lane (P) is a result of the very low  
total protein loaded as illustrated in the !-Actin lane. 
 
16E7 16E6/7 LXSN 16E6 
 
Figure 5.5a: Apoptotic Marker Protein Expression in U2OS Cells  
Expressing HPV16 E6 and E7 and E6/E7 Genes. 
Histograms showing the percent cells positive for C3 and M30 with (+N3) and 
without Nutlin-3 treatment (48H). 
 
C3 
M30 +N3 
C3 +N3 
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5.3.5 General Observations 
Whilst performing the tissue culture and cell counts it was apparent that 
Nutlin-3 treatment was having a significant effect on cell proliferation. Whilst 
morphologically the Nutlin-3 treated and untreated cells looked no different, 
there was a significant decrease in the number of cells per field in the cells 
treated with Nutlin-3 compared to the untreated cells in all of the transduced 
cells. The intensity of staining for both p53 and p21 was greater in the Nutlin-3 
treated cells than the untreated cells. This is illustrated in Figure 5.6a. A 
difference in staining intensity was also observed for C-3 and M30 in Nutlin-3 
treated cells when compared to untreated cells. Whilst non-specific staining 
was present for C-3 and M30, note the presence of occasional positive cells 
(Figure 5.6b). 
 
The reproducibility of the PHK lines was poor. Whilst replicates from the same 
experiment were reproducible, duplicated experiments demonstrated the same 
overall pattern of protein expression levels. However the actual numbers of 
cells expressing the indicator proteins differed significantly. This can be seen 
when comparing the data from the preliminary apoptosis study (Figure 5.3) to 
the 5-day apoptosis study (Figure 5.4). A possible explanation for this is that 
the transduction and selection process induced a stress response in the PHKs. 
The data generated from the U2OS line was more consistent. 
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A1) 16E6 (p53) B1) 16E7 (p53) C1) 16E6/7 (p53)  
A2) 16E6 +N3 (p53) B2) 16E7 +N3 (p53) C2) 16E6/7 +N3 (p53) 
D1) 16E6 (p21) E1) 16E7 (p21) F1) 16E6/7 (p21) 
D2) 16E6 +N3 (p21) E2) 16E7 +N3 (p21) F2) 16E6/7 +N3 (p21) 
Figure 5.6a: PHK Immunocytochemistry for p53 and p21 
Panels to illustrate the difference in staining intensity in PHKs expressing HPV16 genes, in 
untreated cells (1) and cells treated with 5 µM Nutlin-3 (N3) (2), stained for p53 or p21 
(brown, nuclear staining). Note that the positive cells on the +N3 slides are more intensely 
stained. The untreated lines show much more non-specific and weaker staining.  
Taken at x400 magnification. 
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Figure 5.6b: Representative Immunocytochemistry of PHKs 
Panels showing representative images of PHKs expressing HPV16 genes, stained for 
C-3 and M30 (brown). Untreated (1) and treated with 5 µM Nutlin-3 (N-3) (2). 
Taken at x400 magnification. 
 
D2) 16E7 +N-3 (M30) 
D1) 16E7 (M30) 
B1) 16E7 (C-3) A1) 16E6 (C-3) 
B2) 16E7 +N-3 (C-3) A2) 16E6 +N-3 (C-3) 
C1) 16E6 (M30) 
C2) 16E6 +N-3 (M30) 
 
Figure 5.6b: PHK Immunocytochemistry for C-3 and M30 
Panels to illustrate the difference in staining intensity in PHKs expressing HPV16 
genes, in untreated cells (1) and cells treated with 5 µM Nutlin-3 (N-3) (2), stained for 
C-3 or M30 (brown).  Note the occasional positive cell in the +N3 slides; the C-3 stain 
is very dark and nuclear, the M30 stain is cytoplamic. There is non-specific weak 
staining on the untreated slides. 
Taken at x400 magnification. 
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5.4 Discussion 
5.4.1 Over-Expression of HPV16 Oncogenes 
Over expression of 16E6 in the PHKs resulted in very low numbers of cells 
positive for p53 protein and reduced p21 protein positive cells when compared 
to the vector only control. Over expression of 16E6 in the U2OS cell line did 
not change p53 expression, but resulted in a decrease in the number of p21 
positive cells when compared to the vector only control (Figure 5.1). 
 
Over expression of 16E7 did not alter the number of p53 positive cells in either 
cell type, but resulted in a slight increase in the number of p21 positive cells in 
the U2OS cells when compared to the vector only control (Figure 5.2a). 
 
Over expression of 16E6/7 resulted in a significant decrease in the numbers of 
p53 and p21 protein positive cells in the PHK line (less than 5% of cells were 
p53 positive) (Figure 5.1). In contrast, in the U2OS cells, over expression of 
16E6/7, had very little effect on p53 protein expression when compared to the 
vector only control. The percentage of cells positive for p21 was significantly 
reduced in these cells (Figure 5.2a). 
 
Over expression of high risk HPV oncogenes had no effect on the expression of 
apoptotic markers C-3 and M30 when compared to the vector only control 
cells. 
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The very low numbers of p53 positive cells seen in the 16E6 expressing PHKs is 
consistent with HPV16 E6 degradation of p53 [45]. The low percentage of p21 
positive cells seen in the E6 over expressing line may be due to the very low 
levels of p53 as p21 is directly induced by p53 [385, 386, 394], or due to E6 
down regulating p21 [395-397]. Despite the very low levels of p53, p21 protein 
was still expressed, demonstrating p53-independent expression of p21 [380, 
381]. 16E6 was not as efficient at degrading p53 in the U2OS cells. That very 
low numbers of 16E6 expressing U2OS cells were p21 positive indicates that E6 
is more efficient at down regulating p21 (than p53) in the U2OS environment. 
Other possible explanations for this difference are that the endogenous levels 
of p53 are different in PHK and U2OS cells or that E6 is expressed at different 
levels. 
 
It has been previously reported that E7 can stabilise p53 [224, 398-400], 
however 16E7 appeared to have no effect on p53 and p21 protein in the PHKs 
when compared to the vector only control cells. The vector only control line 
expressed relatively high levels of p53 and p21, suggesting a stress response. It 
is possible that this high basal expression has masked any increase that may 
otherwise have been observed in the 16E7 expressing cells, resulting from the 
stabilisation of p53. 
 
As was observed in the E6 over expressing line, p21 protein was expressed in 
the 16E6/7 over expressing PHKS, despite very low levels of p53, again 
demonstrating p53-independent expression of p21. The very low numbers of 
p21 positive cells seen in the U2OS cells over expressing E6/7 is very 
interesting as it is converse to what was seen in the PHK lines. This indicates 
  148 
the cellular background can have a significant effect on the functions and/or 
efficiencies of the protein products.  
 
5.4.2 Induction of p53 and p21 Following Nutlin-3 
Treatment 
 
Nutlin-3 treatment resulted in an increase in the number of cells positive for 
p53 protein in 16E7 over expressing PHKs and all U2OS lines expressing 
HPV16 genes. p21 protein positive cells increased in all the lines over 
expressing high risk HPV oncogenes (Figure 5.1 and 5.2a).  
 
16E6 expressing PHKs showed no induction of p53 protein following Nutlin-3 
treatment and only a slight increase in p21 protein. In U2OS cells both p53 and 
p21 were induced following Nutlin-3 treatment. 
 
16E7 over expressing cells showed induction of p53 and p21 following Nutlin-3 
treatment in PHKs and U2OS cells. The response in these cells mirrored the 
response in the vector only control cells. 
 
16E6/7 over-expressing PHKs showed no p53 induction and a slight p21 
induction following Nutlin-3 treatment. The U2OS cells showed a slight p53 
induction and a significant p21 induction following Nutlin-3 treatment.  
 
In the cell lines with very little p53 protein, treatment with Nutlin-3 was 
unable to induce p53 expression. This is consistent with HPV abrogation of the 
p53 pathway [312]. Treatment with Nutlin-3 resulted in a slight p21 protein 
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induction in these cell lines. The reduced p21 protein induction following 
Nutlin-3 treatment in the 16E6 and 16E6/7 expressing PHKs most likely 
results from the very low levels of p53 resulting in loss of p53-dependent p21 
expression [401]. That more p21 protein positive cells are observed in the 
presence of higher p53 protein (as observed in cells expressing 16E7 alone) 
confirms that p53 levels have a strong effect on p21 levels. That p21 is 
expressed in the absence of p53 confirms p53-independent expression of p21 
[380, 381]. Despite the low numbers of cells positive for p21 protein seen in the 
16E6/7 expressing U2OS cells, treatment with Nutlin-3 was able to induce a 
p21 response. The reduced p53 induction observed in the 16E6 expressing 
U2OS cells, served to demonstrate that whilst E6 was not as efficient in the 
U2OS cell line, it was still functional and able to degrade p53. The response to 
Nutlin-3 treatment seen when both genes were expressed in the same cell 
(16E6/7 expressing cells) mirrored the response seen in the cells expressing E6 
alone. This indicates that E6 exerts a stronger effect than E7. 
 
 
5.4.3 Absence of C-3 and M30 Induction by Nutlin-
3 
 
Nutlin-3 treatment did not induce C-3 or M30 expression in cells expressing 
HPV16 oncogenes. Whilst graphically, Nutlin-3 treatment appeared to produce 
a slight increase in the numbers of cells expressing C-3 and M30, the 
percentages of positive cells are very low and the error bars so large in 
comparison that the differences in expression are unlikely to be significant. 
Whilst the reproducibility of the PHK data was poor (comparing the results 
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from the 48 hour Nutlin-3 treatment to that of day 2 of the 5-day Nutlin-3 
treatment), the data produced from both the PHK lines and U2OS lines 
demonstrates clearly that there was no induction of C-3 and M30 following 
treatment with Nutlin-3. The immunocytochemistry was performed on the 
cells that were still adherent to the surface of the chamber slides, therefore any 
cells that may have rounded-up and floated off would not be included in the 
counts. It was considered that the lack of apoptotic markers may be due to the 
apoptotic cells being in the supernatant. However, the Western blot analysis 
performed on the U2OS cell lines included the supernatant from the cultures. 
The Western blot analysis was also negative for the expression of apoptotic 
marker proteins. There were no apoptotic bodies present in the cytospin. 
 
Nutlin-3 treatment appeared to protect the HCT116 cells from apoptosis. The 
high levels of p21 expression in the HCT116 cells was suggestive of G2 arrest 
induced by Nutlin-3, raising the possibility that Nutlin-3 may cause G2 arrest 
in cells with an intact p53 pathway. Nutlin-3 did not appear to be protective 
against apoptosis in the PHK or U2OS cells and the level of p21 expression 
does not indicate G2 arrest these cell types.  
 
HPV actively controls apoptosis through the actions of E6 and E7 proteins 
(reviewed in Finzer et al., 2002 [261]). Prevention or reduction of apoptosis is 
implicated in cervical carcinoma and increased apoptosis has been reported in 
cervical neoplasia [402, 403]. If the absence of apoptosis was due to the 
actions of E6 and/or E7, it would be expected that apoptosis would occur in the 
vector only control lines. If the vectors had inserted into a part of the cell 
genome that induces/controls apoptosis, this would offer a selective advantage 
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and account for the lack of apoptosis despite the high levels of stress. Whilst it 
is not possible to control where in the genome the HPV genes inserts, it is a 
random event and it is highly unlikely that in every cell and in every 
experiment the gene inserted into the same place in the genome.  
 
5.4.4 General Discussion 
An interesting observation was the decrease in the total numbers of cells per 
field following Nutlin-3 treatment in all the PHK and U2OS cells containing 
HPV16 genes. The lack of detection of apoptosis markers C-3 and M30 suggest 
the cells are not dying. Other possible explanations for the decrease in cell 
numbers following Nutlin-3 treatment are cell cycle arrest or a slower rate of 
replication. Either situation would suggest that Nutlin treatment may have a 
role as part of a combined therapy method for the treatment of HPV infected 
cells.  
 
The objective of the over expression studies was to examine the effects of HPV 
oncogenes on the cell cycle. In PHKs, 16E6 over expression resulted in 
abrogation of p53. 16E7 over expression resulted in a pattern of p53 and p21 
protein expression that mirrored that of the vector only control cells. Over 
expression of E6/E7 produced less p53 and less p21 than seen in the E6 lines, 
this confirms that E6 and E7 work together in synergy to abrogate p53 and p21.  
 
The objective of Nutlin-3 treatment was to investigate whether Nutlin-3 could 
induce a p53 response in HPV16 expressing cells. In all of the cell lines 
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examined (including the vector only control lines), treatment with Nutlin-3 
resulted in a decrease in the numbers of cells per field. The cell line that most 
represents a natural HPV infection is the E6/7 expressing line. Unfortunately 
Nutlin-3 treatment did not activate a significant p53 response in this cell line.  
 
Primary human keratinocytes were chosen as these most closely represent the 
cells the virus would naturally infect. When it became apparent that the 
primary cells would be problematic, whilst not ideal, it was decided to replicate 
the investigations in a transformed cell line. HCT116 was not selected, despite 
it having been utilised in the previous investigations, as it was reported to be 
resistant to apoptosis [389]. It was important to select a line with intact p21, 
MDM2 and p53 and apoptotic pathways. Hence, the U2OS cell line was 
selected. The purpose of the investigations on the U2OS cells was to confirm 
the PHK data and potentially to allow development of Flow Cytomtery and 
Western blot analysis of cells expressing HPV genes. 
 
The Nutlins used in the experiments by Vassilev et al., were sourced directly 
from the Roche Research Centre. In the experiments performed in this thesis, a 
commercially available Nutlin-3 was used. Hence, it was thought necessary to 
establish the dose and time of the commercially available Nutlin-3 treatment 
required to produce a similar response in the HCT116 line.  The dose and time 
response experiments were not repeated in the PHKs as they grow slowly and 
are very sensitive to contact inhibition, making time response assays difficult 
to assess. There are several papers that have utilised Nutlin-3 and have found 
cell cycle arrest and/or apoptosis at 5µM and below in a range of cell lines [357, 
358, 389, 404, 405]. This was taken in combination with the significant 
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induction in expression of p21 following treatment with 5µM Nutlin-3 for 24 
hours. It was therefore decided that the dose selected was adequate to induce 
activation of the p53 pathway. However, given the lack of apoptotic response 
after treatment with 5µM Nutlin-3, determination of a dose response would be 
useful to investigate the effect of Nutlin-3 further.  
 
It was expected that cells expressing high risk HPV genes would have little or 
no response to Nutlin-3 treatment, due to the high affinity with which the high 
risk HPV E6 and E7 proteins bind to host p53 and pRb. The low risk HPV E6 
and E7 proteins bind to p53 and pRb with a lower affinity, therefore Nutlin-3 
treatment may be able to better activate the p53 pathway in cells expressing 
low risk HPV proteins. 
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Chapter 6:  
The Effect of Nutlin-3 on Cells 
Expressing HPV 6 Genes  
 
6.1. Main Themes & Objectives 
 
The main objectives were to examine the effects of low risk HPV E6 and E7 
over expression on the cell cycle and to investigate if treatment with Nutlin-3 
could induce activation of the p53 pathway in cells expressing HPV6 E6 and E7 
genes. This was achieved by examination of the expression of p53 and p21 
proteins as indicators of activation of the p53 pathway and activated caspase-3 
(C-3) and the M-30 neo-epitope (M30) as indicators of apoptosis. U2OS cells 
were included due to the problems with contact inhibition and very slow 
replication times demonstrated by the PHKs, and to control the data generated 
from the experiments on the PHK lines.  
 
6.1.1 Activation of the p53 Pathway 
Aim: To establish if Nutlin-3 treatment can activate the p53 pathway and 
induce cell cycle arrest in cells expressing HPV6 E6  (6E6) and HPV6 E7 (6E7). 
 
6.1.2 Induction of Apoptosis  
Aim: To establish if Nutlin-3 treatment could activate an apoptotic response in 
cells expressing HPV6 E6 (6E6) and HPV6 E7 (6E7). 
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6.2. Materials & Methods 
 
The cells were cultured as described in Section 2.1. and  retroviral transduction 
was performed as described in Section 2.2. The transduced cells were seeded 
into chamber slides as described in Section 2.2.3. Following Nutlin-3 
treatment, the cells were fixed and immunocytochemistry was performed as 
described in Section 2.3. The stained and mounted slides were examined under 
a light microscope and the number of positive and negative cells was scored 
using the running mean method (Section 2.4). The results were plotted as 
histograms of the proportion of positive cells +/- 95% confidence intervals, 
calculated as described in section 2.4. Both the PHKs and U2OS cells were 
cultured & treated in chamber slides, The U2OS cells were also cultured in T25 
flasks and western blot analysis was performed as described in 2.10. 
 
 6.2.1 Activation of the p53 Pathway 
Transduced PHKs and transduced U2OS cells were treated with 5µM Nutlin-3 
for 48 hours, then examined for expression of p53 and p21 proteins. 
 
6.2.2 Induction of apoptosis 
Transduced PHKs were treated 5µM Nutlin-3 for a maximum of 5 days, then 
examined for C-3 and M30 expression at 2 days, 3 days 4 days and 5 days of 
Nutlin-3 treatment.  
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Transduced U2OS cells were treated with 5µM Nutlin-3 for 48 hours. Cells 
were harvested then examined for the expression of C-3 and M30. 
 
A cytospin was performed on the supernatants of Nutlin-3 treated transduced 
PHKs and transduced U2OS cells. Then examined for the presence of apoptotic 
bodies.  
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6.3. Results 
6.3.1 Nutlin-3 Treatment Induces p53 and p21 
Protein in PHKs Expressing HPV6 Genes 
 
Treatment with Nutlin-3 induced expression of both p53 and p21 in 6E6 and 
6E7 expressing PHKs (Figure 6.1a). In 6E6 expressing PHKs, the number of 
p53 positive cells increased from 19 to 89% of cells following Nutlin-3 
treatment and p21 positive cells increased from 24 to 78%. The number of p53 
and p21 positive untreated cells was lower in 6E6 expressing PHKs than that 
seen in vector only control (the vector only control cells are those shown in the 
in the HPV16 PHK experiments). Relatively high numbers of untreated 6E7 
expressing cells were positive for p53 and p21 proteins (higher than that seen 
in the vector only control). Nutlin-3 treatment induced an increase in the 
number of 6E7, p53 positive cells from 65 to 75% for p53 protein and p21 
positive cells increased from 51 to 85%.  
 
6E7 6E6 LXSN 
Figure 6.1: Induction of p53 and p21 Protein Expression in PHKs 
Expressing HPV6 E6 and E7 genes 
Histogram showing percent of PHKs expressing HPV6 genes positive for p53 and p21 
protein with (+N3) and without Nutlin-3 treatment. 
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p53 +N3 
p21 +N3 
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6.3.2 Nutlin-3 Treatment Induces p53 and p21 
Protein in U2OS Cells Expressing HPV6 Genes 
 
Treatment with Nutlin-3 induced expression of both p53 and p21 in all of the 
transduced U2OS lines (Figure 6.2). In 6E6 expressing U2OS cells, p53 
positive cells increased from 29% untreated, to 58% following N-3 treatment 
and p21 positive cells increased from 23% in the untreated cells increasing to 
70% in the Nutlin-3 treated lines. The 6E7 expressing U2OS cells responded in 
the same way as the vector only control lines. The percentage of untreated cells 
positive for p53 was 36% (vector only) and 34% (6E6), increasing to 94% and 
98% respectively, after Nutlin-3 treatment. The percentage of p21 positive 
cells, increased from 25% to 93% following treatment, for both vector only and 
6E7 expressing lines. This response to Nutlin-3 treatment was greater in the E7 
expressing than the E6 expressing U2OS cells.  The Western blot analysis 
reflected the pattern of induction of p53 and p21 following Nutlin-3 treatment. 
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Figure 6.2b: Western Blot of Cell Cycle Proteins in U2OS Cells  
Expressing HPV6 E6 and E7 Genes. 
U2OS cells transduced with HPV6 genes untreated (-) and treated with Nutlin-3 (+). 
 
6E7 6E6 LXSN 
Figure 6.2a: Induction of p53 and p21 Protein Expression in U2OS Cells 
Expressing HPV6 E6 and E7 Genes 
Histogram showing percent of U2OS cells expressing HPV6 genes positive for p53 and 
p21 protein with (+N3) and without Nutlin-3 treatment. 
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6.3.3 C-3 and M30 Protein are not Induced by 
Nutlin-3 in PHKs Expressing HPV6 Genes  
 
There was no induction of C-3 or M30 expression following 48 hours of Nutlin-
3 treatment (Figure 6.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6E6 6E7 LXSN 
Figure 6.3: Apoptotic Marker Protein Expression in PHKs  
Expressing HPV6 E6 and E7 Genes. 
Histogram showing percent of PHKs expressing HPV6 genes positive for C-3 
and M30 protein with (+N3) and without Nutlin-3 treatment. 
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The percentage of 6E6 expressing PHKs, positive for M30 and C-3 appeared to 
increase over 5 days, following Nutlin-3 treatment (Figure 6.4). The error bars 
are very large, and whilst a gradual increase in expression of apoptotic markers 
was also observed in the untreated control cells (the vector only control cells 
are those shown in the in the HPV16 PHK 5 day experiment), the difference in 
expression was not considered significant. There was no change in expression 
of M30 or C-3 in PHKs containing 6E7 following Nutlin-3 treatment. 
Morphologically, there was no evidence of apoptotic bodies on the chamber 
slides, or in the cytospin preparations of the supernatants. 
  162 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Expression of C-3 and M30 Proteins Over 5 Days in PHKs 
Expressing HPV6 E6 and E7 Genes. 
Histogram showing percent of PHK cells expressing HPV 6E6 and 6E7 genes 
positive for C-3 and M30 protein over 5 days with (+N3) and without Nutlin-3 
treatment. 
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6.3.4 C-3 and M30 Protein are not Induced by 
Nutlin-3 in U2OS Cells Expressing HPV6 Genes 
 
There was no induction of C-3 or M3o following Nutlin-3 treatment in either of 
the U2OS lines expressing low-risk genes, or in the vector only control (Figure 
6.5a). The Western Blot analysis reflected the ICC data (Figure 6.5b). 
Morphologically, there was no evidence of apoptotic bodies on the chamber 
slides, or in the cytospin preparations of the supernatants. 
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Figure 6.5b: Western Blot of Apoptosis Marker Proteins in U2OS Cells 
Expressing HPV6 E6 and E7 Genes. 
U20s cells transduced with HPV6 genes treated with Nutlin-3 (+) and untreated (-)  
Positive control sample =P (16 E7 expressing PHK treated with Leptomycin B) 
 
Figure 6.5a: Apoptotic Marker Protein Expression in U2OS Cells 
Expressing HPV6 E6 and E7 Genes. 
Histogram showing percent of U2OS cells expressing HPV6 genes positive for 
C-3 and M30 protein with (+N3) and without Nutlin-3 treatment. 
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6.3.5 General Observations 
As was observed in the high risk transduction experiments, it was apparent 
that Nutlin-3 treatment was having a significant effect on all of the cell lines. 
There was a significant decrease in the number of cells per field in the lines 
treated with Nutlin-3 compared to the untreated lines. In addition, the 
intensity of staining for both p53 and p21 and for C-3 and M30 was greater in 
the Nutlin-3 treated cells than the untreated cells. This is illustrated in Figure 
6.6a. and 6.6b. Again non-specific staining was present for C-3 and M30, 
however, note the presence of occasional positive cells (Figure 6.6b). 
 
As was apparent in the previous PHK experiments, the reproducibility of the 
data generated using the PHK lines was poor. Again, the replicates from the 
same experiments were reproducible and whilst duplicated experiments 
demonstrated the same overall pattern of protein expression levels, the actual 
numbers of cells expressing the indicator proteins differed significantly. The 
data generated from the U2OS line was more consistent. 
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Figure 6.6a: PHK Immunocytochemistry for p53 and p21 
Panels to illustrate the difference in staining intensity in PHKs expressing HPV6 
genes, in untreated cells (1) and cells treated with 5 µM Nutlin-3 (N3) (2). Stained 
for p53 or p21 (brown, nuclear). Note that the positive cells on +N3 slides are more 
intensely stained. The untreated lines show much more non-specific and weaker 
staining.  
Taken at x400 magnification. 
 
 
A1) 6E6 (p53) B1) 6E7 (p53) 
B2) 6E7 +N3 (p53) 
C2) 6E6 +N3 (p21) 
C1) 6E6 (p21) D1) 6E7 (p21) 
D2) 6E7 +N3 (p21) 
A2) 6E6 +N3 (p53) 
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A1) 6E6 (C-3) B1) 6E7 (C-3) 
A2) 6E6 +N3 (C-3) B2) 6E7 +N3 (C-3) 
D1) 6E7 (M30) C1) 6E6 (M30) 
C2) 6E6 +N3 (M30) D2) 6E7 +N3 (M30) 
Figure 6.6b: PHK Immunocytochemistry for C-3 and M30 
Panels to illustrate the difference in staining intensity in PHKs expressing HPV6 
genes, in untreated cells (1) and cells treated with 5 µM Nutlin-3 (N3) (2). Stained 
for C-3 or M30 (brown). The C-3 stain is very dark and nuclear, the M30 stain is 
cytoplamic. There is non-specific weak staining on the untreated slides. 
Taken at x400 magnification. 
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6.4. Discussion 
6.4.1 Over Expression of HPV6 Genes 
Over expression of 6E6 in PHKs resulted in a decrease in the number of p53 
and p21 positive cells, when compared to the vector only control cells (Figure 
6.1). Over expression of 6E6 in U2OS cells resulted in a slight decrease in p53 
positive cells, but no difference in p21 positive cells compared to vector only 
control (Figure 6.2). 
 
Over expression of 6E7 in PHKs resulted in an increase in the number of p53 
positive cells and a slight increase in p21 protein when compared to vector only 
control (Figure 6.1). In U2OS cells over expression of 6E7 did not result in 
induction of p53 or p21 protein when compared to vector only control cells 
(Figure 6.2). 
 
Whilst many studies agree that low risk E6 can bind p53 [406-408], it is still 
controversial as to whether low risk E6 can target p53 for degradation [342, 
406, 409]. The reduction in the number of p53 and p21 positive cells observed 
in the 6E6 over expressing PHKs, suggests that low risk E6 was able to degrade 
p53 in the keratinocyte environment. The low number of 6E6 expressing cells 
that were p21 positive is most likely due to the lack of p53 protein as p21 is 
directly induced by p53 [385, 386, 394]. Or, it may have been a result of E6 
down regulating p21 [395, 397]. It has been previously reported that high risk 
E7 stabilises p53 [224, 398]. If this is also true for low risk HPV E7, this may 
account for the high numbers of positive cells in the 6E7 over expressing PHKs. 
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In the U2OS cells, over expression of the low risk HPV genes did not 
significantly alter the expression of p21 or p53 when compared to the vector 
only control cells (Figure 6.2). 
 
6.4.2 Induction of p53 and p21 Following Nutlin-3 
Treatment       
 
Nutlin-3 treatment resulted in an increase in the number of p53 and p21 
positive cells in the 6E6 and 6E7 over expressing PHKs and U2OS cells. The 
greatest response to Nutlin-3 treatment was seen in the 6E6 over expressing 
PHKs, and the U2OS cells over expressing 6E7 (Figures 6.1 and 6.2).  
 
6E6 expressing PHKs showed significant induction of p53 and p21, despite the 
relatively low protein levels in the untreated cells. Nutlin-3 treatment of 6E6 
over expressing U2OS cells resulted in a moderate induction of p53 and p21. 
 
Despite very high levels of p53 and p21 in 6E7 over expressing cells, treatment 
with Nutlin-3 was further able to induce p53 and p21 protein. Nutlin-3 
treatment of U2OS cells over expressing 6E7 resulted in a significant induction 
of p53 and p21.  
 
6.4.3 Absence of C-3 and M30 Induction by Nutlin-
3 
 
Nutlin-3 treatment did not induce C-3 or M30  expression in cells expressing 
HPV6 genes. Whilst graphically, Nutlin-3 treatment appeared to produce a 
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slight increase in the numbers of cells positive for C-3 and M30 following 
Nutlin-3 treatment (Figure 6.4). The percentages of positive cells were very low 
and the error bars so large in comparison that the differences in expression are 
not significant. The Western Blot analysis performed on U2OS cell lines 
included the supernatant from the cultures. As the Western blot analysis was 
negative for the expression of the apoptotic marker proteins, I conclude there 
was no induction of apoptosis following Nutlin-3 treatment. 
 
As discussed previously, prevention or reduction of apoptosis is implicated in 
cervical carcinoma and increased apoptosis has been reported in cervical 
neoplasia [402, 403]. Increased apoptosis did not occur in the vector only 
control lines and as discussed before, it is highly unlikely that the HPV gene 
inserted into the same place in the genome in every cell and in every 
experiment.  
 
6.4.4 General Discussions 
As was seen in the HPV16 expression studies, Nutlin-3 treatment of HPV6 
expressing lines results in a significant decrease in cell number. However, 
detection of very low levels of apoptosis markers C-3 and M30 suggest the cells 
were not dying. Cell cycle arrest, a Nutlin-3 induced decrease in the rate of 
replication or quiescence are the possible reasons for the decrease in cell 
number. It is possible that the p53 activation induced by Nutlin-3 is strong 
enough to induce cell cycle arrest, but not sufficient to lead to apoptosis. 
Addition of another agent following Nutlin-3 treatment, may be enough to 
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induce apoptosis. This raises the possibility of Nutlin-3 therapy being used as 
part of a combined treatment for HPV infection. 
 
The objective of the over-expression study was to examine the effects of HPV6 
genes on the cell cycle. Over expression of E6 resulted in a decrease in p53 and 
p21, whilst over expression of E7 resulted in an increase in p53 and a slight 
increase in p21 expression. 
 
The objective of the Nutlin-3 treatment was to investigate whether Nutlin-3 
could induce a p53 response in HPV6 expressing cells. It was hypothesised that 
Nutlin-3 treatment of cells expressing low risk HPV genes would induce 
activation of the p53 pathway, due to the lower affinity with which 6E6 and 
6E7 proteins bind to host p53 and pRb. The data presented indicates that 
Nutlin-3 disruption of the MDM2-p53 pathway is sufficient to induce p53 
activation in cells expressing HPV6 E6 or E7. The data suggests that low risk 
HPV E7 was more efficient at stabilising p53 than high risk HPV E7. It is 
possible that all low risk HPV types are able to stabilise p53, which would 
suggest that Nutlin-3 treatment would be effective in inducing a p53 response 
in a natural HPV infection. 
 
Low risk HPVs do not contain a E6/E7 transcript and unfortunately there is 
currently no model for expression of low risk E6 and E7 in the same cell. 
Comparing protein expression and response to Nutlin-3 treatment between 
cells expressing 16E6, 16E7 and 16E6/E7, the results indicate that the effects of 
16E6/E7 are a result of the summation of the results seen with E6 and E7 
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alone. If a similar effect is assumed for low risk infection, it is likely that, in 
natural HPV infection, Nutlin-3 treatment can activate the p53 pathway. 
 
The results demonstrate apparent differences between the data generated from 
the Western blots and the cell counts from the ICC analysis. However, the ICC 
analysis and the Western blot analysis generate different data. The Western 
blot data indicates the total amount of protein expressed in the whole 
population measured. The cell counting method indicates the proportion of 
cells in the population that are expressing the protein. This, in addition to the 
inclusion of the non-adherent cells in the Western blots explains why the two 
sets of data do not always appear to match. 
 
The vector only lines are the control lines in these experiments and as such 
should demonstrate a “normal” response to Nutlin-3 treatment (activation of 
the p53 pathway). In both the high risk and low risk transduction experiments, 
the untreated vector only control cells had relatively high numbers of p53 and 
p21 positive cells before Nutlin-3 treatment. This suggests a stress response, 
which may be due to a number of factors including the presence of foreign 
DNA, and the effects of the treatment the cells have undergone. The stress 
response is stronger in the PHKs than the U2OS cells. It is to be expected that a 
primary cell would be less able than a transformed cell line, to tolerate the 
transduction and selection process. Treatment with Nutlin-3 resulted in a 
further increase in expression of the cell cycle arrest proteins, both in the 
U2OS cells and in PHKs. This confirmed that insertion of the vectors did not 
interfere with the ability of the cell to undergo Nutlin-3 induced p53 activation.  
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In the PHK environment, over expression of HPV genes produces different 
expression patterns and different responses to Nutlin-3 treatment, depending 
on the risk-type of the viral genes. In the U2OS cell environment, over 
expression of HPV genes resulted in a response similar to that of the vector 
only control cells, yet the response to Nutlin-3 treatment varied according to 
gene (E6, E7), but not viral type (16 or 6). These results confirm that HPVs are 
specifically adapted to abrogation of the normal cell cycle in keratinocytes. 
HPVs would not infect U2OS naturally, so it is not adapted to stabilise p53 in 
the U2OS cell environment. The differences in protein expression may be a 
reflection of the ability of HPV to target p53 for ubiquitination in U2OS cells. 
U2OS is a transformed cell line and whilst it is known to have intact p53 and 
pRb gene products [410], it is highly likely that the pathways are disrupted. 
E6AP may have a different confirmation in U2OS cells and PHKs. The U2OS 
cells replicate much faster than PHKs (doubling times are 25-30 hours 
compared to 40-45 hours). It is possible they required a greater concentration 
of Nutlin-3 than the PHKs to induce the same effect.  
 
It is possible that, due to the lack of E2-dependent transcription control, the 
PHK system is more representative of what occurs in an integrated state rather 
than an episomal state. It is widely accepted that it is the loss of E2 control 
over E6 and E7 levels that promotes the development of cervical cancer. 
Nevertheless, PHKs expressing the low risk and the high risk HPV genes still 
behave very differently from each other and the responses to Nutlin-3 
treatment are different.  The host cells that are over expressing the viral genes 
are from the same original source, it is likely that both high and low risk E6 
and E7 are over expressed at similar levels. As such the results from these 
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experiments indicate that the binding affinities of E6 and E7 are more 
important than the quantities, in the differences in disruption of the cell cycle.  
Each transduced line demonstrated different levels of p53 and p21 protein 
expression. The different expression levels correlated with what would be 
expected according to the known function of the particular HPV gene that had 
been transduced and was consistent with expression of the appropriate 
protein. It was assumed that each HPV protein was expressed at similar levels 
in each of the transduced lines. However, without measuring the levels of E6 
and E7 protein, this cannot be confirmed. It is therefore possible that the 
differences in p53 and p21 expression levels observed may be due to different 
expression levels of E6 and E7 protein in the different transduced lines. It is 
not possible to confirm if it is the binding affinities or protein level that 
resulted in the differences in p53 and p21 expression between high and low 
risk HPV without measuring the levels of E6, E7 and E6/E7 protein expression. 
This is a difficult issue as antibody reagents are generally poor and attempts in 
our laboratory to detect HPV16 E6 and E7 proteins by Western blotting using 
commercially available antibodies have been unsuccessful. The development of 
good antibodies to these proteins would be extremely useful. 
 
When this project began, a working flow cytometry instrument was not 
available hence it was not possible to use this technology to elucidate the 
nature of the observed cell cycle arrest. A Fluorescence Activated Cell Counting 
(FACs) instrument became available towards the end of project, Unfortunately, 
several attempts to generate a normal scatter plot from (untreated and un-
transduced) PHKs failed to generate any sensible data. U2OS cells were also 
used in an attempt to generate cell cycle data. Given more time and more 
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resources, FACs analysis would add significant weight to the findings. It is 
regretful that it was not possible to trouble shoot and optimise the FACs 
analysis protocol within the time scale of this thesis. FACs would be invaluable 
in further investigations on the cell cycle, firstly on the transduced cell lines 
and secondly on the effects of Nutlin-3 treatment. 
 
In the absence of flow cytometry, biomarkers such as a senescence-associated-
!-galactosidase biomarker could have been employed. Metabolic activity 
assays that measure mitochondrial activity as a read-out of cellular damage 
(for example MTT) can be employed to quantitate cell proliferation and 
cytotoxicity. Whilst these would not provide as much information as flow 
cytometry, they would have provided an indicator of senescence and 
cytotoxicity. 
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Chapter 7:  
Concluding Remarks and Further Work 
 
7.1 Concluding Remarks 
 
The aims of this thesis were to examine productive genital HPV infection with 
respect to expression of cell cycle proteins and to examine activation of the p53 
pathway by Nutlin-3 in HPV infected cells. This is the first detailed 
morphological study of cell cycle protein expression that has been performed 
on condylomata acuminata infected with low risk HPV types. It is also the first 
time the response to Nutlin-3 has been investigated in detail in HPV infected 
cells.  
 
 
Investigation into Cell Cycle Protein Expression in Condylomata Infected 
With Low Risk HPV Types 
Condylomata infected with low risk HPV have aberrant expression of p53, p21, 
cyclins A, D1, E and Ki67 protein. The findings presented suggest that the 
mechanisms employed by low risk HPV6 or HPV11 to subvert cellular 
functions in condylomata acuminata are similar to those employed by high risk 
HPVs, with the exception of cyclin D1 and p53 protein over-expression. The 
differences in cyclin D1 and p53 expression seen between high and low risk 
HPV infection reflect the known differences between high and low risk types 
and are in agreement with the known differences between high risk and low 
risk E6 and E7 proteins.  
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The observations in the basal/parabasal layers are consistent with the virus 
driving maintenance replication (increase in D1, p53, Ki67). It is apparent that 
cyclin D1 is still required in low risk infection to release E2F from pRb to drive 
G1 to S-phase progression. In the low-mid strata S-phase associated cyclins A 
and E were expressed, indicating a virus-driven reactivation of S-phase. HPV 
DNA was detectable in the superficial layers, consistent with an increase in 
viral copy number. The expression pattern of Ki67 suggests that this protein 
may play a key role in HPV DNA replication. Ki67 was re-expressed in areas of 
viral DNA amplification, in the superficial layers, but no Ki67 expression was 
identified at the level of the epithelium where DNA was detected. This suggests 
that Ki67 may act as a switching mechanism. 
 
The pattern of cell cycle disruption observed is similar in condylomata 
acuminata infected with HPV6 or HPV11 to those infected with high risk HPV 
and concurs with other published findings concerning the three distinct phases 
of productive viral infection; early and late phase and assembly and release 
[298, 336]. The data are in strong agreement with the findings of Middleton et 
al., (2003) [336] who propose a model of productive infection based on the 
detection of HPV life cycle markers. 
 
The data presented indicate that disruption of the cell cycle is related to the 
viral life cycle. Therefore, targeting of the early events in the abrogation of the 
cell cycle may be able to prevent progression and integration.  
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HPV in the Post Vaccination Era 
Since this thesis began, a prophylatic vaccination programme has been 
introduced into the UK. From the 1st of September 2008, all 12 year old 
females are to be offered the vaccine. The vaccine has demonstrated almost 
100% efficacy [106]. However it is only directed against HPV16 and 18. Whilst 
there are some reports of cross protection, the vaccine does not protect against 
all HPV types and is of no therapeutic use for those already infected. It is 
estimated to be between eight and ten years before the impact of the vaccine 
will be effective in reducing HPV16 and 18 related disease in those countries 
with a successful vaccination programme [411]. In developing countries, it is 
unlikely that the programme will be affordable and it will be difficult to 
implement. 
 
The vaccine is a “cervical cancer” vaccine. HPV is also responsible for genital 
warts, skin warts and laryngeal papillomas. Increasingly HPV is being 
implicated in head and neck cancers [412, 413], in particular some tonsillar 
cancers [414], and is implicated in some conjunctival squamous carcinomas 
[415]. Thus the need for detailed investigations into the viral lifecycle and for 
the development of agents to treat HPV-associated disease will remain for the 
foreseeable future. 
 
Ability of Nutlin-3 to Activate the p53 Pathway in Cells Expressing HPV 
Genes 
The data generated from this study demonstrate clearly that Nutlin-3 
treatment is able to slow proliferation in cells containing wild-type p53. This 
effect was observed in both normal cells and cells containing HPV genes. 
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Whilst Nutlin-3 treatment appeared to be more effective in cells containing low 
risk HPV genes, unfortunately during this study, Nutlin-3 treatment failed to 
induce apoptosis in cells expressing HPV genes. A much more detailed study 
on the nature of the effects of Nutlin-3 treatment on the cell cycle would be 
required before any conclusions concerning its suitability as a therapeutic in 
HPV infected cells could be made. 
 
Potential For Nutlin-3 as a Therapeutic in Non-HPV Related Cancers 
Before this project began there had been several studies published whose data 
indicated that Nutlin-3 treatment may have a role as a therapeutic in those 
cancers in which p53 remains wild-type (including HPV related cancers)[358, 
404, 416, 417]. As the project progressed, there were very few further papers 
published to support these claims. However, There have been publications to 
support the role of Nutlin-3 in combined therapies for the treatment of non-
HPV related cancers. Nutlin-3 can be used as an adjunct to increase the 
sensitivity of cells to radiotherapy [418] and tumour necrosis factor alpha-
related apoptosis inducing ligand (TRAIL) [419, 420] and used in combination 
with CDK inhibitors [421]. Kranz et al., 2006 [422] suggest that pre-treatment 
with Nutlin-3 can be used to induce cell cycle arrest in “normal cells” (p53 
wild-type), the arrested cells are then protected from the chemotherapeutic 
agents.  
 
Nutlin-3 Potential as a Research Tool 
Nutlin-3 has been used as research tool. It is employed to induce non-genotoxic 
activation of the p53-pathway to assist in investigations into the p53 network [389, 
423]. 
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7.2 Future Investigations 
 
As with most research, often more questions are raised than answered during 
investigations. There are many further investigations that could be performed 
based on the findings presented. 
 
Effects of Nutlin-3 on the Cell Cycle 
Further investigation is warranted into the exact effect Nutlin-3 treatment is 
having on the cell cycle. Unfortunately, preliminary fluorescent activated cell 
counting (FACs) analysis performed on the PHKs failed to generate a reliable 
scatter plot from “normal” cells (unstressed & untransduced).  
 
Absence of Induction of Apoptosis 
Induction of apoptosis by UV irradiation of PHK and U2OS cells could be used 
to confirm the cell lines can undergo apoptosis, and that the lack of apoptosis 
is not due to the cells inability to apoptose. 
 
Effects of Nutlin-3 Treatment in vivo 
Ideally, the use of explant cultures could be employed to investigate the effects 
of Nutlin-3 treatment. As ethical permission may be difficult to obtain, raft 
cultures of HPV-transduced PHKs would prove a valuable tool. 
 
Investigation into Viral Gene Expression 
As yet, there are no good antibody markers for E6 or E7 protein. Hence it was 
not possible to detect expression levels in the transduced cells. Valuable data 
could be generated by investigation of HPV L1 protein and HPV E1^E4 protein 
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expression in condyloma acuminata. It would be particularly interesting to 
examine the expression of these proteins in relation to Ki67. 
 
Other experiments that would be of interest include; investigation of pRb 
protein expression in transduced cells and investigation of the over expression 
of HPV genes on growth rate. Finally, it would be interesting to transduce 
HPV11 and HPV18 genes into PHKs and compare the findings to HPV6 and 
HPV16.  
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“If you do not have the 
experience, ask. There is no 
shame in asking, but do not 
pretend when you do not know” 
 
Mother Theresa of Calcutta 
  183 
Appendix 1: Example of a Counting Plateau 
SEP =  
 
 
p (1 - p) 
n 
 
 
" 
Standard error of the proportion was calculated according to the following formula: 
CI = Proportion +/- (1.96 x SEP) 
95% confidence intervals (CI) were calculated according to the following formula: 
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